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Avipoxviruses are large, genetically diverse DNA viruses which are particularly 
desirable for use as vaccine vectors as a result of their excellent safety profile and 
host range restriction.  
 
In this study, 8 novel South African (SA) avipoxvirus isolates were characterized. 
They could be divided into five groups, according to gross pathology and pock 
appearance on CAMs. Histopathology revealed distinct differences in epidermal and 
mesodermal cell proliferation, as well as immune cell infiltration, caused by the 
different avipoxviruses. Phylogenetic analysis was performed based on several 
conserved poxvirus genetic regions, corresponding to vaccinia virus (VACV) A3L 
(fpv167 locus, VACV P4b), G8R (fpv126 locus, VLTF-1), H3L (fpv140 locus, VACV 
H3L) and A11R–A12L (fpv175–176 locus). The SA isolates all grouped in clade A, 
either in subclade A2 or A3 of the genus Avipoxvirus, with branching patterns which 
differed according to the locus analysed.  
 
An in-depth characterisation of a novel SA avipoxvirus from a Feral Pigeon 
(Columba livia) (FeP2) was performed. The growth kinetics and morphogenesis of 
FeP2, as well as the ability of this virus to induce/inhibit apoptosis was investigated 
in permissive and non-permissive cell lines. FeP2 was shown to grow productively in 
primary CEF cells and exhibit complete morphogenesis in these cells. Conversely, 
growth of FeP2 was inhibited in mammalian cells and the block in morphogenesis in 
human cervix adenocarcinoma (HeLa) cells occurred prior to the formation of 
immature virus. FeP2 was shown to inhibit apoptosis in both permissive CEFs and 
non-permissive HeLa cell lines. 
 
The full genome of FeP2 was sequenced and compared to the published canarypox 
virus (CNPV) and fowlpox virus (FWPV) sequences. Phylogenetic as well as in-
depth sequence analysis supports the hypothesis that FeP2 evolved independently 
from an ancestral virus common to FWPV and CNPV. The FeP2 sequence (282kbp) 
shares 85.3% nucleotide identity with FWPV and 62.0% nucleotide identity with 
CNPV. Overall, FeP2 and FWPV have syntenic gene arrangements; however, major 
differences exist throughout their genomes, the most striking of which is a large 
deletion of ~16kbp from the central region of the genome of FeP2 deleting a cc-
chemokine-like gene, two variola virus B22R orthologues, an N1R/p28-like gene and 
a V-type Ig domain family gene, all of which are involved in host range and/or 
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immunomodulation. FeP2 encodes orthologues of vaccinia virus C7L and Interleukin 
10.  
 
In order to investigate the effect of different poxviruses on mammalian host gene 
expression, we compared host gene expression profiles in the spleens of BALB/c 
mice in response to infection (105 pfu/mouse) with six different poxviruses, namely 
Lumpy Skin Disease virus (LSDV), wild type CNPV, FWPV (DCEP 25 modified 
strain), modified vaccinia Ankara (MVA), PEPV and FeP2. The findings presented 
here indicate that six, genetically diverse host-restricted poxviruses produce 
qualitatively and quantitatively distinct host responses in an in vivo mouse model. 
Differential gene expression associated with the different poxviruses is discussed 
with emphasis on immunity-related responses. Of particular interest, CNPV and 
FWPV induce the up regulation of two immunoglobulin genes (Ighg and Ighg3 
(IgG3)) with CNPV inducing a third, Ighm (IgM). HIV-1–specific IgG3 antibodies 
have been found to correlate with decreased risk of HIV-1 infection in the RV144 
trial, which included a CNPV-based vector. Up regulation of IgG3 by CNPV and 
FWPV but not the other poxviruses tested in vivo, implies that these two 
avipoxvirus-vector backbones may be involved in stimulation of the clinically 
important IgG3 antibody subclass. 
  
The work presented here provides a basis from which to expand and further 
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The Poxviridae are a family of complex DNA viruses which replicate solely in the 
cytoplasm of host cells [1]. The Poxviridae family consists of two subfamilies; the 
Chordopoxvirinae (ChPV) which are specific to vertebrate hosts, and the 
Entomopoxvirinae (EnPV) which infect insects. The ChPV subfamily can be further 
divided into nine genera (Table 1.1) and the EnPV subfamily into three genera 
(Alphaentomopoxvirus, Betaentomopoxvirus and Gammaentomopoxvirus) [2].  
 
The evolutionary relationships between members of the Poxviridae family have been 
based on phylogenetic analysis and genome content [3, 4]. The EnPVs are 
divergent amongst themselves and compared to the ChPVs [3]. Within the ChPV 
subfamily, the Avipoxviruses, Parapoxviruses, molluscum contagiosum virus (MCV) 
and crocodilepox virus (CRV) are considerably divergent from the others [5]. 
According to analysis of the conserved DNA polymerase amino acid sequences, the 
Avipoxviruses and Parapoxviruses share the lowest percentage identity (40-50%). 
CRV also has <50% aa identity to other chordopoxviruses and is most closely 
related to MCV [5].  Orthopoxviruses, Yatapoxviruses, Cervidpoxvirus (Deerpox 
virus), Suipoxviruses and Capripoxviruses share the highest intergenus percentage 
amino acid identity (65-80%). Within both the Orthopoxvirus and Capripoxvirus 
genera, virus species share between 97-99% identity. Species within the 
Parapoxviruses and Yatapoxviruses share approximately 85% identity whereas 
members of the Avipoxvirus genus (canarypox and fowlpox viruses) share 79% 
amino acid identity [8]. For the purpose of this review, focus has been placed on two 
specific genera within the ChPV subfamily; the Orthopoxviruses (OPV) and the 
Avipoxviruses (APV). 
 
1.1.2 Poxvirus genome and morphology 
 
Poxviruses are large, ―brickshaped‖ viruses ranging between 200-400nm in length 
and which contain a dumbbell-shaped, internal core consisting of the genome and 
lateral bodies of heterogeneous material between the core and the outer membrane 
[1]. 
 
Poxviruses have linear, double-stranded DNA genomes between 130 and 300kbp in 
size [1]. Inverted terminal repeats (ITRs) of variable size consisting of homologous 
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sequences exist in opposite orientations on each end of the genome and terminal 
hairpin loops are present which connect the two DNA strands [1, 6]. Genes within 
these ITRs are present as diploid copies. Within the OPV, the size of the ITRs range 
from 200-500bp for variola virus (VARV) to almost 12kbp for vaccinia virus (VACV) 
strains [7]. 
 
Many complete poxvirus genomes have been sequenced [3]. Generally the central 
region of the genome consists of highly conserved genes involved in essential 
replication functions (RNA and DNA synthesis, virion assembly, structural proteins) 
and the terminal regions are more divergent, encoding genes involved in host range,  
immunomodulation and virulence [1], [3]. The A+T content varies significantly 
between poxvirus genomes (36-85%) but most poxviruses are A+T rich [8]. 
Exceptions to this include the parapoxviruses and MCV which each have an 
average of 36% A+T [9, 10]. There are 90 genes that are common to all ChPV and 
49 that are conserved in all poxviruses [3]. The gene content and arrangement 
within the central genomic region of ChPV is highly conserved, with the exception of 




Table 1.1 The Chordopoxvirinae (ChPV). A list of genera and their respective species [2]. 
Genus Species 
Orthopoxvirus 
vaccinia virus (prototypic species),  camelpox virus,  cowpox virus,  ectromelia virus,  
monkeypox virus, raccoonpox virus, taterapox virus,  variola virus,  volepox virus,  skunkpox 
virus (tentative species),  uasin gishu disease virus (tentative species) 
Parapoxvirus 
orf virus (prototypic species),  bovine papular stomatitis virus, pseudocowpox virus,  squirrel 
parapoxvirus,  parapoxvirus of red deer in new zealand,  auzduk disease virus  (tentative 
species),  camel contagious ecthyma virus  (tentative species),  sealpox virus  (tentative species),  
chamois contagious ecthyma virus  (tentative species) 
Avipoxvirus 
fowlpox virus  (prototypic species),  canarypox virus,  juncopox virus,  mynahpox virus,  
pigeonpox virus,  psittacinepox virus,  quailpox virus,  sparrowpox virus,  starlingpox virus,  
turkeypox virus,  crowpox virus (tentative species),  penguinpox virus (tentative species),  
peacockpox virus (tentative species) 
Capripoxvirus sheeppox virus (prototypic species),  goatpox virus,  lumpy skin disease virus 
Leporipoxvirus 
myxoma virus  (prototypic species),  hare fibroma virus,  rabbit fibroma virus,  squirrel fibroma 
virus 
Suipoxvirus swinepox virus (prototypic species) 
Molluscipox virus molluscum contagiosum virus (prototypic species) 
Yatapox virus yaba monkey tumor virus (prototypic species),  tanapox virus 
Cervidpoxvirus deerpox virus 
Unassigned squirrelpox virus 
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1.1.3 Poxvirus cell entry, replication and morphogenesis 
 
Different forms of infectious poxvirus particles exist which differ with respect to their 
outer membrane. These include the mature virions (MV) which have a single 
membrane, the intracellular enveloped virion (IEV) or ―wrapped virion (WV)‖ which 
has undergone additional membrane wrapping and the extracellular (wrapped) 
virions (EEVs) which are either cell-associated (CEV) or unattached and consist of 
an MV surrounded by an additional membrane [11]. 
 
Poxvirus morphogenesis, as defined by studies on vaccinia virus, is represented 
diagrammatically in Figure 1.1. Poxvirus infection and replication begins with 
membrane binding and virion entry into a susceptible cell [12]. Poxvirus entry into 
cells occurs via two distinct pathways – direct plasma membrane fusion at a neutral 
pH and endosomal entry at a low pH [1, 11]. Virus entry is facilitated by interaction 
of viral proteins with cell surface proteins and polysaccharides [13]. Before fusion, 
the EEV outer membrane must be removed as viral entry-fusion proteins are 
situated on the MV membrane [1]. The MV fuses with the cell or endosomal 
membrane during virus entry, depositing the core into the cytoplasm of the cell 
where gene expression is initiated [11]. After the removal of the MV membrane or 
both EEV membranes, the viron core enters the cell and is transported via 
microtubules within the cytoplasm [14]. The cores contain a functional early 
transcription system and early viral mRNAs are produced within the core itself [1]. 
 
The poxvirus replication cycle involves the temporal expression of early, 
intermediate and late viral genes, involved in each stage of viral morphogenesis and 
release [1]. Early genes encode mRNAs which are translated to initiate DNA 
replication, host interactions and intermediate gene expression [1]. In VACV, these 
genes are divided into immediate- and delayed-early genes [15]. Once DNA 
replication has commenced, intermediate genes are transcribed which encode 
regulatory proteins which induce the expression of late genes. Late genes encode 
the proteins required for the production of progeny virus including structural proteins 
and the packaged transcriptional enzymes [12].  
 
Assembly of progeny virions occurs in viral factories within the cytoplasm. The first 
distinct structures are viral crescents which grow to form spherical immature virions 
(IV) that contain core constituents and the DNA genome [12]. Proteolytic cleavage of 
core proteins and internal reorganisation transforms the circular IV into a brick-
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shaped MV particle. The MV is the most common and abundant form of infectious 
poxvirus and is released upon cell lysis [1, 12]. Alternatively, virions become 
enveloped in a double membrane derived from endosomal or trans-Golgi cisterna, 
producing the aforementioned WV particles which are then released via exocytosis 
or budding to form the extracellular EV [1, 12]. 
 
Figure 1.1. Poxvirus morphogenesis. Adapted from Moss, 2007 [1]. Major steps in the 
poxvirus life cycle are represented above and numbered sequentially.  
 
1.2 Avipoxviruses 
1.2.1 Avipoxvirus classification and phylogenetics 
 
APVs are divergent members of the ChPV [2] which have been shown to naturally 
infect more than 278 of the approximately 9000 species of wild and domestic birds 
[16]. Despite the large number of host species, according to the International 
Committee on Taxonomy of Viruses (ICTV) there are currently only ten defined- and 
three tentative APV species [2], with species names originally assigned according to 
the bird species which they infect or from which they were isolated [17]. Since APV 
are often not host specific and differ with respect to their virulence the current host-
based means of taxonomy and classification has been criticised [18, 19].  An 
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alternative approach to classification, which takes into account phylogenetic 
grouping of these viruses, may provide a feasible alternative to the host species-
based means of APV taxonomy [18]. 
  
APV phylogenetic studies have previously been based on the gene corresponding to 
VACV P4b (fpv167, VACV A3L) [18-21] which encodes a 75.2 kDa virion core 
protein, 4b, and is highly conserved amongst all poxviruses [22]. Phylogenetic 
analysis of this locus indicates that all strains cluster into 3 major clades, A (Fowlpox 
virus-like), B (Canarypox virus-like) and C (Psittacine). Clades A and B can be 
further divided into 10 minor clades, namely A1-A7 and B1-B3 [23]. Two additional 
conserved genes have been used to validate the findings based on P4b, the genes 
encoding virion envelope protein p35 (fpv140, VACV H3L) [18-20] and VLTF-1 
(VACV G8R; fpv126 locus), which encodes the most conserved protein between 
FWPV and CNPV with 95% amino acid identity [20, 24]. P4b (A3L), VLTF-1 (G8R) 
and H3L are conserved in all ChPV [3]. It is possible that more robust phylogenetic 
analyses, such as those based on the concatenated sequences of multiple 
conserved genes [8], will provide a more accurate means of taxonomy and 
classification of these viruses. 
 
The most well characterised APVs are the species prototypes, fowlpox virus 
(FWPV) and canarypox virus (CNPV). Both genomes have been sequenced and 
found to be considerably divergent, including an average of 47% amino acid 
divergence between homologues, over 75kbp additional sequence, suggesting that 
there may be substantial genomic diversity between other APV species [24, 25]. 
Genetic identities between species within the APV genus are lower (<95%) than the 
identities between species in other ChPV genera (>96%), suggesting that the APVs 
may constitute separate genera within the ChPV, or APVs could possibly be 
classified as a separate subfamily within the Poxviridae [24, 26].  
 
1.2.2 Avipoxvirus genome  (CNPV and FWPV) 
 
APV genomes are the largest of all poxviruses, ranging between 260-365kb in 
length and with low G+C content (30-40%) [25]. Thus far, only three APV genomes 
have been published; a pathogenic American strain of FWPV (FPVUS) [25], an 
attenuated European strain of FWPV derived from European FWPV HP1 passaged 
over 400 times in chick embryo fibroblasts (FP9) [27], and a virulent CNPV isolated 
from a canary (CNPVATCC VR-111) [24]. FP9, FPVUS and CNPV have large 
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genomes of 258, 280 and 365kbp encoding 238, 260 and 320 open reading frames 
(ORFs) respectively [24, 25, 27]. 
 
Comparison of the CNPV and FWPV genomes reveals overall synteny in genome 
arrangement with similar genetic complements. They do, however, exhibit significant 
differences including rearrangement, insertion and deletion of genes in the terminal, 
variable regions as well as in three internal, variable regions which is in contrast to 
the conservation of central genomic regions in other ChPVs. These variable regions 
within the conserved central region of the genomes occur near the junctions of 
areas that were identified in FWPV as rearranged relative to other ChPVs and 
contain genes involved in virus-host interactions [24, 25]. Despite this synteny, 
amino acid identity between CNPV and FPVUS ORF homologues (55-74%) is 
similar to that between ChPV genera [24]. The CNPV genome is also 80-100kbp 
larger than the FWPV genomes [24, 25, 27]. 
 
Laidlaw and Skinner (2004) compared virulent (FPVUS (American) and HP1 
(European)) and attenuated, tissue culture adapted (FP9 (European)) FWPV strains. 
Instead of the predicted changes in immunomodulators as the mechanism of 
attenuation, members of multigene families, especially those encoding ankyrin 
repeat proteins were seen to be the drivers of attenuation [27]. Ankyrin repeat 
proteins are thought to be involved in poxvirus host-range [28], and have previously 
been implicated in the attenuation of sheeppox virus [29]. Over 49% (137 genes) of 
the CNPV genome and 38% (89 genes) of the FWPV genome are comprised of 
genes belonging to gene families, 51 and 31 of which are ORFs containing ankyrin 
repeats respectively [24, 25]. These and other differences in immunomodulatory 
gene families encoded by APVs may account for the extensive variability in 
virulence, host range and host interaction [24]. 
 
1.2.3 Avipoxvirus pathogenicity 
 
APV-infected birds display various clinical symptoms of poxvirus infection, 
depending on viral virulence and host susceptibility to the infecting strain. The 
disease presents in either cutaneous or diptheric forms, whilst non-symptomatic 
infection is also possible [17]. Cutaneous infection is characterised by nodular, wart-
like lesions on the skin, usually in sparsely feathered regions of the body such as 
the beak, eyelids, legs and combs [17] (Figure 1.2). Diptheric infection presents with 
proliferative lesions in the upper respiratory and digestive tracts of the infected birds 
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[17]. These clinical symptoms, however, are sometimes ambiguous and therefore 
laboratory diagnosis is necessary to determine the causative agent of the condition. 
Laboratory diagnosis is usually performed by experimental infection of chick 
chorioallantoic membranes (CAMs), histopathology [30, 31], electron microscopy 
















1.3 Poxviruses as vaccine vectors 
1.3.1 History 
 
Historically, poxviruses have been integral to the development and study of 
vaccines, virology and immunology. In 1748, Dr Edward Jenner discovered that 
inoculation of humans with cowpox virus (CPV) afforded protection against 
smallpox, caused by VARV [33-35]. CPV for smallpox vaccination was later 
replaced with the closely related poxvirus, VACV. These three viruses, although 
different in their disease causing capabilities, all belong to the genus, Orthopoxvirus, 
and thus have the ability to cross-protect [35]. In 1980, Smallpox was declared 
officially eradicated by the Assembly of the World Health Organization (WHO), as a 
direct result of vaccination with VACV [36]. The year 1980 also saw the application 
of recombinant DNA technology to VACV, thus enabling the development of 
genetically engineered expression vectors for vaccination against other diseases 
[37]. 
Figure 1.2 Juvenile Speckled Pigeon 
displaying cutaneous pox lesions on 
the eyes and beak. Photograph 
courtesy of Tertius A.Gous 
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1.3.2 Advantages of poxviruses as vaccine vectors 
 
Poxviruses are undergoing extensive evaluation as vaccine candidates against 
several pathogens and diseases. There are many advantages of using poxviruses 
as vaccine vectors. (1) They replicate solely in the cytoplasm of host cells [1], 
ensuring that no viral DNA integration into the host genome can occur; (2) they are 
stable as freeze-dried vaccines and can withstand high temperatures [38]; (3) 
production and administration of poxviruses are relatively inexpensive [37]; (4) 
poxvirus-based vaccines can be administered via several routes [35] and (5) they 
can induce both humoral and cell mediated immune responses [39-41]. In addition, 
(6) poxviruses have large, flexible genomes which can accommodate insertion of up 
to 25kb [42] of foreign DNA, allowing for the expression of multiple genes within the 
same vector and allowing for the production of polyvalent vaccines [43]. 
 
The use of replication-deficient or host range-restricted poxviruses, such as MVA, 
NYVAC and APVs, for vaccination confers additional safety advantages. The 
inability of these poxviruses to complete a full replication cycle and produce 
infectious progeny in non-permissive cells represents a significant bio-safety 
advantage [44-48]. 
 
1.3.3 Rational design of poxvirus vaccine vectors 
 
Although many vaccine vectors have been tested, there is no one ideal vaccine 
vector. Therefore, there is a need for the discovery of novel vectors and the 
development of improved vectors. Rational vaccine design involves defining the 
correlates of protection and the development of specific vaccines which induce the 
desired responses [49]. Potential vaccine vector candidates must fulfil specific 
criteria, which may differ according to the required application. Guidelines set out by 
the WHO [50] indicate that the vector backbone should not be pathogenic and 
viruses with specific tropism should be avoided unless otherwise indicated [50]. 
Non-replicative poxviruses, such as APVs, modified vaccinia Ankara (MVA) and 
others have considerable safety benefits and may make good vaccine vector 
candidates in this regard. 
Existing immunity to VACV has been shown to negatively influence the immune 
response elicited upon vaccination with the same or cross-reacting viruses [51]. 
Furthermore, as seen in the STEP trial testing an adenovirus based candidate HIV 
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vaccine (Merck rAd5) previous immunity to the vaccine vector may enhance 
susceptibility to HIV infection in vaccinated subjects [52].  
 
Because of their large genomes and their ability to accommodate large inserts of 
foreign DNA, poxviruses are promising candidate vectors for rationally designed 
vaccine strategies [49]. These strategies include the control of transgene expression 
by poxvirus promoter design, co-expression of cytokines or other immune 
modulators to enhance immunogenicity, the use of heterologous prime-boost 
vaccination regimes to enhance target-specific immune responses, targeted deletion 
of host-range genes to enhance safety and immunogenicity and taking advantage of 
the early innate immune system by targeting specific innate effector molecules 
which modulate the subsequent adaptive responses [49]. 
 
1.3.4 Vaccinia virus as a vaccine 
 
The OPV, VACV was used in the global program to eradicate smallpox and is the 
prototype of the poxvirus family. The last recorded natural case of smallpox 
occurred in Somalia in October 1977 [36]. However, interest in VACV has continued 
due to its use as a vaccine vector and as a model for the study of virus-host 
interactions [53]. Although VACV has many attributes that make it an attractive 
vaccine vector candidate, high incidence rates of complications associated with its 
use [54] has led to safety concerns and the contraindication of VACV in 
immunocompromised individuals [37]. Smallpox vaccination of human 
immunodeficiency virus (HIV) positive individuals has been shown to induce 
vaccine-associated disease and multiple vaccinations may accelerate HIV-1 
progression and acquired immunodeficiency syndrome (AIDS)-related complications 
[55]. It has also been reported that transmission and dissemination of VACV can 
occur from vaccinees to individuals in close contact. This contact vaccinia has been 
known to cause complications and VACV-related adverse events [56]. In order to 
address these safety concerns a number of attenuated VACV strains have been 
developed including MVA, defective vaccinia Lister (dVV-L) and NYVAC. 
 
1.3.5 Attenuated poxviruses as vaccine vectors 
 
Highly attenuated, non-replicative poxvirus strains have been developed for use as 
vaccine vectors which confer a significant safety advantage over infectious strains 
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[57]. Selected attenuated poxvirus based vaccine candidates in clinical trial for 







The highly attenuated MVA was developed by Mayr et al. (1975) after extensive 
serial passage of the chorioallantoid vaccinia Ankara (CVA) in primary chick embryo 
fibroblasts [66]. Genomic sequencing revealed that MVA (178kbp) has lost 
approximately 30kbp of its genome compared to the parental CVA strain [67]. MVA 
displays abortive growth in human cells and has been shown to be safe even in 
immunocompromised individuals [68]. It has been found that both early and late viral 
genes are expressed by MVA in human cells and that viral assembly is inhibited 
after DNA replication has taken place [69]. Despite the block in virus life cycle MVA 
has been shown to be highly immunogenic and protective as a vaccine vector 





The attenuated NYVAC strain was derived from the Copenhagen VACV vaccine 
strain (VACV-COP) by the targeted deletion of 18 ORFs of non-essential genes 
encoding virulence factors and affecting host range. NYVAC-based vectors have 
Table 1.2 Selected poxvirus based vaccines in clinical development for human use 
Recombinant viral 




MVA-BN Phase IIb - Smallpox Protection [58, 59] 
ALVAC containing 
the gene encoding 
HIV-1 gp160, and 
protein gp120 
Phase III gp160 and gp120 HIV-1 
Partial protection  
[60]  
 
Prime: FP9, Boost : 




+SOC Phase III 
Trophoblast 
glycoprotein 
Metastatic renal cell 
carcinoma 
Well tolerated. 




and rFWPV) Phase III 




No difference in 
overall survival 
[63, 64] 














been found to be safe and immunogenic in humans and animals [44]. NYVAC 
displays reduced ability to replicate in human cells and is unable to produce 
infectious progeny virus in humans [44]; however, similar to MVA, it has been shown 




APVs have a restricted host range and replicate only in birds. Despite this, they 
have been shown to have the ability to infect non-avian hosts and undergo abortive 
infection in mammalian cells [45, 71]. Attenuated APVs have been used to vaccinate 
birds against APV-infection (FWPV, CNPV, quailpox) [26] and recombinant FWPV 
vectors have protected birds against avian influenza [72], Marek‘s disease virus [73] 
and Newcastle disease virus [74]. In mammals, both FWPV and CNPV have been 
used successfully as vaccine vectors for a variety of different pathogens and 
malignancies, including prostate cancer [75], equine influenza virus [76], rabies [45, 
77], canine distemper virus [78] and malaria [48]. APVs are particularly desirable as 
HIV-1 vaccine vectors as a result of their excellent safety profile and host range 
specificity [60, 79-84]. The only successful HIV-1 vaccine clinical trial to date has 
been the RV144 trial, held in Thailand, involving four priming vaccinations with a 
CNPV (ALVAC) vector expressing HIV-1 gp120/Gag-Pro, followed by two booster 
injections with a recombinant glycoprotein 120 subunit, AIDSVAX [60]. This trial 
decreased the rate of HIV-1 infection by 31.2% in vaccinated subjects compared to 
the placebo group, and although promising, indicates that further optimization of the 
vaccine is required. This success has stimulated interest in the assessment of other 
APVs as vaccine vectors.  
 
1.4 Poxvirus-host interactions 
 
The host innate immune system is activated early in viral infection, a response 
which is important for the activation of adaptive immunity and the subsequent 
generation of an efficient immune response to virus-encoded proteins. Host-range 
restricted poxviruses have been shown to successfully activate the host immune 
system [85, 86]. However evidence exists to indicate that each virus does this in a 
different way, with an accompanying different pattern of gene expression [87-92]. A 
recent study has shown that ALVAC, MVA and NYVAC produce distinct innate 
immune profiles, characterised by different induction of pro-inflammatory and 
27 
 
antiviral cytokines and chemokines in both rhesus monkeys and human peripheral 
blood mononuclear cells (PBMCs) [93].  
 
1.4.1 Innate immune recognition 
 
The innate immune system is activated when cells sense foreign pathogen 
associated molecular patterns (PAMPs) through pattern-recognition receptors 
(PRRs). These include the Toll-like receptors (TLRs), retinoic acid-inducible gene-I 
(RIG-I)-like receptors (RLRs) and the nucleotide-binding and oligomerization domain 
(Nod)-like receptors (NLRs) [94]. Sensing of viruses by these PRRs activates 
intracellular signalling pathways that result in the expression of pro-inflammatory 
cytokines and Type-I interferons (IFNs) which act to limit viral replication and to 
stimulate the induction of the adaptive immune response [95]. Poxviruses are 
recognized by a number of different PRRs (summarised in Figure 1.3) with innate 
immune sensing patterns differing considerably between species and even between 
different derivatives of the same parent species (VACV, MVA and NYVAC) [96].  
 
The important role played by TLRs in both the innate and adaptive immune 
responses to pathogens is undisputed. TLRs activate signalling pathways to induce 
appropriate immune system effector responses. Specifically, TLR3, TLR4, TLR7, 
TLR8 and TLR9 induce antiviral responses by inducing type I IFN responses [97]. In 
turn, IFN‘s have been shown to upregulate TLR gene expression in viral infections 
[98]. Several studies have implicated different TLRs required for innate recognition 
of poxviruses [99]. Ectromelia virus (ECTV) recognition by murine dendritic cells is 
TLR9 dependent [100]. Recombinant FWPV is recognised in a TLR7 and TLR9-
dependent manner in DCs and both TLRs are important for type I IFN production. 
[101]. Innate immune recognition of VACV is mediated by TLR2 [99] and TLR2 and 
TLR6 are important for MVA recognition and subsequent cytokine production [95]. 
Conversely, TLR3 activation has been shown to contribute to VACV pathogenesis 
[102] demonstrating that activation of TLRs in poxvirus infection may have a dual 
role, acting to initiate the host response to infection and as an important mediator of 
poxvirus pathogenicity. 
 
RLRs such as RIG-I and melanoma differentiation associated gene 5 (MDA5) play 
an important role in the recognition of cytosolic viral RNA. MDA5 and RIG-I have 
been shown to be involved in sensing viral RNA species produced by VACV and 
MVA infection in a cell type dependent manner [95, 103]. In addition, poxviruses 
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also activate the inflammasome. MVA has been shown to potently activate the 
NLRP3 inflammasome in the macrophage. The secretion of IL-1β in response to 
MVA infection requires TLR2 and NLRP3 inflammasome for pro-IL-1b production 
and caspase-1 activation, respectively [95] 
 
Activation of Inflammasomes during Viral Infection 
To date, the NLRP3-, AIM2-, IFI16- and RIG-I-dependent inflammasomes have 
been shown to be activated during viral infection [104]. Poxviruses have been 
shown to activate the NLRP3 inflammasome. MVA initiates the NLRP3 
inflammasome in human and murine macrophages [95] and myxoma virus (MYXV) 
activates it in a reactive oxygen species (ROS) and cathepsin B-dependent way 
[105]. VACV has been shown to be sensed by the AIM2 but not the NLRP3 
inflammasome in murine macrophages [106].  
 
1.4.2 Type-I Interferon 
 
The hallmark of the anti-viral response is the production of a type I IFN (IFNα/β) 
response which can be produced by all nucleated cells in response to viral infection 
[107]. Studies have revealed that IFN responses are crucial for anti-viral resistance 
[108]. A number of ―classical‖ Interferon stimulated genes (ISGs) have been well 
established, including EIF2AK2 (PKR), MX1, OAS1, APOBEC3G, TRIM5, ZAP, 
ISG15, ADAR, IFITM1/2/3, BST2 (tetherin) and viperin (RSAD2) [109]. The effect of 
type I IFNs on poxvirus-induced immune responses is complex. Co-administration of 
IFN-α with VACV resulted in a decrease in cell mediated immunity whereas IFN-α 
enhanced antigen-specific T-cell proliferation and cytotoxic T lymphocyte responses 
when co-administered with FWPV [110]. Conversely, type I IFN is not necessary for 
the induction of adaptive immunity to FPV-encoded antigen [111]. Taken together, 
the role that type I IFNs play in the immune response to poxviruses is poorly 
understood. While type I IFN responses are important for the induction of the 
immune response to virus infection, they may decrease the immunogenicity of viral-
vectored vaccines by promoting anti-viral responses and subsequent viral vector 
clearance [96]. Therefore a balance is necessary for vaccination purposes, where 
enough type I IFN needs to be produced to activate the immune system but not so 
much as to inhibit viral replication and gene expression before antigen presentation 


























































































































































































































1.4.3 Poxviruses and cell death 
 
Programmed cell death plays a key role in the innate immune response to viral 
infection. The mechanism of cell death influences the response of neighbouring cells 




Apoptosis is a form of programmed cell death which eliminates damaged, virally-
infected or unwanted cells without disruption of surrounding tissues or the induction 
of an inflammatory response. The mechanism of apoptosis involves a complex and 
highly organised energy-dependent, molecular cascade, which can occur via 
multiple intricate pathways [112, 113]. Apoptosis occurs in two discrete stages; first 
the formation of apoptotic bodies, followed by their phagocytosis. The formation of 
apoptotic bodies involves dynamic membrane blebbing [114], cell shrinkage, tight 
packing of the organelles and both cytoplasmic and nuclear condensation (pyknosis) 
[115]. In the second stage, these apoptotic bodies are phagocytosed and rapidly 
degraded [115]. 
 
Characteristic biochemical processes take place in cells undergoing apoptosis, 
including protein cleavage and cross-linking, and DNA degradation [112, 113]. The 
key players in these events are a set of cysteine proteases or caspases which are 
proteolytic and cleave proteins at aspartic acid residues. There are ten major 
caspases; the initiators (caspase 2,-8,-9,-10), the effectors (caspase 3,-6,-7) and the 
inflammatory caspases (caspase 1,-4,-5) [116, 117]. Several caspase substrates are 
important in the apoptotic process, and their cleavage results in some of the 
characteristic molecular and morphological features of an apoptotic cell, including 
DNA degradation into 180-200bp fragments [118], the expression of surface 
molecules to ensure rapid phagocytosis and breakdown of the nuclear envelope 
[119]. 
 
The mechanisms of apoptosis involve a complex, energy-dependent cascade of 
molecular events. Apoptosis typically proceeds through one of two signalling 
cascades, the extrinsic or death receptor pathway or the intrinsic or mitochondrial 
pathway. A third pathway involves T cell-mediated cytotoxicity and perforin-
granzyme-dependent cell death, via either granzyme A or granzyme B. Extrinsic, 
intrinsic and granzyme-B-dependent pathways converge on the same execution 
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pathway involving caspase 3 and -7 [112], whereas the granzyme-A-dependent 
pathway results in the activation of a caspase-independent pathway [120]. 
 
The intrinsic signalling pathway of apoptosis is induced by an array of non-receptor 
mediated stimuli. These stimuli include negative signals such as the absence of 
some growth factors, hormones and cytokines, which result in the failure to 
suppress cell death signals, thus initiating apoptosis. Positive intrinsic pathway 
stimuli include radiation, toxins, viruses, hypoxia, free radicals and others [112]. In 
the intrinsic pathway of apoptosis, stimuli induce mitochondrial outer membrane 
permeabilisation, leading to the release of pro-apoptotic proteins (eg: cytochrome c), 
from the mitochondrial intermembrane space [121]. This process is tightly regulated 
by members of the B cell lymphoma 2 (BCL-2) protein family [122]. 
 
In the extrinsic pathway, transmembrane death receptor-mediated interactions 
(FasL/FasR, TNF-α/TNFR1, Apo2L/DR4/5 Apo3L/DR3) transmit pro-apoptotic 
signals from the cell surface to the intracellular signalling pathways [112]. These 
receptor/ligand reactions recruit adaptor molecules such as FAS-associated death 
domain protein (FADD) which bind, dimerize to form the death-inducing signalling 
complex (DISC) which then activates caspase 8, before proceeding to the execution 
pathway [112, 123]. 
 
The perforin/granzyme pathway of apoptosis is used by cytotoxic T lymphocytes 
(CTLs) to remove tumor- or virus infected cells. CTLs secrete perforin which forms 
pores within the membrane of the target cell. Granzymes are then released through 
the pore and trigger apoptosis in the target cell. Granzyme B cleaves protein within 
the target cell and is the most potent activator of both caspase-mediated and –
independent apoptosis [124]. Granzyme A is unable to activate caspases, but 
induces single-stranded DNA breaks by cleaving nuclear proteins [125]. 
 
Extrinsic, intrinsic and granzyme-B-dependent pathways converge on the same 
execution pathway involving caspase 3, -6 and -7 as ‗executioner‘ caspases which 
activate endonucleases and proteases within the cytoplasm, causing the 
morphological and biochemical changes characteristic of apoptosis [112].  
 
Viral induction of apoptosis 
Viruses can induce apoptosis either directly to assist their own dissemination, or by 
unintentionally triggering the cellular defense mechanisms that initiate protective 
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programmed cell death [126]. The induction of apoptosis is an important host 
defense mechanism in virally infected cells. Apoptosis can eliminate potentially 
harmful cells via two major mechanisms; the first relies on the recognition of viral 
peptides and major histocompatibility complexes by CTLs, which then triggers 
apoptosis in the affected cell. The infected cell can also autonomously sense the 
abnormal activation of the cell cycle by viral proteins [127] and induce apoptosis 
itself. The induction of apoptosis in a virally infected cell can, in this way, have a 
negative effect on virus replication and, in response to this many viruses have 
evolved mechanisms of controlling the host‘s cell death pathways to suit its own 
needs [126].  
 
In some instances, the induction of apoptosis is beneficial to the infecting virus. 
Viruses may actively induce apoptosis at late stages of infection to facilitate 
dissemination of progeny viruses without initiating an inflammatory and immune 
response in the host [128]. Virus-induced apoptosis and the subsequent production 
of membrane-bound apoptotic bodies may play a key role in the egress of non-
enveloped, non-lytic progeny viruses from the infected cell, as well as their 
protection from neutralising antibodies [128, 129]. Several viruses have been 
reported to produce proteins which induce apoptosis in some way [130]. An example 
of this is the Hepatitis B protein, pX, which upregulates tumour necrosis factor (TNF) 
and Myc protein family members and sequesters p53, thereby facilitating the 
induction of apoptosis [131, 132].  
 
Apoptosis and Vaccines 
Virus induced apoptosis is an important consideration when determining the 
potential of a poxvirus for use as a vaccine vector. If apoptosis occurs too early in 
the life cycle of the virus, gene expression and antigen presentation will be reduced. 
Apoptosis is, however, desirable once the transgene of a recombinant vaccine has 
been expressed, as the formation of apoptotic bodies loaded with antigen and the 
uptake thereof via the alternative class I antigen presentation pathway (cross-
presentation) is important in the induction of an immune response [133]. The 
mechanisms of apoptosis and its effect on vaccine efficacy are not clearly 
understood. Both induction and delay/prevention of apoptosis in poxvirus vectors 





The ALVAC-based HIV-1 vaccine candidate, engineered to express anti-apoptotic 
PKR inhibitors E3L and K3L from VACV, has been shown to produce reduced levels 
of apoptosis and enhanced viral antigen production in human cells [134] and is 
therefore expected to induce enhanced immune responses to HIV antigen 
compared to the ALVAC-HIV vector without E3L and K3L. In contrast, it has been 
shown that immunogenicity of CNPV-based vectors is improved by the induction of 
apoptosis of infected dendritic cells, as a result of the subsequent stimulation of 
maturation of the surrounding dendritic cells [137]. 
 
It would be important to assess any novel vaccine vector candidates for the ability to 
induce or inhibit apoptosis in permissive and non-permissive cells. This is a potential 
avenue for the improvement of APV vectors, with the insertion of immunomodulatory 




Pyroptosis is an inflammatory process that is defined as caspase 1 dependent 
programmed cell death and is a more recently identified pathway of host cell death 
in response to pathological stimuli, including microbial infection [138]. Pyroptosis is 
mediated by caspases and was not initially distinguished from apoptosis [139-142]. 
However, several important differences distinguish the two processes [138, 143, 
144]. 
 
One of the main differences between pyroptosis and apoptosis is the mediation of 
cell death by caspase 1 for pyroptosis [138] and caspases 3, 6 and 8 for apoptosis 
[138, 141, 145]. In addition, mitochondrial integrity is maintained and cytochrome c 
is not released during pyroptosis as is the case for apoptosis [145, 146]. 
 
Mechanism of pyroptosis 
NLRs recognise cytosolic danger signals, triggering a signalling cascade resulting in 
inflammatory cytokine production [147] and/or caspase 1-activation [148]. The 
subset of caspase 1-activating NLRs (NALPs, NAIP and IPAF) often act together 
with TLRs, enhancing susceptibility to caspase 1 activation [138, 149].  
 
NLRs trigger the formation of an oligomeric complex termed the inflammasome 
[148]. The different inflammasomes are named after the NLR they comprise [150] 
and are assembled in a pathogen dependent manner [151]. The inflammasome is a 
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large, multi-protein complex assembled through protein interaction between the 
caspase recruitment -(CARD) and pyrin domains (PYD) of NLRs and the adaptor 
apoptosis-associated speck-like protein (ASC), forming a scaffold for pro-caspase 1 
recruitment and activation [150]. 
 
Activated caspase 1 then serves to mediate processes that facilitate pyroptotic cell 
death which involves rapid membrane rupture and subsequent release of the cell‘s 
proinflammatory contents [138]. Caspase 1 induces the formation of a membrane 
pore which leads to increased osmotic pressure, water influx, cellular swelling and 
subsequent osmotic lysis of the infected host cell [143]. In addition, DNA cleavage 
occurs by means of an unidentified caspase 1-activated nuclease, and does not 
produce the characteristic DNA ladder pattern formed during apoptosis [138, 143, 
152]. Accompanying nuclear condensation is observed but, unlike in apoptosis, 
nuclear integrity is maintained during pyroptosis [153]. 
 
Caspase 1 
Other than its involvement in pyroptosis, caspase 1 has several important functions 
including activation of the inflammatory cytokines, Interleukin-1 beta (IL-1β) and 
Interleukin-18 (IL-18), both of which are important in the response to infection and 
contribute to the inflammatory response elicited by pyroptotic cells [138, 154]. IL-1β 
affects a diverse range of innate immune functions including immune cell 
recruitment, tissue destruction, bone resorption and others [154]. IL-18 also has 
several roles including the induction of IFNγ and activation of T cells [154]. 
 
1.4.4 Poxviral immune evasion strategies 
 
Poxviruses encode a number of host range proteins (Table 1.3) which make use of 
diverse strategies to modulate several mediators of the host immune response 
[156]. Without the function of these proteins the virus is more vulnerable to the host 
immune system. This is demonstrated in the comparison of the two VACV-derived 
viruses, MVA and NYVAC. The respective arsenals of host range, 
immunomodulatory genes encoded by the two viruses are largely different, with 
MVA retaining several genes which target inflammatory responses and NYVAC 
retaining those which antagonize IFN responses [44, 67]. These differences are 
reflected in the host responses induced by the two viruses in vitro, with MVA 






































inflammatory response [87-89]. Furthermore, the removal of additional host range 
genes from MVA (VACV C6L and K7R) and NYVAC (VACV B8R and B19R) further 
increased their immunogenicity [157], [158]. Differences in immunomodulatory 
genes between VACV, MVA and NYVAC are depicted in Table 1.4 
 
Differences in the various proteins encoded by viral vectors, their expression levels 
and amino acid substitutions which may influence protein-protein interactions, may 
play a role in the innate immune activation and subsequent adaptive immunity 
against transgenes. Here we highlight several poxvirus strategies of immune 
evasion with specific emphasis on innate immunity. 
 
Poxvirus evasion of cell-mediated immunity 
Cell-mediated immunity is important for poxvirus clearance [159] and an effective 
response of this nature requires both innate and adaptive effector cells. Poxviruses 
have thus evolved mechanisms to reduce the cell-mediated immune response to 
infection including the down regulation of cell surface receptors involved in antigen 
presentation and immune cell recognition. MYXV has been shown to induce the 
down regulation of CD4 expression by an unknown mechanism [160]. Several 
poxviruses have been shown to decrease expression of major histocompatibility 
complex (MHC) class I, which are involved in antigen presentation to CD8+ CTLs 
[161, 162]. This may occur indirectly as a result of poxvirus inhibition of pro-
inflammatory cytokines (IFN, TNF) that regulate MHC expression or directly by the 
action of specific viral proteins, such as the MYXV M153R gene product [163]. 
Despite protecting from CTL-mediated killing of infected cells, MHC class I down 
regulation also reduces the MHC class I-dependent signal which prevents killing by 
natural killer (NK) cells [155]. Presumably to counteract this susceptibility to NK 
cells, some poxviruses encode decoy MHC class I molecules [164, 165].  
 
Poxvirus inhibition of inflammation, complement, cytokines and chemokines 
Following viral infection, an early inflammatory response is initiated to promote 
immune cell infiltration into the site of infection and to limit viral spread. Poxviruses 
have evolved several immune modulators which affect multiple aspects of the early 
anti-viral response networks, including complement factors, cytokines and 







Table 1.4 Immunomodulatory genes in vaccinia virus Copenhagen strain (VACV-C), 
modified vaccinia Ankara (MVA) and NYVAC. Deleted genes are represented as 
(deleted); disrupted or non-functional genes are in brackets. Table adapted from [70] 
 
VACV-C MVA NYVAC Function 
C23L/B29R (001L/193R) 
C23L/B29
R CC chemokine-binding protein 




008L (C12L) IL-18 binding protein and inhibits IL-18 induced IFN-γ production 
C10L 006L C10L IL-1 receptor antagonist (IL-1Ra) homologue. 
C7L 018L (deleted) Inhibits eIF2-α phosphorylation and apoptosis 
C3L (deleted) (deleted) complement 4b binding protein 
C2L (deleted) (deleted) Kelch-like protein 
N1L (020L) (deleted) 
Bcl2-like anti-apoptotic protein, contributes to virulence by inhibition 
of host NF-kappa-B activation in response to pro-inflammatory stimuli 
such as TNFαa or IL1β 
M2L (deleted) (deleted) Prevents phosphorylation of the ERK2 protein and subsequent NF-kB activation 
K1L (022L) (deleted) Prevents IκB degradation and so inhibits  NF-kB activation 
K3L 024L K3L decoy eIF2-α which acts as a pseudosubstrate for EIF2AK2/PKR kinase. 
F1L 029L F1L Protein with a BCL2-like fold, regulates mitochondria-mediated apoptosis 
F3L 031L F3L Kelch-like protein 
E3L 050L E3L Binds dsRNA 
H1L 091L H1L Viral phosphatase that reverses STAT1 activation 
H5R 095R H5R late transcription factor VLTF-4, phosphorylated by B1R kinase and mediates the inhibition of CD1d1-mediated antigen presentation 
A39R (150R/151R) A39R semaphorin 
A40R 152R A40R Type II integral membrane protein related to C-type lectins, including NK cell receptors. 
A41L 153L A41L May interact with several cellular chemokines 
A44L 157L A44L 3β-hidroxysteroid dehydrogenase 
A46R 159R A46R Targets TLR adaptors inhibiting both MyD88 and TRIF dependent pathways 
A52R (deleted) A52R Targets IRAK-2 and TRAF-6 to block the NFkB activation pathway by various TLRs 
A53R (deleted) (A53R) TNF receptor homologue 
A55R (deleted) A55R Kelch-like protein 
B1R 167R B1R Virus encoded kinase 
B7R 175R B7R Affects virus virulence 
B8R (176R) B8R IFN-γ binding protein 
B13R/B14R (181R/182R) (deleted) Serine protease inhibitor SPI-2 




184R (B16R) IL-1β binding protein 










Poxvirus evasion of complement 
Poxviruses encode proteins which modulate or inhibit various aspects of the 
complement system [166]. VACV encodes a secreted complement control protein 
(VCP) which inhibits both alternative and classical complement pathways by binding 
to C3b and C4b proteins [167]. Orthologs of VCP are present in CPV, monkeypox 
virus (MXPV) and VARV [168]. Poxviruses may also evade complement by retaining 
host regulators of complement, derived from the host cell membrane, on the EEV 
outer membrane [169]. 
 
Poxvirus evasion of Interferon 
The IFN response is an important innate anti-viral defence mechanism and 
poxviruses have developed several strategies to disrupt the IFN response at 
different levels. Poxviruses limit IFN production by decreasing the amount of double-
stranded RNA (dsRNA) produced during early infection and by encoding proteins 
that sequester dsRNA species. Poxvirus ORFs and transcriptional termination 
signals are arranged in such a way as to minimize dsRNA production [170]. VACV 
gene, E3L encodes a dsRNA-binding protein which inhibits host sensing of dsRNA 
and the function of IFN-induced anti-virus proteins that require dsRNA binding for 
activation [170]. 
 
Many poxviruses encode IFN-γ-receptor homologs which function as competitive 
antagonists of IFN-γ [170]. OPV encoded IFN-γ-R homologs bind cross-species 
IFN-γ whereas MYXV IFN-γ-R, M-T7, binds and inhibits only rabbit IFN-γ [155]. In 
addition, VACV and other OPVs encode an IFN-α/β receptor (VACV WR B18R) 
which binds type I IFNs and prevents their function [171, 172]. 
 
As well as decreasing IFN induction and blocking IFN interaction with cellular 
receptors, poxviruses encode intracellular inhibitors of IFN-induced antiviral 
proteins. Examples of these are the products of VACV genes E3L and K3L [170]. 
E3L has been shown to block the activity of IFN-induced and dsRNA-activated 
protein kinase R (PKR) [173]. K3L functions as a decoy of eIF2α, inhibiting 
phosphorylation of eIF2α and reducing the activation of PKR [174]. E3L and K3L 
orthologs have been identified in VARV [175] and an E3L-like gene has been found 
in the parapoxvirus, orf [176].  
 
FWPV is resistant to chicken IFN in chick embryo fibroblasts (CEFs) and FWPV was 
found to be a poor and late inducer of IFN [177]. Two FWPV ankyrin repeat family 
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genes have been shown to inhibit chicken Type I IFN: fpv012 blocks the induction of 
chicken beta IFN whereas fpv014 confers resistance to chicken beta IFN itself [178, 
179]. These data identify anti-IFN functions of two members of the ankyrin repeat 
family of genes, which exist in multiple copies in APV and which have not been 
previously associated with inhibition of the IFN response [178, 179]. 
 
Poxvirus inhibition of chemokines and cytokines 
IL-18 induces IFN-γ and other cytokines and chemokines, regulates Th1/2 
responses, and can activate NK and cytotoxic T cells [180]. Poxviruses encode IL-
18 binding proteins (IL-18BP) which block IL-18 from binding its receptor, so 
inhibiting its function [155]. 
 
TNF is a pro-inflammatory cytokine that is produced by macrophages and activated 
T cells [181]. Poxviruses encode viral homologs of TNF receptors (TNFR) which 
bind TNF before cellular TNFR engagement can occur [182]. 
 
The Interleukin 1 (IL-1) family of pro-inflammatory cytokines control several aspects 
of the innate and early inflammatory response [183]. OPVs encode secreted IL-1β 
receptor decoys (VACV B15R and CXPV B14R) [184]. Furthermore, poxviruses 
disrupt IL-1 receptor signalling by producing proteins (VACV A46R and A52R) 
containing the Toll/IL-1 receptor (TIR) domain found in members of the IL-1/ TLRs 
superfamily of receptors which prevent intracellular IL-1R signalling [185]. 
 
The cytokine Interleukin-10 (IL-10) has both immunostimulatory and 
immunosuppressive functions [186]. Putative orthologues of IL-10 are found in Orf 
virus, bovine papular stomatitis virus (BPSV) [9], lumpy skin disease virus (LSDV) 
[187], yaba-Like disease virus (YLDV) [188] and CNPV [24]. The Orf virus IL-10 
orthologue has been shown to be immunomodulatory in function [189, 190].  
 
Many poxviruses, including members of the leporipoxvirus and OPV genera encode 
high affinity cc-chemokine binding proteins, which prevent cc-chemokine binding to 
their G protein–coupled receptors (GPCRs) [191]. In addition, molluscum 
contagiosum (MCV) virus gene MC148 encodes an antagonist of cc-chemokine 
receptor 8 (CCR8) that is expressed by Th2 cells to downregulate Th2-cell mediated 
immune responses [192]. 
Most poxviruses encode homologs of cellular growth factors [155]. Epidermal growth 
factor (EGF) regulates cell differentiation and proliferation by binding to ErbB 
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receptors [193]. Pox EGF homologs, such as VACV growth factor (VGF), are 
expressed early to induce proliferation of infected and uninfected cells [155, 194]. 
The Orf virus encodes a vascular endothelial growth factor (VEGF) homolog which 
functions to stimulate cell proliferation and angiogenesis [195]. The VEGF homolog 
plays an important role in Orf virus infection promoting a distinctive pattern of 
epidermal proliferation and the formation of Orf virus-containing scabs which may 
contribute to virus transmission [196]. 
 
Poxvirus inhibition of cell death 
The induction of early apoptosis by the host in response to viral infection would have 
a detrimental effect on virus replication and production and therefore most viruses 
have evolved strategies to evade or postpone apoptosis (summarised in Figure 1.4). 
During their evolution, viruses have acquired genes from hosts or co-infecting 
pathogens, proteins that interfere with different aspects of the host‘s apoptotic 
signalling pathways.  
 
Caspases play a key role in the apoptosis process, and viruses have developed 
several ways of interfering with their activity. In CPV, the serine protease inhibitor, 
cytokine response modifier A (CrmA), is a specific inhibitor of caspases [197] and 
inhibits apoptosis induced in response to Fas ligand interactions, TNF-α and CTLs 
[198-200]. CrmA was first established as an inhibitor of caspase 1 [201], but can 
also inhibit CTL-induced granzyme B as well as caspase 8 and 10 [202]. The CrmA 
homolog, VACV B13R (SPI-2), inhibits apoptosis in a similar way but is generally 
less potent than CPV CrmA [203]. In addition to serpins, MCV inhibits caspase 8 
activation by producing two FLICE/caspase 8 inhibitory proteins (vFLIPs) (MC159, 
MC160) that bind to Fas-associated death domain (FADD) and pro-caspase 8 and 
inhibit apoptotic signals [204]. 
 
The conserved family of pro- and anti-apoptotic Bcl-2 proteins are responsible for 
the regulation of apoptosis at the mitochondrion [205]. Several viruses encode Bcl-2 
homologs which inhibit the progression of apoptosis by inhibiting the release of 
cytochrome c at the mitochondria [206]. FWPV encodes a Bcl-2 homologue (fpv039) 
that neutralizes the pro-apoptotic Bcl-2 family member, Bak [207].  
 
In addition to Bcl-2, some poxviruses encode proteins that localize to the 
mitochondrion and inhibit apoptosis, but are not homologous to Bcl-2 proteins. 
VACV encodes a gene, F1L, which lacks homology to Bcl-2 but inhibits apoptosis at 
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the mitochondria by constitutively interacting with Bak [208, 209]. Similarly, Myxoma 
virus encodes the gene, M11L, which interacts with Bak to inhibit apoptosis 
[210][211]. Orthologues of F1L are found only in other OPV, and M11L orthologues 
in leporipoxviruses, capripoxviruses, suipoxviruses and yatapoxviruses [207].  
 
Oxidative stress induced by viral infection can cause apoptosis, and can be 
produced by macrophages or neutrophils. MCV gene MC066L encodes a 
selenocysteine which functions as a glutathione peroxidase, reducing ROS in 
infected tissue and preventing apoptosis [212]. APVs, FWPV and CNPV, encode 
glutathione peroxidase homologs (fpv064 and cnpv087) [24, 25] which may have a 
similar function.  
 
 
Figure 1.4 Poxvirus modulation of apoptosis. Figure adapted from Taylor et al, 2006, Everett et al. 2002 and 
Turner et al. 1998 [219-221]. A summary of the known poxvirus strategies to counteract apoptosis. (MYXV = 




1.5 Project rationale and aims  
 
There is a need for the discovery of novel vaccine vectors for many different 
antigens. Repeated use of the same vector for vaccination against different 
diseases can be limited by the induction of anti-vector immunity, which in some 
cases may diminish the response to the foreign gene being expressed [213-217]. 
Vaccination strategies against most HIV-1, have shifted towards the use of prime-
boost regimens, often with the use of heterologous vaccine platforms [60, 218, 219]. 
For HIV, it is anticipated that even a successful vaccine will require multiple boosts 
throughout an individual‘s life to maintain effective immunity, and it may be 
necessary for these booster vaccines to express different HIV-1 antigen genes. 
There is thus an important requirement for novel vaccine vectors. APVs make 
attractive candidates for use in this regard, as these viruses are highly divergent and 
limited cross-protection occurs between isolates from different clades and sub-
clades [220-222]. 
 
None of the APVs isolated in Africa have been developed as vaccine vectors. APVs 
can be important pathogens of birds and to date very little work has been done on 
any aspect of these viruses in Africa. APVs can be used as vaccine vectors for 
birds, mammals and humans alike. Considerable success has been demonstrated 
using the canarypox virus ALVAC as a vaccine vector [47, 60, 75, 76]. However 
there is room for improvement of the APV vaccine vectors and it is possible that 
novel APVs may make better vaccine vectors for certain diseases than the 
established ones being used, namely FWPV and CNPV.  
 
We hypothesise that there are novel South African APVs that could be developed as 
vaccine vectors.  
Aim 1: The preliminary characterization and epidemiology of 8 novel South 
African Avipoxviruses to select one isolate for more in depth analysis. 
a. Growth and histopathological characterisation of 8 South African 
avipoxviruses on chick CAMs. 
b. Phylogenetic analysis of these avipoxviruses using genetic loci 
corresponding to fpv 26 (VLTF-1), fpv167 (P4b), fpv140 (H3L) and fpv175-




Aim 2: Further characterization of a selected virus to assess its suitability for 
use as a potential vaccine vector. 
a. Analysis of the growth and morphogenesis of the selected avipoxvirus in 
permissive and non-permissive cells. 
b. Analysis of apoptosis induced/inhibited by selected avipoxviruses. 
 
 Aim 3:  Whole genome sequence analysis of a South African avipoxvirus. 
 Extraction and purification of DNA from the selected avipoxvirus. 
 Sequencing of the selected avipoxvirus genome.  
 Annotation of both the nucleic acid and putative amino acid avipoxvirus 
sequences and comparison with published avipoxvirus sequences (FPVUS, 
CNPV-ATCC, FP9). 
Aim 4: Assessment of early host responses induced by different poxviruses in 
mice by transcriptomic profiling.  
 Extraction of total (viral and cellular) RNA from infected and mock-infected 
mouse spleens and microarray analysis of this RNA. 
 Analysis of gene profiling data and comparison of the responses induced by 
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The aim of this study was to characterise some of the APV isolates circulating in 
South Africa. This will allow us to select one isolate for more in depth analysis. 
Relatively little information is available regarding the APV strains circulating in South 
African (SA) birds. APV infection of an African Penguin (Spheniscus demersus) [20, 
71], a Flamingo (Phoenicopterus minor) [223], Ostriches (Struthio camelus australis) 
[224], Cape Turtle Doves (Streptopelia capicola) [225] and a Cape Thrush (Turdus 
olivaceus) [225] have been described.  
 
Poxviruses can be grown on the nutrient rich CAMs of embryonated hens‘ eggs [71, 
226, 227] which provide ideal conditions for high titre viral growth. Poxvirus growth 
on CAMs produce raised, circular lesions, or ―pocks‖ with variable morphology 
dependent on several factors, including the strain of infecting virus and conditions of 
growth. Most work describing the differences in poxvirus growth characteristics has 
been done on OPV [228-232]. However, Manarolla et al. (2010) [19] have described 
differences in gross lesions, membrane thickening and histopathology of 15 APV 
from Northern Italy and a recent study in Egypt described the gross pock 
morphologies of 7 APV isolates [233]. Case reports have also described the growth 
characteristics of individual APV isolates [234-237]. It has been shown that different 
phenotypes or growth characteristics may influence the immune response in the 
CAM tissue [231, 238].  
 
A thorough comparison of the macroscopic and histopathological growth 
characteristics in the CAM model will help to differentiate between several closely 
related APVs, which, according to phylogenetic analysis of conserved genetic 
regions, are indistinguishable. In addition, the comparison of the immune cell 
infiltration and inflammation in the CAMs infected by different viruses may provide a 
means of predicting which viruses would induce better immune responses in other in 
vivo models and will help to inform the choice of one or more APVs for further 
characterisation as a potential vaccine vector. 
 
APV phylogenetic studies have previously been based on the genes corresponding 
to VACV P4b (fpv167, VACV A3L) [18-21], virion envelope protein p35 (fpv140, 
VACV H3L [18-20] and VLTF-1 (VACV G8R; fpv126 locus) [20] (See chapter 1, 
section 1.2.1). APVs cluster into 3 major clades, A (Fowlpox (FWPV)-like), B 
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(Canarypox (CNPV)-like) and C (Psittacine). Clades A and B can be further divided 
into 10 minor clades, namely A1-A7 and B1-B3 [23].  
 
Members of the Columbidae family, consisting of pigeons and doves are susceptible 
to APV infection and cases have been reported in several Columbiform species 
including the Mourning Dove [239], Laughing Dove [240], White-tailed Laurel Pigeon 
[241], Rock Pigeon [18] and others [242]. Poxvirus infection of Columbiformes 
causes up to 90% morbidity, however mortality is usually limited [243]. Due to the 
host species based approach to APV taxonomy poxviruses infecting the 
Columbiformes are designated as pigeonpox viruses. Phylogenetic analysis has 
indicated that different ―pigeonpox‖ viruses group independently and pigeonpox 
virus isolates have been shown to group in clade A (subclade A2 according to 
analysis of the P4b gene [18, 244], or subclade A3 according to the H3L gene [18, 
233, 244]) as well as in clade B, subclades B1 and B2 [18, 19, 245]. The 
Columbiformes are therefore susceptible to several different strains of APV and the 
species designation ―pigeonpox‖ does not account for this variation. 
 
In this study, 8 novel SA APVs have been isolated from pigeons and doves 
(members of the family Columbidae, order Columbiformes) from different locations 
in SA (Table 2.1). These isolates were characterised and compared to FWPV and 
CNPV (Table 2.1) in terms of their growth on CAMs. This is a comparative study of 
the macroscopic and histopathological characteristics of 11 APV isolates and is the 
first of its kind in sub-Saharan Africa. To determine the divergence of the APVs, 
phylogenetic analysis has been performed based on the 3 previously published loci 
corresponding to fpv167 (P4b), fpv 26 (VLTF-1) and fpv140 (H3L), as well as an 
additional locus corresponding to fpv175-176 (VACV A11R-A12L) [246]. FWPV 
ORFs 175-176 are orthologs of conserved VACV A11R and A12L, which encode a 
non-structural protein involved in virion formation [247] and a 25kDa core protein 
involved in multiple stages of morphogenesis [248], respectively. 
 
This is the first investigation on what species of APV are circulating in SA birds. 
Furthermore, the comparison of the growth and morphology of different SA APV will 
be the first to thoroughly compare the macroscopic, microscopic and 
histopathological characteristics of several isolates simultaneously. This data will 





2.2 Materials and methods 
2.2.1 Virus isolates 
 
Avipoxviruses were isolated from lesions on infected birds obtained from various 
sources in South Africa (Table 2.1). Small sections of approximately 2mm2 were 
aseptically separated using sterile surgical blades, homogenized in phosphate 
buffered saline (PBS) containing penicillin, streptomycin and fungin (PSF) (appendix 
1) using a Tenbrook grinder and centrifuged at 14000rpm (Eppendorf Centrifuge 
5417C) for 5 minutes. The supernatant fluid, containing virus, was collected and 
used for growth on CAMs of 10-11 day old fertilized hens‘ eggs. 
 
Wild-type CNPV was obtained from Prof. K. Dumbell‘s collection housed at the 
University of Cape Town and was originally from Prof. A. Mayr (Veterinary Faculty, 
University of Munich, Munich, Germany). The FWPV vaccine is DCEP 25 modified 
strain (Sanofi Merial, Duluth, GA, USA) obtained from a licensed veterinarian. 
 
 
Table 2.1. List of avipoxvirus isolates used in this study. 
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2.2.2 Virus growth and titration on CAMs 
 
Virus isolates were grown and titrated on the CAMs of two species of embryonated 
10-11 day old chicken eggs using a method described by Joklik (1962) [227], 
Stannard, et al. (1998) [71] and Kotwal & Abrahams (2004) [226]. Specific 
pathogen–free (SPF) White Leghorn eggs were obtained from Avifarms (Pty) Ltd 
(Lyttelton, South Africa) and healthy Cobb Avian 48 eggs were obtained from a 
commercial company; health status of the layers was checked by an experienced 
veterinarian.  
 
The eggs were swabbed with 70% ethanol and candled to locate their air sac and 
blood vessels. Using an egg pricker, small holes were made both at the air sac and 
on the vascular dorsal region of each egg (Fig. 2.1). A drop of PBS + PSF (appendix 
1), was placed on the dorsal opening and a pipette bulb was used  to create a 
vacuum, producing a new air sac on the dorsal side of the egg (see figure). The 
eggs were inoculated with 100ul virus/egg, using a Tuberculin syringe, into the 
dorsal air sac, between the CAM and the shell before gentle rotation and incubation 
at 37°C for 4-5 days. The chicks were killed, either by placing at 4°C for >4hrs or by 
decapitation, and the CAMs were harvested. Membranes were rinsed in 
physiological saline and shaken in glass Universal bottles containing glass beads 
with 1ml McIlvains buffer + 20% Vertrel ® (1,1,1,2,3,4,4,5,5,5-decafluoropentane) 
(DuPont, Wilmington, DE, USA ) per membrane. Thereafter they were centrifuged 
(Sigma 1-15) at 800rpm for 10mins and the supernatant fluid was centrifuged at 
3000rpm for 30mins. The resulting supernatant fluid was transferred to a gas 
sterilized 50ml Oakridge style Nalgene ® tube (Sigma Aldrich, St. Louis, MO, USA) 
and a sucrose cushion consisting of a 36% Sucrose solution in TE buffer pH9 
(appendix 1) was added to the base of each tube. This was then centrifuged at 
11000rpm for 1hr at 4°C in a Sorvall RC5C Plus centrifuge and Sorvall S534 rotor. 
For further purification, the resulting resuspended viral pellet was centrifuged 
through a gradient of 36% sucrose and 10% Dextran (in TE buffer pH 9) at 
11000rpm for 1hr at 4°C and resuspended in TE buffer (pH 9). 
 
To titrate virus stocks, serial dilutions made in PBS + PSF (appendix 1), were 
inoculated onto CAMs in triplicate as described and incubated at 37°C for four days. 
Thereafter, the membranes were spread out on petri dishes and the average 
number of pocks per dilution was determined.  
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The pock forming units per millilitre (pfu/ml) was determined by the following 
equation: 
 








For histopathological analysis, each virus was inoculated onto the CAMs of three 
10-day-old commercial Cobb Avian 48 eggs at a constant titre of 103 pfu per egg 
and incubated for 5 days at 37°C before harvesting as above. A titre of 103 pfu per 
egg was chosen for analysis as it gave a good indication of virus growth differences 
on CAMs. Higher titres were seen to be pathogenic to the chicks, and lower titres 
did not produce confluent layers of viral growth on the membranes. Determination of 
gross pathology of the virally-infected CAMs was performed multiple times on 
different batches of eggs, and the growth characteristics of the respective viruses 
Figure 2.1. Diagrammatic representation of the anatomy of an embryonated hen’s egg.  
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did not differ. Harvested membranes were photographed and a representative 
membrane was chosen for histopathology analysis of each virus. The membranes 
were fixed in 10% buffered formalin (appendix 1). Infected portions of tissue with 
similar pock densities were chosen and cut for histopathology. These were rolled up 
to include multiple pocks on a large surface area, and embedded in paraffin. The 
samples were cut into 4 mm2 sections and stained with haematoxylin and eosin 
(HE) (courtesy of Dr Ross Millin and Ms Anna Marie Beukes, Pathcare). Slides were 
examined and photographed using a light microscope. Results were confirmed with 
a specialist avian pathologist, Dr Tertius Gous. 
 
2.2.4 PCR amplification and phylogenetic analysis 
 
Extraction of viral DNA for PCR 
Viral DNA was extracted from virus which had been subjected to one high-speed 
spin through a sucrose cushion. Proteinase K was added to the virus preparation at 
2mg/ml and incubated at 55°C for 30mins. An equal volume of lysis buffer (appendix 
1) was then added before further incubation at 55°C overnight. An equal volume of 
phenol:chloroform (1:1) was added and the mixture was inverted and centrifuged at 
14000rpm (Eppendorf Centrifuge 5417C) for 5mins. The aqueous phase was 
removed and incubated with RNAse (100ug/ml) at 37C for 1hr. Thereafter 
conventional phenol/chloroform extraction followed by sodium acetate and ethanol 
precipitation was performed [249]  
 
Polymerase Chain Reaction 
PCR was performed for the P4b and H3L loci using previously described primers 
[18]. For VLTF-1 and fpv175-176 (VACV A11R-A12L), the following primers were 
used to amplify 700bp products for both regions: 
 
VLTF-1 Forward Primer: 5‘-TAAATGAGTTTGCGTATAAAAATCGATAAG-3‘ 
VLTF-1 Reverse Primer: 5‘-TTCAGCATCCATAACTATCTTTGACTC-3‘ 
fpv175-176 Forward Primer: 5'-GGTACCGTATATTTCTATAAAACAATATCAC-3' 
fpv175-176 Reverse Primer: 5'-ACTAGTGCTAAATCATATTAATGCTATTACGG-3' 
 
A 2x PCR reaction mix, Immomix™ (Bioline, Taunton USA) was used according to 
manufacturer‘s instructions and PCR thermocycling was performed in a GeneAmp® 
PCR system (Applied Biosystems, Carlsbad USA). Amplicons were purified using a 
commercial kit (Zymo research DNA clean and concentrate™-25, Irvine USA), and 
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sequenced using the BigDye Teminator V3.1 sequencing kit (Applied Biosystems, 
Carlsbad USA) using an ABI3130xl sequencer (Applied Biosystems, Carlsbad USA) 
by the University of Stellenbosch Central Analytical Facility.  
 
Sequence and phylogenetic analysis 
Sequence analysis was performed using CLC Bio Main Workbench software and 
MEGA5 [250]. Appropriate models for each data set were tested using MEGA5 and 
Maximum Likelihood trees were constructed based on MUSCLE nucleotide 
alignments of P4b, VLTF-1, H3l, and fpv175-176. Maximum likelihood (ML) trees 
were constructed using the Tamura 3-parameter model with gamma distrubution 





2.3.1 Gross pathological and histopathological characterisation of 
avipoxviruses in South Africa 
 
Nine out of the 10 APV isolates (Table 2.1) were analysed in terms of their growth 
and histopathology on CAMs. SP1 (Speckled Pigeon) caused no visible pocks on 
CAMs and was excluded. 
 
The 9 APV isolates could be divided into five groups based on pock and CAM 
morphology (Table 2.2). CNPV (Canary) caused no obvious membrane thickening 
and resulted in small, yellow pocks (Fig 2.2). FWPV caused haemmorhagic pocks, 
RP2 (Rock Pigeon), LD2 (Laughing Dove) and Pi5 (Racing Pigeon) caused slight 
thickening of the CAM (Fig. 2.2). RP2 and Pi5 presented white pocks which were 
variable in size with some pocks having slightly hemorrhagic centres (Fig. 2.2). 
FeP2 (Feral Pigeon) and LD1 (Laughing Dove) caused a substantial amount of 
membrane thickening (Fig. 2.2). The pocks resulting from FeP2 and LD1 infection 
were white and variable in size. FeP1 (Feral Pigeon) and RP1 (Rock Pigeon) 
caused such extreme membrane thickening that individual pocks were not visible 
(Fig. 2.2). 
 
Histopathology of these virally-infected CAMs revealed significant differences (Fig. 
2.2 and Table 2.2). Although viruses which caused severe macroscopic proliferation 
of the CAM were noted to have extensive mesodermal hyperplasia and less 
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epidermal hyperplasia (Fig. 2.2), a more detailed histological analysis showed all 
viruses to be different from one another (Table 2.2). 
 
All infected CAMs showed varying degrees of hyperplasia and hypertrophy of both 
epidermal and mesodermal cells. Infected tissue exhibited ballooning degeneration 
of keratinocytes, necrosis and large, eosinophilic, intra-cytoplasmic inclusions which 
are the Bollinger bodies described in poxvirus infections [30, 252] (Fig. 2.3). Varying 
degrees of heterophil and lymphocyte infiltration were most notably observed in the 
mesoderm and to a lesser degree in the epidermis of the infected membranes. The 
viruses FeP2 (Feral Pigeon), Pi5 (Racing Pigeon) and LD2 (Laughing Dove) 
exhibited pronounced immune infiltration and angiogenesis was seen in the 
mesoderm (Fig. 2.3). Hyperkeratosis and vacuolisation was noted in CAMs infected 
with RP1 (Table 2.3). Hyperplastic epithelial nests were noted in the mesoderm of 
FeP2 and FeP1 (Table 2.3). Angiogenesis and fibroplasia were observed to varying 
degrees in most isolates (Table 2.3). 
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Figure 2.2 Macroscopic and histological comparison of uninfected and infected chorioallantoic 
membranes of embryonated chicken eggs. 103 pfu of each virus were inoculated onto the CAMs of 10-11 
day old embryonated hens‘ eggs. Differences in pock morphology and degree of inflammation of the CAM 
tissue were observed. Other observations have been tabulated in Table 3. Histology: 10x, H & E stain, Scale 
























2.3.2 The phylogenetic analysis of avipoxviruses in South Africa. 
 
Nucleotide and amino acid sequences corresponding to fpv 26 (VLTF-1), fpv167 
(P4b), fpv140 (H3L) and fpv175-176 (VACV A11R-A12L) were aligned with 
published sequences obtained from Genbank (See annotations for accession 
numbers) and phylogenetic relationships were determined based on these 
alignments. Because of the highly conserved nature of the genes analysed, 
nucleotide sequences rather than amino acid sequences were used to determine 
divergence [18, 20]. Clades and subclades have been named according to previous 
APV phylogenetic studies based on the P4b gene locus [18, 23] 
 
P4b (VACV A3L; fpv 167 locus).  
The P4b gene was amplified by PCR and gave the expected 578bp product for all 8 
of the SA APV isolates (data not shown). The ML tree based on nucleotide 
sequences at this locus (Fig. 2.4) clearly distinguishes between known APV clades 
and subclades. All 8 SA isolates analysed in this study group in clade A (FWPV-like 
viruses) with strong bootstrap support (Fig. 2.4). The isolates RP2 and FeP2 group 
in subclade A2 with a previously analysed SA APV, PEPV [20] and share 100% 
Figure 2.3 High magnification comparison of uninfected CAM and 
CAM infected with 103 pfu CNPV, FeP2 and RP1. Histology: 40x, H & E 
stain, Scale bar = 50µm 
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nucleotide identity with the rest of the subclade (Fig. 2.4). Pi5 has a single 
nucleotide mutation and branches off from this subclade (Fig. 2.4). SP1, RP1 and 
LD1 share 100% nucleotide identity, grouping together with an isolate from a South 
Korean Oriental Turtle Dove [23] and a Spanish Great Bustard [23], in a new branch 
of subclade A3, annotated here as subclade A3.1 (Fig. 2.4). FeP1 and LD2 both 
exhibit one synonymous mutation in these sequences and group in subclade A3.1 a 
(Fig. 2.4). 
 
H3L (VACV H3L; fpv140 locus).  
Amplification of this region produced positive results of 1100bp for all 8 SA viruses 
(data not shown). Upon sequencing, these products were trimmed to 718bp and 
aligned to the available published APV sequences at this locus. The ML tree based 
on the nucleotide sequence of H3L (fpv 140) locus (Fig. 2.5) groups RP2, Pi5 and 
FeP2 in subclade A3 (A3c) which differs from the grouping in the P4b ML tree. 
Analysis of H3L provides greater resolution of clade A viruses. According to 
phylogenetic analysis of the P4b gene locus these viruses group in subclade A2 with 
previously analysed SA isolate, PEPV [20]. The viruses RP1, FeP1, SP1, LD1 and 
LD2 also group in subclade A3 (A3b) and share 98.75% nucleotide identity with 
RP2, Pi5 and FeP2.  
 
VLTF-1 (VACV G8R; fpv126 locus).  
All 8 SA APV isolates produced the expected 700bp product upon PCR 
amplification. These products were sequenced in duplicate and truncated to 570bp 
for alignment with published VLTF-1 orthologues. The ML tree was constructed 
using the Tamura 3-parameter model [251] with gamma distribution and the rate 
variation model allowed for some sites to be evolutionarily invariable ([+I], 28.7650% 
sites). The ML tree based on the VLTF-1 nucleotide sequence alignment (Fig. 2.6) 
shows that SA isolates belong to the APV genus and group with FWPV, in a 
separate clade from CNPV. Similar to the H3L gene tree (Fig. 2.5), analysis of the 
VLTF-1 locus indicates that FeP1, LD1, LD2, RP1 and SP1 group together within 
subclade A3 (A3b) (Fig. 2.6) with 100% nucleotide identity and FeP2, RP2 and Pi5 
also group together with 100% nucleotide identity within subclade A3 (A3c). 
 
fpv 175-176 (VACV A11R-A12R).  
PCR of this region produced the expected 700bp product for all 8 analysed isolates. 
The tree based on the nucleotide sequences of this conserved region (Fig. 2.7) 
provided even further resolution of subclade A3c, grouping the viruses Pi5 and FeP2 
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(A3c (2)) separately from RP2 (A3c (1)) with strong bootstrap support. At the VLTF 
locus, these 3 viruses shared 100% nucleotide identity, and in the P4b gene Pi5 had 





This study compares the gross pathological and histopathological characteristics of 
CAMs infected with 9 different APV isolates. Studies describing gross pathology and 
histology of different APVs in CAMs have been done elsewhere, including Italy [19] 
and Egypt [233]. This is the first comparison of the growth characteristics of different 
APVs isolated from different bird species in South Africa. Different APV were grown 
using the same method and each virus stock was titrated so that a constant amount 
of virus was inoculated onto each CAM. This allowed for accurate comparisons of 
growth characteristics between viruses isolated from different bird species and 
geographical regions. 
 
Manarolla et al. (2010) reported variable levels of thickening, ranging from mild to 
severe, in CAMs infected with APV isolates from Italy [19]. In an Egyptian study, 
isolates from chickens and a turkey produced compact, grayish-white pocks and 
marked thickening of the infected CAM tissue [233]. In this same study, a PGPV 
isolate produced nodular yellowish pocks and moderate thickening of the CAM 
tissue [233]. SA APV isolates also exhibited differing pock morphologies and 
degrees of membrane thickening (Tables 2.2 and 2.3). 
 
Interestingly, all viruses isolated from pigeons (RP2, Pi5, FeP2) produced white 
pocks of variable size except for those isolates where the membrane thickening was 
so severe that no individual pocks were visible  (FeP1, RP1). At lower titres (102, 101 
PFU/egg) where membrane thickening was reduced, these viruses produced distinct 
white pocks (not shown). This pock morphology in SA pigeonpox virus isolates was 
different from the yellowish nodular pocks seen in CAMs infected with an Egyptian 




Figure 2.4 Maximum Likelihood tree based on the MUSCLE nucleotide alignments of P4b (fpv 
167, VACV A3L). Novel South African isolates (SP1, RP2, LD2, Pi5, FeP2, LD1, FeP1 and RP1) 
(marked with asterisks; see Table 1 for abbreviations) were aligned to published sequences from 
Genbank (See annotated accession numbers). This ML tree was constructed using the Tamura 3-







Figure 2.6 Maximum Likelihood trees based on the MUSCLE nucleotide alignment of the 
VLTF-1 gene (fpv126, VACV G8R). Novel South African isolates (SP1, RP2, LD2, Pi5, FeP2, 
LD1, FeP1 and RP1) (marked with asterisks; see Table 1 for abbreviations) were aligned to 
published sequences from Genbank (See annotated accession numbers). This ML tree was 
constructed using the Tamura 3-parameter model model with gamma distrubution, and a 
bootstrap test of 100 replicate samples. 
Figure 2.5 Maximum Likelihood tree based on the MUSCLE nucleotide alignment of the 
region corresponding to the p35 gene locus (fpv140, VACV H3L). Novel South African 
isolates (SP1, RP2, LD2, Pi5, FeP2, LD1, FeP1 and RP1) (marked with asterisks; see Table 1 
for abbreviations) were aligned to published sequences from Genbank (See annotated 
accession numbers). This ML tree was constructed using the Tamura 3-parameter model with 















While few studies have compared APV growth characteristics on CAMs, there have 
been many reports which describe differences in growth characteristics of the OPV 
[228-232]. Factors that influence poxvirus growth on CAMs include incubation 
temperature [232], age of embryos and the source of eggs [253]. Variability in pock 
colour has also been ascribed to mutation of specific viral genes [228, 229].  
 
The FWPV vaccine strain (DCEP 25 modified strain (Merial)) produced red pocks 
with signs of haemorrhage (Fig. 2.3). Histology revealed that the FWPV-infected 
membranes showed signs of extensive angiogenesis and large blood vessels full of 
red blood cells. This is not dissimilar to the red pock phenotype induced by CPV. 
Unlike the pock phenotype of most other OPV, wild type CPV produces hemorrhagic 
red pocks on CAMs. However, CPV can produce spontaneous white-pock variants 
resulting from the deletion or mutation of a specific gene encoding the serine 
proteinase inhibitor (serpin), CrmA (SPI-2) protein [228, 229]. On histological 
examination, the CPV red pock is shown to lack inflammatory cells and have 
increased virus antigen and infectivity levels [238]. The CPV white pock phenotype 
is characterised by the presence of large numbers of heterophils and macrophages 
[231, 238] and produces extensive thickening of CAM tissue caused by proliferation 
of the epidermal and mesodermal cells [254]. Therefore, different phenotypes or 
growth characteristics may be indicative of different levels of immune responses in 
the CAM tissue [231, 238], caused by genetic make-up of the virus. It is unknown 
why this vaccine strain of FWPV produces such haemorrhagic pocks compared to 
Figure 2.7 Maximum Likelihood tree based on the MUSCLE nucleotide alignment of 
the region corresponding to the locus, fpv 175-176 (VACV A11R-A12L). Novel South 
African isolates (SP1, RP2, LD2, Pi5, FeP2, LD1, FeP1 and RP1) (marked with asterisks; 
see Table 1 for abbreviations) were aligned to published sequences from Genbank (See 
annotated accession numbers). This ML tree was constructed using the Tamura 3-
parameter mode with gamma distrubution, and a bootstrap test of 100 replicate samples. 
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the other APV isolates. FWPV encodes 5 serpin homologues (fpv010, fpv040, 
fpv044, fpv204 and fpv251) and 2 homologues of cellular β-nerve growth factor (β-
NGF) (fpv072, fpv076), which, when expressed by the virus, may interfere with early 
innate immune responses and may be important for viral infection [25]. It could be 
speculated that one or more of these serpin genes may be responsible for the red 
pock phenotype observed in FWPV-infected CAMs. 
 
Several genes over and above the serpins have been associated with differences in 
phenotype of different poxviruses. VACV C22L codes for a tumor necrosis factor 
receptor (TNF-R) homologue which inhibits inflammation [255, 256]. FWPV encodes 
a gene similar to IL-18-binding protein (fpv073), which may inhibit inflammation [25]. 
It is possible that the viruses which do not cause significant inflammation (CAM 
thickening), such as CNPV (Canary), LD2 (Laughing Dove), Pi5 (Racing Pigeon) 
and RP2 (Rock Pigeon), may contain one or more of these anti-inflammatory genes 
or novel anti-inflammatory genes which may be responsible for their phenotype on 
CAMs. Whole genome sequencing and gene function analysis will be necessary to 
determine the cause of the different growth phenotypes of these viruses. 
 
Differences in virus-induced responses in the CAMs, such as membrane thickening, 
immune cell infiltration, angiogenesis and hyperplasia, were observed in this study 
and one can only speculate why these differences exist. In the CAM model, 
administration of transforming growth factor β1 (TGF-β1) initiates a response that is 
similar in appearance to the CAM tissue infected by the isolates that caused 
extensive inflammation, namely FeP1 (Feral Pigeon), RP1 (Rock Pigeon), FeP2 
(Feral Pigeon) and LD1 (Laughing Dove) [257]. 
 
TGF-β1 has proinflammatory properties and can inhibit growth, increase cellular 
accumulation through chemotaxis or cellular migration and increase microvascular 
angiogenesis. It is important in wound healing, tumour progression and 
embryogenesis [257, 258]. The isolates mentioned above caused epithelial and 
mesodermal thickening due to cellular hypertrophy and hyperplasia, angiogenesis, 
sloughing and infiltration of mononuclear immune cells which is similar to the 
appearance of CAM tissue that has been treated with TGF-β1 [257].  
 
FWPV (fpv080) encodes a homologue of the eukaryotic TGF-β which is thought to 
be involved in suppression of the host immune response and/or cell growth and 
63 
 
differentation [25]. It is possible that the viruses that cause inflammation (FeP1, 
RP1) could encode functional homologues of a TGF-like protein.  
 
The proliferative diseases caused by several poxviruses, including MCV have been 
attributed to the production of epidermal growth factor – like (EGF-like) proteins by 
virally infected cells [259, 260]. Poxvirus EGF-like growth factors have been shown 
to stimulate cell proliferation at regions of viral replication [261]. FWPV (fpv211) also 
encodes an EGF-like domain [25] which may contribute to the hyperplasia observed 
in FWPV-infected tissue [262]. FWPV does not produce extensive membrane 
thickening; however, hyperplasia is observed when compared to uninfected CAM 
tissue. The viruses causing inflammation (FeP1, RP1, FeP2, LD1), may contain 
additional growth factor-like genes, which may cause the increased inflammation 
observed in the CAMs infected with these viruses.  
 
Although the phylogenetic analysis of 4 conserved regions suggests that these 
viruses are closely related to one another, the variation in pock morphology and 
histology amongst these viruses indicates that many of our novel APVs differ 
significantly. For example, phenotypically, Pi5 (Racing Pigeon) and FeP2 (Feral 
Pigeon) differ considerably, with FeP2 causing more hyperplasia and membrane 
thickening than Pi5. Phylogenetically, however, they group together in subclade A3c 
(according to the VLTF-1, H3L and fpv175-176 loci). In addition, the isolates LD2 
(Laughing Dove) and FeP1 (Feral pigeon), which were both obtained from the same 
geographical region (Port Elizabeth (PE)) differ with regard to their pock morphology 
and histology but cluster together in the subclade A3b. The differences in resolution 
between the trees constructed based on these four loci, suggest that the viruses 
may vary at different genomic regions, and that phylogenetic analysis based on a 
few highly conserved genes may not be sufficient to determine divergence amongst 
the APVs. This has also been observed in the two different FWPV strains that have 
been sequenced. FPVUS and FP9 both group in clade A2, and yet analysis of the 
genome sequences of FP9 and FPVUS revealed 118 mutations, affecting 71 ORFs 
[27]. More detailed analyses, in the form of genomic sequencing, microarray 
analysis to reveal dysregulation of host immunomodulatory proteins and pathway 
analysis, will help to explain why these differences exist. 
 
It is important to note that the viruses in this study were isolated from discrete 
geographical locations, up to nearly 1000kms apart (Cape Town (CT) to Port 
Elizabeth (PE) - 790kms). This geographical separation does not, however, coincide 
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with clustering of the viruses according to the phylogenetic trees, with isolates from 
the same region grouping separately. Although FeP1 and LD2, both from PE, group 
together in subclade A3b, FeP2, from the same region in PE, groups in subclade 
A3c (according to the ML trees constructed based on the H3L, VLTF-1 and fpv175-
176 loci). All three viruses from PE differ with respect to CAM morphology. 
Moreover, several viruses from different regions cluster together phylogenetically. 
This is seen in RP1, isolated from a Rock Pigeon in Table View, CT, which clusters 
together in subclade A3b with FeP1 (Feral Pigeon) and LD2 (Laughing Dove) 
isolated in PE. Pi5 (Racing Pigeon) and FeP2 (Feral Pigeon) also cluster together in 
subclade A3c, and were isolated from Grabouw in the Western Cape, and PE in the 
Eastern Cape respectively. The A3b and A3c viruses differ with respect to pock and 
CAM morphology.  
 
In a similar study conducted in New Zealand (NZ), where APV infection is known to 
be endemic in free-ranging bird populations, it was shown that most NZ APV 
isolates, including those isolated from a Song Thrush (Turdus philomelos), 
Saddlebacks (Philesturnus carunculatus rufusater) (Philesturnus carunculatus 
carunculatus), Sparrow (Passer domesticus), Black Robin (Petroica traversi), 
Silvereye (Zosterops lateralis), Shore Plovers (Thinornis novaeseelandiae), Variable 
Oyster Catchers (Haematopus unicolor) and a Paradise Shelduck (Tadorna 
variegate), belong to subclade A1, sharing 100% nucleotide identity to the FWPV 
vaccine strain used in NZ [263]. This suggests that several NZ free-ranging birds are 
susceptible to the specific A1 strain used as an attenuated fowlpox vaccine. Certain 
NZ samples grouped in subclades A3 and B1 [263]. APVs isolated from SA birds all 
group within Clade A (FWPV-like viruses), in either subclades A2 or A3. Although 
we know that FWPV exists in A poultry, none of the viruses analysed in our study 
were identical to SA FWPV or FWPV vaccine strains used in SA (Clade A1) (data 
not shown).  
 
Based on the phylogenetic analysis of four conserved regions, the viruses 
characterised from SA columbiformes cluster into two groups. The viruses from 
Feral Pigeon (FeP2), Rock Pigeon (RP2) and Racing Pigeon (Pi5) group in 
subclade A3c and the viruses from a Rock Pigeon (RP1), two from Laughing Doves 
(LD1, LD2), a Feral Pigeon (FeP1), and a Juvenile Rock Pigeon (SP1) group in 
subclade A3b. Therefore, in this study as well as others [18, 19, 263] APVs from the 
same species of bird are classified in different subclades. Conversely, it has also 
been shown that the same viruses can infect different birds [233, 244, 264]. 
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Pigeonpox viruses (PGPVTP2, PGPVP, HM481409, HM481408) group in subclade 
A2 according to P4b [18, 244, 265] and based on the H3L gene, they group in 
subclade A3, along with isolates from an albatross, falcon and flamingo [18, 233, 
244]. Pigeonpox isolates grouping in subclades B1 and B2 [18, 19, 245] have also 
been noted.  
 
The complicated nature of the host-range of APVs has led to the suggestion that the 
taxonomy of these viruses should be changed. Jarmin et al. (2006) criticised the 
host species-based approach to APV taxonomy because different viral samples 
taken from a particular species can be found to group in different subclades or 
clades [18]. This was seen in our study where isolates from Feral Pigeons, FeP1 
and FeP2 grouped separately (subclade A3b and A3c respectively) and also differed 
considerably with regard to their growth characteristics. Similarly, this was also seen 
in viruses isolated from 2 Rock Pigeons, RP1 and RP2. Therefore, the results of this 
study, along with several others [18, 19, 233, 244], provide evidence that the 
existing host species-based classification may be oversimplified for the complicated 
host-range of APVs. 
 
Preliminary phylogenetic analysis and characterisation of the pathology of novel SA 
APVs on CAMs has been performed in this study. For the first time, information is 
available on which APVs are circulating in SA birds. According to the phylogenetic 
analyses presented here, the viruses circulating in SA birds group with FWPV-like 
viruses in clade A, subclades A2 and A3, and are shown to cluster into two groups 
which are seemingly independent of the species of bird from which they were 
isolated. Current convention is to name the virus after the species in which it was 
originally described; however, it is suggested that alterations to the existing 
taxonomy of APV be made, which take into account genetic diversity and the 
variability of virus-host interactions, growth characteristics and infectivity. Prior to 
this study, the genomes of only three APVs had been published; a pathogenic 
United States strain of fowlpox (FPVUS) [25], a plaque purified, tissue culture 
adapted, attenuated European strain of FWPV (FP9) [27] and a virulent CNPV 
(CNPVATCC VR-111) isolate [24]. FPVUS and FP9 group in clade A1 and 
CNPVATTC groups in clade B1. According to the genetic regions fpv 26 (VLTF-1), 
fpv167 (P4b), fpv140 (H3l) and fpv175-176 (VACV A11R-A12L), the novel APVs 
analysed in this study are grouped differently from the three APVs (FPVUS, FP9 
and CNPVATCC) which have been sequenced [24, 25, 27]. 
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As discussed in chapter 1, section 1.3.5, APVs make promising candidates for use 
as vaccine vectors. Considerable success has been demonstrated using the 
canarypoxvirus ALVAC as a vaccine vector [47, 60, 75, 76]. However there is room 
for improvement of the APV vaccine vectors and it is possible that novel APVs may 
make better vaccine vectors than the established ones being used, namely FWPV 
and CNPV, for specific diseases. Therefore, there is a need for the discovery of 
novel vectors and the development of improved vectors. In this study we show that 
although the phylogenetic analysis of highly conserved genetic regions indicates 
that the SA APVs are closely related to each other, variation in growth 
characteristics on CAMs suggests that many of our novel APVs differ significantly. 
From these results we have chosen one novel APV, FeP2, for further 
characterisation and determination of its potential for use as a vaccine vector 
candidate. This virus was chosen as a result of its interesting phenotype on CAMs 
and the fact that, phylogenetically, it grouped differently according to the different 
genetic regions analysed. Furthermore, this was the only one of our SA viruses 
which was able to grow in tissue culture (data not presented for all viruses, see 
section 3.3.1. for FeP2) Further characterisation in the form of growth kinetics, 
transmission electron microscopy and the induction or inhibition of apoptosis by this 
virus in different cell lines would provide valuable information regarding the in vitro 
behaviour of FeP2. More detailed analyses, in the form of genomic sequencing as 
well as pathway analysis/immunomodulation by microarray, will allow for more 
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In comparison to the extensively studied Orthopoxvirus (OPV) genus, little is known 
about the morphogenesis and growth characteristics of APVs. APVs have a 
restricted host-range and are only able to productively replicate in permissive avian 
species. However, APVs can infect non-avian hosts and are generally accepted to 
undergo abortive replication in mammalian cells [45, 46, 71]. Limited exceptions 
have been reported and replication of APVs in some mammalian cells, such as 
embryonic bovine tracheal cells [266] and baby hamster kidney cells have been 
reported [267].  
 
APVs are commonly grown in primary chick embryo fibroblasts (CEFs). However 
growth in other cell lines, such as the Japanese quail cell line, QT-35 [268, 269] has 
been reported, although the presence of endogenous herpes virus and Marek‘s 
disease virus (MDV) in these cells limits their use for vaccine preparation [270]. CEF 
cells have been shown to be permissive for CNPV and FWPV [271]. Penguinpox 
virus (PEPV) does not produce infectious progeny in CEF cells, although progeny 
virions were apparently morphologically complete following one cycle of infection 
[71]. No permissive avian cell line for PEPV has been identified [71]. 
 
In permissive cells, APVs follow a similar process of morphogenesis as other 
poxviruses (described in detail in section 1.1.3) [272, 273]. However, in contrast to 
the OPVs which exit the infected cell via exocytosis of the IEV [274], APV MV 
preferentially bud out of membranes. Exocytosis can also occur [273]. In non-
permissive cells there is a block in the APV life cycle. For FWPV and PEPV this 
block occurs after the formation of IV [71, 275]; but for CNPV the block occurs prior 
to viral DNA replication [45]. 
 
FWPV is capable of infection of mammalian cells and expression of both early and 
late genes in fibroblast-like monkey cells (Vero, CV-1) and human MRC-5 cells. In 
these cells FWPV undergoes DNA replication and morphogenesis proceeds to the 
formation of immature particles, similar to that observed for MVA in human cells 
[275]. Notably, in the epithelial-like HeLa human cell line, barely any FWPV gene 
expression was observed [275]. Preliminary experiments on CNPV growth in Vero 
cells indicate that, in contrast to FWPV, CNPV-infection fails to produce any 
detectable expression of post-replicative genes [275]. Pacchioni et al (2010) also 
found that human cells are less permissive to APV replication compared to monkey 
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cells and that FWPV advances further than CNPV in its life cycle in monkey cells 
[271]. Virus-like particles were observed following infection of replication restrictive 
human cells with a FWPV recombinant containing a HIV gag/pol transgene, under 
the control of the H6 early/late promoter, demonstrating that FWPV infection and 
transgene expression can occur in the absence of visible viral morphogenesis [271]. 
 
Few direct comparisons of poxvirus vector candidates have been reported. In a 
comparison of MVA and CNPV, antigen production was shown to be greater (due to 
longer duration of antigen production) by recombinant MVA than recombinant 
CNPV. Increased levels of apoptosis induction in non-permissive HeLa cells were 
observed in response to CNPV compared to MVA; however, inclusion of a 
gag/pro/env expression cassette altered apoptosis kinetics such that both 
recombinant viruses induced similar levels of apoptosis. These results suggest that 
differences in both poxvirus vector- as well as insert-host interactions are relevant to 
the use of poxviruses as vaccine vectors [136]. 
 
Significant differences in vector-generated cytopathic effect (CPE), growth 
characteristics, apoptosis induction and stage of replication block were observed in 
cell culture systems in a comparison between the closely related VACV derivatives, 
MVA and NYVAC [276]. The growth characteristics of MVA and NYVAC under 
permissive and non-permissive conditions were assessed in BHK-21 and HeLa cells 
respectively [276]. Under permissive conditions (BHK-21 cells), MVA and NYVAC 
growth kinetics were similar. In HeLa cells, MVA replication is blocked following 
formation of IVs without alteration of early or late gene expression; however, in 
NYVAC-infected HeLa cells, the block in morphogenesis occurs prior to IV formation 
[276, 277]. Transmission electron microscopy indicated that upon infection with 
NYVAC, and not MVA, HeLa cells display morphological and biochemical features 
of apoptotic cell death, including chromatin condensation, cytoplasmic vacuolisation 
and DNA fragmentation [276]. 
 
A study of the morphogenesis of novel APVs in permissive and non-permissive 
mammalian cell lines by means of transmission electron microscopy will reveal how 
far the virus progresses in its life-cycle. In non-permissive host cells, different 
poxviruses can progress to different stages of morphogenesis [71, 271, 276, 277]. 
The stage at which the morphogenesis of the virus is blocked in non-permissive 
cells may impact on the expression of transgenes and therefore may have an impact 
on immunogenicity of the vaccines. A longer period of transgene expression and the 
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induction of local inflammation by the vaccine vector may result in the improved 
recruitment of antigen-presenting cells at the site of inoculation and possibly, the 
generation of a better immune response [271]. 
 
Virus induction or inhibition of apoptosis is an important consideration when 
determining the potential of a poxvirus for use as a vaccine vector. Apoptosis, or 
programmed cell death, eliminates virally infected, damaged or unwanted cells 
without disruption of surrounding tissues (reviewed in chapter 1, section 1.4.3.1). 
Poxviruses have evolved several mechanisms which modulate virus infection-
induced apoptosis in the host [278, 279] (reviewed in chapter 1, section 1.4.4). This 
has important implications in vaccine design because if apoptosis occurs too early in 
the life cycle of the virus, gene expression and antigen presentation will be affected. 
Apoptosis is, however, desirable once the transgene of a recombinant vaccine has 
been expressed, as the formation of apoptotic bodies loaded with antigen and the 
uptake thereof via the alternative class I antigen presentation pathway (cross-
presentation) is important in the induction of an immune response [133]. The 
mechanisms of apoptosis and its effect on vaccine efficacy are not clearly 
understood. Both induction and delay/prevention of apoptosis by poxvirus vectors 
have been shown to improve foreign antigen expression as well as immunogenicity 
[134-136]. It would be important to assess any novel vaccine vector candidates for 
the ability to induce or inhibit apoptosis in permissive and non-permissive cells. This 
is a potential avenue for the improvement of APV vectors, with the insertion or 
deletion of immunomodulatory genes. 
 
In this study, a novel South African APV isolated from a Feral Pigeon (Columba 
livia) (FeP2) has been characterised in terms of growth, morphogenesis and 
induction/inhibition of apoptosis in permissive and non-permissive cells. This study 
will provide fundamental characterisation and a better understanding of in vitro 
behaviour of this poxvirus.  
 
 
3.2 Materials and methods 
3.2.1 Virus isolates 
 
Poxviruses were obtained from various sources (Table 3.1) and grown as described 
in chapter 2, section 2.2.1. PEPV seedstock was kindly obtained from Olivia Carulei 
a fellow PhD student at University of Cape Town, originally isolated by D. Kow and 
71 
 
K. Dumbell [71]. MVA was obtained from Prof. K. Dumbell‘s collection housed at the 
University of Cape Town, originally obtained from Prof. A. Mayr (Veterinary Faculty, 
University of Munich, Munich, Germany). CNPV and FWPV are described in chapter 
2, section 2.2.1. 
 
Table 3.1. List of avipoxvirus isolates used for further analysis. 












SANCCOB: Southern African Foundation for the 
Conservation of Coastal Birds, Cape Town 
 
FWPV 
Fowl pox virus, (DCEP 25 




CNPV (wild type) Canary 
Serinus canaria From Dumbell collection, originally from Mayr 
Modified vaccinia Ankara 
(MVA)  unknown From Dumbell collection, originally from Mayr 
 
 
3.2.2 Cell lines and culture conditions 
 
Human cervix adenocarcinoma cells (HeLa, ATCC CCL-2™), Syrian baby hamster 
kidney cells (BHK-21, ATCC CCL-10™) and Japanese quail myoblasts (QM7, CRL-
1962™) were obtained from and grown under conditions suggested by the American 
Type Culture Collection (ATCC, Manassas, VA, USA). Cells were maintained at 
37°C in 5% CO2. HeLa and BHK-21 cells were grown in Dulbecco‘s modified 
Eagle‘s medium (DMEM) (Lonza, Basel, Switzerland) supplemented with 10% fetal 
calf serum (FCS) (Biochrom, Cambridge, UK), 1% penicillin and streptomycin 
(Lonza, Basel, Switzerland) and 0.001mg/ml Fungin (Invivogen, San Diego, USA). 
QM7 cells were grown in 80% Medium 199 with Earle's Balanced Salt Solution 
(Lonza, Basel, Switzerland), 10% tryptose phosphate broth, 10% FCS, 1% penicillin 
and streptomycin and 0.001mg/ml Fungin (Invivogen, San Diego, CA, USA).  
 
Fresh primary CEFs were isolated from 10-11 day old embryonated SPF White 
Leghorn chicken eggs which were obtained from Avifarms (Pty) Ltd (Lyttelton, South 
Africa). Embryos were aseptically removed from the egg, decapitated and the limbs 
carefully removed. They were then washed twice in PBS and incubated with 0.2% 
trypsin (Lonza, Basel, Switzerland) in PBS at 37°C for 30-60mins. An equal volume 
of FCS was added to neutralize the trypsin and the suspension was filtered through 
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autoclaved cheesecloth. The filtrate was centrifuged at 1500rpm (Eppendorf 5810) 
and the cell pellet was resuspended in DMEM with 10% FCS and counted. Cells 
were seeded into 75cm2 polystyrene tissue culture flasks (Corning®, New York, NY, 
USA) at 2 x 106 cells per flask and grown in DMEM supplemented with 10% FCS 
(Biochrom, Cambridge, UK), 1% penicillin and streptomycin (Lonza, Basel, 
Switzerland) and 0.001mg/ml Fungin (Invivogen, San Diego,CA, USA). 
 
3.2.3 Virus growth in different cell lines 
 
Monolayers of HeLa, BHK-21, QM7 and CEFs in 25cm2 flasks were grown to 80% 
confluency. Virus was diluted in DMEM, without serum but including 1% penicillin 
and streptomycin and 0.001mg/ml Fungin. The culture media was removed and 
cells were infected at a multiplicity of infection (m.o.i) of 0.01 PFU/cell. Following 
virus adsorption for 2 hours at 37°C, the inoculum was removed and replaced with 
fresh DMEM containing 4% FCS and incubated at 37°C with 5% CO2. At different 
times post infection (0hrs, 24hrs, 48hrs, 72hrs, 96hrs and 120hrs), flasks were 
examined for CPE and placed at -20°C. Following four freeze/thaw cycles, the few 
attached cells remaining were scraped and the supernatants were collected. This 
was diluted and titrated on CAMs as described in chapter 2, section 2.2.2. 
 
3.2.4 Electron microscopy 
 
HeLa and CEF cells were seeded into 12 well plates and adhered cells were 
infected with FeP2 (moi=10) and allowed to adsorb for 1hr. Thereafter media 
containing 2% FCS was added and cells were incubated for 6hrs, 15hrs, 24hrs or 
48hrs. The cells were then scraped and, together with the supernatant, were spun at 
5000rpm for 5mins. The resulting pellet was then washed in 1ml PBS and subjected 
to centrifugation at 5000rpm for 5mins. The supernatant was then discarded and the 
pellet was resuspended in 100ul 2.5% glutaraldehyde and incubated overnight at 
4°C. Following two washes in 0.1 M phosphate buffer pH 7.4, the cell pellets were 
resuspended in 4% low melting point agarose, allowed to set and cut into ~1mm2 
blocks. The blocks were then immersed in 0.5% tannic acid at room temperature for 
1 hour and washed with PBS. Secondary fixation was performed in 1% (wt/vol) 
OsO4 in 2xPBS for 1 hour at room temperature. Samples were then washed twice in 
PBS and twice in distilled water for 5 minutes for each wash. Samples were 
dehydrated through a 30-100% (vol/vol) ethanol series, infiltrated with acetone and 
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Spurrs resin (1:1, 3:1, 100%) (Polysciences Inc., Warrington, PA, USA) and 
embedded with Spurrs resin (100%). Polymerization of resin blocks was performed 
at 60°C for 24hrs. Ultra-thin sections were made using a diamond knife and stained 
with uranyl acetate and lead citrate. The specimens were observed under a Zeiss 
912 OMEGA EFTEM or a FEI/Tecnai F20 CRYO FEGTEM transmission electron 
microscope (TEM) [71, 271, 276]. We acknowledge Mr Mohammed Jaffer and 
others at the UCT Electron Microscope Unit for training and assistance with the 
electron microscopy performed. 
 
3.2.5 Measurement of induction or inhibition of apoptosis 
 
Primary CEFs or HeLa cells were seeded in 10% DMEM at 2 x 104 cells per well in 
a 96 well plate. 24hrs later, the medium was removed and either 2% DMEM alone 
(uninfected control), 4ug Camptothecin alone (positive control), virus (moi=10) or 
virus and Camptothecin together (moi=10, 40ug/ml ie: 4ug) were added to the wells 
and incubated at 37°C for different times. Thereafter the enzyme-linked 
immunosorbant assay (ELISA)-based Cell Death Detection ELISAPLUS kit (Roche, 
Basel, Switzerland) protocol was performed as per the manufacturer‘s instructions 
(except that 2 x 104 cells per well were used instead of 1 x 104 cells per well in a 96 
well plate). Plates were read at a wavelength of 405nm with a reference wavelength 




3.3.1 Growth kinetics of FeP2 in permissive and non-permissive cell 
lines and comparison to other poxviruses 
 
Avian cells 
If a virus is to be used as a potential vaccine vector, a permissive cell line is 
necessary for the construction of a recombinant virus as viral growth in tissue 
culture is needed for homologous recombination of the transfer vector with the APV 
genome. We therefore investigated the growth of FeP2 in two cell lines of avian 
origin, primary CEFs and Japanese quail myoblasts (QM7).  
 
In primary CEFs, FeP2 showed an increase in virus titre of approximately 2 logs 
over 5 days (Fig. 3.1). Similarly, CNPV, FWPV, MVA also increased in virus titre 
from day 0 (0hrs) up to day 5 (120hrs), but not as much as FeP2 (Fig. 3.1). PEPV, 
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included in this experiment as a negative control, did not grow in primary CEFs and 
virus yield decreased over the 120hrs (Fig. 3.1) confirming previous studies [71]. 
Limited CPE in these cells was observed (not shown). MVA produced the highest 
viral yield, with an increase of more than 3 logs over 3 days (Fig. 3.1).  
 
Growth of FeP2 in an additional, permanent cell line of avian origin (QM7) was 
investigated. Growth in QM7 cells was unproductive and virus titre decreased over 
120hrs (Fig. 3.3). Infectious FeP2 appeared to be relatively stable in these cells and 














































Figure 3.1. Virus growth of PEPV, FeP2, CNPV, MVA and FWPV in primary chick 
embryo fibroblast (CEF) cells. CEF cell monolayers were infected at 0.01 PFU/cell and 
harvested at different times post infection (day 0 (0hrs), day 1 (24hrs), day 2 (48hrs), day 3 
(72hrs), day 4 (96hrs) and day 5 (120hrs)). Virus was titrated and averages of three titrations 





















































Figure 3.2. Virus growth of PEPV, FeP2, CNPV, MVA and FWPV in HeLa cells. HeLa 
cell monolayers were infected at 0.01 PFU/cell and harvested at different times post 
infection (day 0 (0hrs), day 1 (24hrs), day 2 (48hrs), day 3 (72hrs), day 4 (96hrs) and day 
5 (120hrs)). Virus was titrated and averages of three titrations are shown with error bars 
calculated with standard error for each dataset. 
Figure 3.3. Virus growth of FeP2 in QM7, BHK-21, CEF and HeLa cells. Cell 
monolayers were infected at 0.01 PFU/cell. At different times post infection (day 0 (0hrs), 
day 1 (24hrs), day 2 (48hrs), day 3 (72hrs), day 4 (96hrs) and day 5 (120hrs)) virus was 
titrated and averages of three titrations are shown with error bars calculated with standard 






















In order to establish whether or not FeP2 can multiply in mammalian cells, we 
investigated FeP2 growth kinetics over 120hrs in HeLa cells and compared this to 
the growth of CNPV, FWPV, PEPV and MVA. There was no increase in virus titre 
for any of the viruses and all viruses displayed similar patterns of growth kinetics 
(Fig.3.2).  
 
Previous studies have shown that BHK-21 cells are permissive to certain APV 
strains [267]. We therefore investigated whether FeP2 could multiply in this cell line 
over 5 days (120hrs). Overall, no increase in virus titre was observed; however, 
stability of infectious FeP2 was demonstrated over 5 days (Fig. 3.3). In HeLa cells, 
there is more of a drop in FeP2 titre than in BHK-21 cells. This could mean that low 
levels of FeP2 replication is occurring. 
 
3.3.2 Morphogenesis of FeP2 
 
Permissive cells 
To characterise the morphogenesis of FeP2 in permissive cells, transmission 
electron microscopy (TEM) was performed on infected CEFs at 15 and 24hrs post 
infection. In CEFs, morphogenesis of FeP2 followed the same sequence of events 
as those reported for PEPV [71], FWPV [271, 273] and CNPV [271]. Viral crescent 
membranes were seen surrounding cytoplasmic masses of granular material. These 
progressed to spherical IV with amorphous content (Fig. 3.4A-D). IV particles at 
various stages of development were observed (Fig. 3.4A-D). First partly open 
circular membranes originating from viral crescents enclose viral nucleoplasm to 
form closed double-shelled spheres consisting of homogenous granular matter (Fig. 
3.4A-D). Thereafter, the contents become condensed and differentiate into the viral 
cores and lateral bodies and the virions become oblong MV particles (Fig. 3.4E, F, 
G and H). Mature particles become wrapped (enveloped) as they bud through the 
membranes of cytoplasmic organelles (possibly Golgi cisternae) (Fig. 3.4 E). No 
definite budding through plasma membranes was observed, however MV at different 
stages of maturity were observed in the extracellular space and cytoplasm of 








In FeP2-infected HeLa cells, FeP2 particles were seen adhering to cell membranes 
or in the extracellular space (Fig. 3.5A); however no virions were seen entering any 
cells. Areas of electron dense viroplasm (v) were observed in some cells (Fig. 3.5B) 
and suspected aberrant forms of IV particles were present (Fig. 3.5C), however this 
cannot be confirmed. In one isolated cell (Fig. 3.5D) several mature virus particles, 
similar to those observed in permissive cells (Fig. 3.4) were observed within the 
cytoplasm, possibly a result of a clump of virus particles entering the cell. No 
evidence of productive infection or early morphogenesis was observed at 6hrs, 
15hrs, 24hrs or 48hrs (not shown).  
 
Figure 3.4 Morphogenesis of FeP2 in CEF cells. Electron microscopy was performed 15 and 
24 hrs p.i. Pools of viroplasm (V) can be seen surrounded by viral crescent membranes (c). 
Immature virus (IV) particles at various stages of development are seen in the cytoplasm of the 
infected cell: (1) partly open circular membrane structures enclosing/associated with 
nucleoplasm. (2) Completely closed spherical particles with amorphous content. (3) IV contents 











Figure 3.4 (Continued) Morphogenesis of FeP2 in CEF cells. (4) The contents of the IV 
contracts and become differentiated, forming oblong mature virus particles (MV) with a 
characteristic biconcave core. Mature particles become wrapped (enveloped) as they bud 
through the membranes of cytoplasmic organelles (possibly Golgi cisternae) (E). MV were 












Figure 3.5 Electron microscopy of FeP2 in HeLa cells.  FeP2 particles are seen adhering to 
cell membranes or in the extracellular space (A). (B) Areas of electron dense viroplasm (v) are 
observed in some cells and suspected aberrant forms of immature virus particles are present 




3.3.3 Investigation of the induction/inhibition of apoptosis by FeP2 in 
comparison to different poxviruses in permissive and non-
permissive cells 
 
We performed a quantitative investigation of apoptosis induction/inhibition by FeP2 
in comparison to CNPV, FWPV, PEPV and MVA using an ELISA-based assay 
(Roche Cell Death Detection ELISAPLUS) for detection of histone-complexed DNA 
fragments in the cytoplasm of permissive (primary CEFs) and non-permissive 
(HeLa) cells. 
 
To examine induction of apoptosis, cells were infected with virus at a moi=10. To 
examine inhibition of apoptosis, infected cells were treated with Camptothecin (4μg). 
The negative control consisted of mock-infected cells and the positive control 
consisted of cells treated with 4μg Camptothecin. Camptothecin induces apoptosis 
in a dose-dependent manner [280] and has been used as a positive control for 
similar apoptosis assays [136].  
 
In CEFs, Camptothecin treatment resulted in a significant increase in apoptosis 
levels compared to that in the negative (mock-infected/untreated) control (Fig. 3.6A 
and B) cells, which also underwent apoptosis, but to a lesser extent, at both time 
points (Fig. 3.6A and B). Although a certain level of apoptosis is expected in 
untreated cells, it is possible that the increased levels of apoptosis exhibited here 
was due to the high concentration of cells used for the assay. In CEFs at 6hrs and 
12hrs all viruses alone failed to induce apoptosis (Fig. 3.6A and B). Furthermore, in 
CEFs treated with virus and Camptothecin, apoptosis levels were reduced to below 
that of the negative control for all viruses (Fig. 3.6A and B), indicating that the 
addition of virus inhibited the Camptothecin-induced apoptosis in these cells. 
 
Similar observations were made in HeLa cells at 24hrs and 48hrs (Fig. 3.7C and D). 
In HeLa cells at 6hrs and 12hrs p.i. (Fig. 3.7A and B respectively) increased levels 
of apoptosis were observed in cells treated with Camptothecin and infected with 
FWPV, CNPV and MVA respectively, especially at 6hrs (Fig. 3.7B) and to a lesser 










Figure 3.6 Measurement of induction and inhibition of apoptosis by FeP2 in 
comparison to PEPV, FWPV, CNPV and MVA in primary CEF cells at (A) 6 hours and 
(B) 12 hours post infection. Apoptosis was measured using the Roche Cell Death 
Detection ELISAPLUS kit for detection of histone-complexed DNA fragments in the 
cytoplasm. For induction of apoptosis, cells were infected with virus at a moi =10. For 
inhibition of apoptosis, cells were treated with Camptothecin (CAM) and virus 
simultaneously. The negative control consisted of mock-infected cells and the positive 
control consisted of cells treated with Camptothecin. Each sample was tested in duplicate 







Live, attenuated or host range restricted poxviruses make attractive candidates for 
use as vaccine vectors. It is crucial to understand the behaviour of these vectors in 
vitro and in vivo. In this study, a novel South African APV isolated from a Feral 
Pigeon (Columba livia) (FeP2) has been characterised in terms of growth and 
apoptosis in permissive and non-permissive cells, and compared to other poxviruses 
strains. This study will provide fundamental characterisation and a better 
Figure 3.7 Measurement of induction and inhibition of apoptosis by FeP2 in 
comparison to PEPV, FWPV, CNPV and MVA in HeLa cells at (A) 6 hours, (B) 12 
hours (C) 24 hours and (D) 48 hours post infection. Apoptosis was measured using 
the Roche Cell Death Detection ELISAPLUS kit for detection of histone-complexed DNA 
fragments in the cytoplasm. For induction of apoptosis, cells were infected with virus at a 
moi=10. For inhibition of apoptosis, cells were treated with Camptothecin (CAM) and 
virus simultaneously. The negative control consisted of mock-infected cells and the 
positive control consisted of cells treated with Camptothecin. Each sample was tested in 




understanding of in vitro behaviour of this poxvirus which may help to determine its 
potential for use as a future vaccine vector. 
 
FeP2 was shown to be permissive in CEFs with an increase in virus yield of 
approximately 2 logs over 5 days (Fig. 3.1). The morphogenesis of FeP2 in CEFs, 
as viewed by EM, was complete and followed the same sequence of events as 
those reported for PEPV [71], FWPV [271, 273] and CNPV [271] in CEF cells.  
 
For both CEF (Fig. 3.1) and HeLa (Fig. 3.2) cell growth curves the 5 viruses differed 
in titre at day 0 – day 1. Virus stocks were titrated multiple times to ensure accuracy 
and for each growth curve care was taken to ensure consistent multiplicities of 
infection. Similarly, there were differences in FeP2 titre at day 0 – day 1, when 
grown in 4 different cell lines (Fig. 3.3). Here, the titre of FeP2 increased between 
day 0 and day 1 in the two avian cell lines, and decreased in the two mammalian 
cell lines. Therefore, the variable titres early after infection (day 0 - day 1) may 
reflect differences in viral attachment or entering. 
 
FeP2 showed the greatest increase in virus yields compared to the other APVs; 
however MVA grew the most productively in CEFs (Fig. 3.1). This is not suprising as 
MVA was derived from the VACV Ankara strain by over 500 passages in primary 
CEFs [66, 68]. FeP2 is a novel virus and was initially grown on the CAMs of 
embryonated chicken eggs as detailed in chapter 2. Passage and subsequent 
adaptation of FeP2 to growth in CEFs may improve virus yields in these cells. FeP2 
did not productively grow in QM7 cells of quail origin, which may be due to the fact 
that these cells are muscle myoblast cells and not fibroblasts like CEFs. A 
comparison of MVA growth in different cell lines showed that permissive cells were 
all fibroblastic in morphology [281].  
 
Productive growth of FeP2 is inhibited in HeLa cells and virus yields decrease in 
HeLa cells over time (Fig. 3.2). FeP2 morphogenesis in HeLa cells was severely 
restricted with limited cytoplasmic regions of viroplasm, no characteristic viral 
crescents or IVs (Fig. 3.5). This was similar to the morphogenesis of CNPV 
observed in mammalian cell lines and of FWPV in human cell lines [271]. The 
production of significant levels of CPE in FeP2-infected HeLa cells (not shown) 
suggests that viral proteins are being produced to some extent. Alternatively the 
viral proteins present in the infecting virions have an effect on the cell. Reduced 
levels of CPE in MVA compared to NYVAC and VACV Western Reserve strain has 
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been attributed to the absence of certain viral proteins in MVA as a result of 
extensive genomic deletion [276]. 
 
Viral late gene expression occurs in MVA-infected HeLa cells and viral 
morphogenesis is interrupted at a late stage of the replication cycle [69]. In NYVAC 
infected HeLa cells, the block in viral morphogenesis occurs much earlier, prior to 
the formation of IVs and could be related to the absence of expression of genes 
encoding late structural proteins[276]. 
 
There is limited evidence of APV growth in mammalian cell lines. PEPV has been 
shown to undergo partial maturation in simian CV-1 (monkey kidney) cells, with 
morphogenesis inhibited before the stage of mature infectious particles [71]. Growth 
of FWPV in monkey cells (CV-1 and African green monkey Vero cells) resulted in 
DNA replication and early and late gene expression [275]. In the human MRC-5 cell 
line, FWPV early gene expression and DNA replication occurs but at lower levels 
than in Vero and CV-1 cells [275]. Studies of FWPV in HeLa cells showed only very 
low levels of genome replication and gene expression [275]. These results suggest 
that monkey-derived cells are more permissive to APVs than cells of human origin. 
VACV requires at least one of the host range genes, C7L or K1L, for replication in 
human MRC-5 cells but not in Vero cells suggesting that the lack of a FWPV 
equivalent of these genes may be responsible for the differences in gene expression 
in human versus monkey cell lines [28, 275]. 
 
A study comparing growth of CNPV and FWPV showed that in non-human 
mammalian cells (Vero and CV-1 monkey cells), CNPV replication is more restricted 
than for FWPV. In human MRC-5 cells, CNPV and FWPV display similar abortive 
replication [271]. Since CNPV has been used successfully as a vaccine vector, 
transgene expression in mammalian cells (despite the restricted replication) must 
occur at some level. Future studies on FeP2 as a vaccine vector will require the 
analysis and comparison of how transgene expression is affected by the block in 
virus replication in non-permissive cells and the correlation of this information with 
immunogenicity studies.  
 
Both induction and delay/prevention of apoptosis in poxvirus vectors have been 
shown to improve foreign antigen expression as well as immunogenicity [134-136, 
282]. Vaccine-induced apoptosis is not well understood and poxviruses encode 
several inhibitors of apoptosis (reviewed in chapter 1 section 1.4.4). Several 
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poxvirus vector candidates show differential induction of apoptosis in vitro in a cell-
type dependent manner.  
 
Human dendritic cells (DCs) are professional antigen-presenting cells (APC) that are 
important for the generation of the immune response to viral infection. In DCs, both 
MVA and VACV undergo abortive replication with the block occurring at the 
formation of intracellular viral replication centres [283]. Both VACV and MVA result 
in apoptosis of DCs but MVA-infected DCs undergo apoptosis earlier than VACV-
infected DCs [283]. Since both MVA and VACV induce significant immune 
responses in vivo, the fact that these viruses both induce apoptosis in DCs is of 
interest. Cross presentation, where uninfected DCs present exogenous viral antigen 
acquired from dying cells, may therefore be a major mechanism of the generation of 
an immune response to OPV infection [283]. These results suggest that the 
induction of apoptosis of specific cell types may have positive implications for the 
generation of an enhanced immune response. 
 
Although APC and immune cells, including DCs, macrophages and B cells, undergo 
apoptosis after OPV infection [284, 285], the induction of apoptosis by OPV is 
relatively uncommon in non-APC cell types and these cells generally demonstrate 
cell lysis (rather than apoptosis) in response to viral infection [286]. Investigation of 
virus-induced apoptosis in non-APC cell types may not accurately reflect what 
happens in immune cells. However, several studies have compared poxvirus vector-
induced apoptosis in HeLa cells: 
 
The ALVAC-HIV vector that expresses HIV-1 Gag, Env, and a Nef/Pol polyepitope 
string (vCP205) was modified (vCP1452) to encode VACV E3L and K3L genes 
(inhibitors of apoptosis) in an attempt to improve antigen production by this vaccine 
vector and so increase the potential for greater immunogenicity [134]. vCP1452 
showed significantly decreased levels of apoptosis in HeLa cells and increased 
antigen production. However, consequent cellular immune responses elicited by this 
vaccine vector in human trials were substantially lower than for vCP205 [287, 288]. 
The reason for this is unknown; however, it is possible that the reduced apoptosis 
induction by vCP1452 could have contributed to the reduction in immunogenicity 
[136]. 
 
In contrast, NYVAC induces significant levels of apoptosis in HeLa cells, whereas 
MVA does not, and this induction of apoptosis is attributed to the loss of the viral 
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C7L gene [276]. The extent to which this difference in apoptosis induction 
contributes to the higher immune responses induced by the HIV-1 clade B-based 
vaccine candidate regimen comprising of a DNA-B prime/NYVAC-B boost compared 
to a DNA-B prime/MVA-B boost is unknown and remains to be delineated [282].  
 
In our study, we show that FeP2 as well as the APVs CNPV, FWPV, PEPV and the 
orthopoxirus, MVA, all significantly inhibit apoptosis in permissive CEFs as well as 
non-permissive HeLa cells (Fig. 3.6 and 3.7). Previous studies with MVA and CNPV 
showed low levels of apoptosis induction in HeLa cells infected with these viruses, 
especially in MVA-infected cells; although virus-induced inhibition of apoptosis was 
not analysed [136]. The increase in apoptosis induction by CNPV seen by Zhang et 
al, (2007) may be strain specific. Passage and subsequent attenuation of an APV 
may render it less able to inhibit apoptosis. The implications of this inhibition of 
apoptosis in human HeLa cells are not known and future work would require further 
characterisation of this phenomenon in further cell types, including human DCs and 
other immune cells.  
 
Although the comparison of vector-specific characteristics is necessary, the addition 
of transgenes into the genomes of poxvirus backbones may alter apoptosis 
induction. Zhang et al. (2007), showed that while empty vector CNPV induced 
slightly higher levels of apoptosis than MVA alone, the addition of HIV inserts 
(gag/pro/env) significantly increased MVA- and CNPV- induced apoptosis in HeLa 
cells to the point that vector-based differences were insignificant [136]. This 
highlights the necessity of investigating both vector backbone and insert effects in 
vitro and in vivo [136].  
 
Here we describe the growth characteristics of a novel SA APV isolated from a Feral 
Pigeon (FeP2). We show the growth kinetics of this virus in permissive avian cells 
and non-permissive mammalian cells, and compare these to other poxviruses. 
Furthermore, we show that morphogenesis of FeP2 in permissive CEF cells 
proceeds as in other APVs, and that morphogenesis in non-permissive HeLa cells is 
blocked prior to the formation of immature viral particles. Lastly we show that FeP2, 
as well as other poxviruses, inhibit apoptosis in CEFs and HeLa cells at different 
time points which may have implications for immunogenicity of this virus (and the 
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4.1  Introduction 
 
The pigeonpox virus, FeP2 was selected for whole genome sequencing. When 
grown on the CAMs of embryonated 10-11 day old chicken eggs, this virus caused 
greater cell proliferation and immune cell infiltration as compared to other APV 
isolates (chapter 2). Furthermore, based on phylogenetic analysis of four conserved 
genetic regions, FeP2 groups in clade A, subclade A3. FPVUS and FP9 group in 
clade A1 and CNPV groups in clade B1 (chapter 2). FeP2 grows productively in 
primary CEF cells, which is an important consideration were this virus to be used as 
a vaccine vector, whereby growth in cell culture is a requirement for the construction 
of recombinant virus. 
 
The genomes of only three APVs have been published; a pathogenic American 
strain of FWPV (FPVUS) [25], an attenuated European strain of FWPV derived from 
European FWPV HP1 passaged over 400 times in chick embryo fibroblasts (FP9) 
[27], and a virulent CNPV isolated from a canary (CNPVATCC VR-111) [24]. 
Comparison of the CNPV and FWPV genomes reveals overall synteny in genome 
arrangement with similar genetic complements. They do, however, exhibit significant 
differences in the terminal, variable regions as well as in three internal, variable 
regions which is in contrast to the conservation of central genomic regions in other 
ChPVs. These variable regions within the conserved central region of the genomes 
occur near the junctions of areas that were identified in FWPV as rearranged 
relative to other ChPVs and contain genes involved in virus-host interactions [24, 
25]. APVs are considerably divergent from other ChPV [24, 25] and may constitute a 
separate subfamily within the Poxviridae family [24, 26, 289].  
 
FP9, FPVUS and CNPV have large genomes of 258, 280 and 365kbp encoding 
238, 260 and 320 ORFs respectively [24, 25, 27]. The genomes have low G+C 
content (30-40%) and comprise of a central, conserved region flanked by terminal 
divergent regions and two identical terminal repeats (ITRs) which are covalently 
closed by hairpin loops [25]. The conserved central region of the genome encodes 
highly conserved genes encoding proteins involved in RNA and DNA synthesis, 
virion assembly and virus structure [24]. 90 genes have been found to be conserved 
amongst all ChPVs and to comprise the minimum essential genome [290]. The 
remainder of the genetic component of avian poxviruses is largely made up of 
immunomodulatory and host specific genes located in the terminal regions of the 
genome, that have allowed the viruses to take advantage of their unique hosts.  
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Laidlaw and Skinner (2004) compared virulent (FPVUS (American) and HP1 
(European)) and attenuated, tissue culture adapted (FP9 (European)) FWPV strains. 
Comparative genomics of FWPVUS and FP9 revealed 118 differences, affecting 71 
ORFs. Of these, 68 mutations affecting 25 ORFs differentiated the FWPVs 
geographically. The combination of adaptation to CEFs and attenuation was a result 
of only 50 mutations, 26 of which were single nucleotide substitutions, involving 46 
ORFs that would not necessarily have been pinpointed as factors of attenuation 
[27]. Instead of the predicted changes in immunomodulators as the mechanism of 
attenuation, members of multigene families, especially those encoding ankyrin 
repeat proteins were seen to be the drivers of attenuation. Ankyrin repeat proteins 
are thought to be involved in poxvirus host-range [28], [291] and have previously 
been implicated in the attenuation of sheeppox virus [29]. Over 49% (137 genes) of 
the CNPV genome and 38% (89 genes) of the FWPV genome are comprised of 
genes belonging to gene families, 51 and 31 of which are ORFs containing ankyrin 
repeats respectively [24]. These and other differences in immunomodulatory gene 
families encoded by APVs may account for the extensive variability in virulence, 
host range and host interaction [24]. 
 
FPVUS and CNPV are significantly divergent. Comparison of CNPV and FWPV 
reveals variability in internal genomic regions, which is in contrast to the 
conservation of central genomic regions in other ChPV. Amino acid identity between 
ORF homologues is between 55-74% which is similar to that observed between 
different ChPV genera [24]. The CNPV genome contains 39 ORFs not present in 
FWPV, 29 of which encode unique, hypothetical proteins. CNPV contains two 
additional nucleotide metabolism genes (thymidylate kinase (TMPK) and the small 
subunit of ribonucleotide reductase), a tumour necrosis factor receptor (TNFR) 
(CNPV086), an IL-10-like protein (CNPV018), cellular ubiquitin (CNPV096), a 
protein tyrosine phosphatase (CNPV085), a thioredoxin binding protein (CNPV149), 
and two Rep like proteins (CNPV153 and CNPV200). FWPV contains 15 ORFs not 
present in CNPV, 13 of which encode hypothetical proteins. Homologues of fpv217 
and fpv250 are notably absent, which are similar to ORFs from insect baculoviruses, 
and from avian herpesviruses and adenoviruses respectively. 
 
There is evidence of the occurrence of integrated reticuloendotheliosis virus (REV) 
sequences within the genomes of some field isolates and vaccine strains of fowl and 
pigeon poxviruses [292-297]. REV infection, arising from the expression of the 
integrated provirus within FPV, has been suggested to play a role in the progression 
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of disease in FPV-infected birds [292]. Reticuloendotheliosis is a tumorigenic and 
immunosuppressive disease, and the presence of integrated REV sequences in 
FPV vaccines has severe implications for the poultry industry [220, 298]. FPVUS 
contains a 253nt remnant of REV long terminal repeat between nucleotides 232464 
and 232717, however REV env, gag and pol genes are not present [25]. CNPV 
lacks sequences similar REV [24]. 
 
The FeP2 genome was sequenced and compared to the published FPVUS, FP9 
and CNPV sequences. 
 
 
4.2  Materials and methods 
4.2.1 Viral genomic DNA isolation 
 
FeP2 was grown on the CAMS of embryonated 10-11 day old chicken eggs as 
previously described (chapter 2, section 2.2.2) The virus-containing supernatant 
fluid was purified through a cushion of 36% sucrose in TE buffer (pH 9) and then 
through a gradient of 36% sucrose and 10% Dextran (in TE buffer pH 9) and 
resuspended in TE buffer (pH 9). 
 
For 454 sequencing, genomic DNA was extracted using a method described 
previously in chapter 2, section 2.2.4 with an additional incubation with DNase I 
(Thermoscientific, Waltham, MA, USA) (25U/100ul virus) at 55°C for 1hr and 
subsequent inactivation of DNase at 80°C for 30minutes, prior to treatment with 
proteinase K.  
 
For Ion Torrent sequencing, special care was taken to prevent host (chicken) 
chromosomal and mitochondrial DNA contamination of the viral DNA preparation. 
Before DNA extraction virus preparations were treated with equal volumes of 
Vertrel® (1,1,1,2,3,4,4,5,5,5-decafluoropentane) (DuPont, Wilmington, DE USA ) 
which is a component that has been shown to separate virus from infected cellular 
debris in some viral purification methods [299]. The virus preparations were then 
freeze/thawed three times to lyse any remaining cells, and then treated with DNAse 






4.2.2 DNA sequencing and bioinformatics 
 
High quality viral DNA was subjected to high-throughput sequencing using a Roche 
454 GS Junior system (Roche, Basel, Switzerland) at the University of the Western 
Cape. For 454 sequencing the amount of input DNA was ~380ng and not 500ng as 
recommended. The library was prepared with the GS Junior Titanium Rapid Library 
preparation kit as per manufacturer's instructions except with a 15s nebulization 
instead of 1 min and library preparation was checked using an Agilent Bioanalyser 
High sensitivity chip to ensure the average fragment length was between 500 and 
900bp. For emulsion PCR the GS Junior Titanium emPCT kit (Lib-L) was used and 
sequencing was performed using the GS Junior Titanium Sequencing kit and 
PicoTiter Plate as per manufacturer‘s instructions. Primary sequence analysis was 
performed using the GS Junior Software version 2.5p1 and de novo assembly was 
done using GS De Novo Assembler software and CLC Genomics Workbench. 
 
Thereafter, viral DNA was sequenced using the sequencing platform, Ion Torrent 
[300] Personal Genome Machine (PGM) (Life Technologies, Carlsbad, CA, USA) at 
the Central Analytical Facilities, Stellenbosch University. The starting amount of 
DNA was 400ng, and the Covaris S2 physical shearing system was used. The Ion 
Plus Fragment Library kit was used for library construction, which was amplified for 
6 cycles prior to enrichment using the Ion OneTouch V2 Template kit. The average 
size of the library was calculated using the Agilent 2100 BioAnalyzer (312bp). The 
Ion PGM 200 Sequencing kit was used for sequencing on a 316 chip as per 
manufacturer‘s instructions. 
 
To offset possible remaining host DNA contamination, we made use of a customized 
bioinformatics pipeline (appendix 2) as described here (performed by Anelda van 
der Walt). For 454 data, the SFF file was converted to FastQ in Galaxy, and filtered 
such that only reads shorter than 500nt and with a mean QC< 20 were included. For 
the Ion torrent data, primary analysis was performed in Torrent Suite version 3.2.1. 
Firstly, the Raw SFF file was submitted to SFFTrim (Torrent Suite 3.2.1) and reads 
were trimmed when the average base quality values in a window size of 10 were 
less than 25 (Q-value of 25). Reads shorter than 50nt were discarded. Reads were 
trimmed of adaptor sequences and filtered to remove polyclonal reads and trimmed 




These two datasets were then mapped to the Chicken (Gallus gallus) genome 
(WASHUC2 assembly) with Newbler 2.6 to filter out possible host contamination. 
Read IDs that did not map to the Chicken genome were obtained from the Newbler 
output and these unmapped reads were extracted from the original SFF files using 
Linux commandline tools and SFFFile that forms part of the 454 NGS data analysis 
software. The resulting SFF files were used as input data for de novo assembly. De 
novo assembly was performed in Newbler 2.6 using default parameters, as well as 
in Mira (Version 3.4.0) where de novo assembly was assisted by a reference 
genome (FPVUS). 
 
Roche 454 sequencing resulted in 93,654 reads with an average length of 404bp. 
Following filtering, only 2369 (2.5%) of these reads did not map to the chicken 
genome and met the quality requirements.  
 
Ion Torrent sequencing resulted in a total of 3,239,283 reads with a mean read 
length of 191bp. The filtered data set contained 1,068,645 reads or 32.99% of the 
total raw reads. Newbler assembly resulted in 7 contigs greater than 500bp (278380 
bases total). MIRA assembly also resulted in 7 contigs greater than 500bp (279145 
bases total). The assemblies were merged using the Genome Assembler, 
Reconciliation and Merging (GARM) version 0.70 meta assembler pipeline which 
resulted in 3 contigs and the remaining gaps were closed by PCR and Sanger 
sequencing and visual inspection. Raw PGM reads were then mapped back to the 
draft sequence. Anelda van der Walt performed the above analysis and we 
acknowledge and thank her for her input.  
 
A total of 3,142,379 raw reads mapped to the draft sequence (98% of total) resulting 
in an average coverage of 2130 X. Remaining gaps between contigs were closed by 
PCR and Sanger sequencing and raw reads were mapped back to the draft 
sequence using CLC Genomics workbench 4.7.2 and TMap as part of the Torrent 
Suite (Version 3.2.1) software.  
 
ORFs longer than 30 amino acids with a methionine start codon (ATG) and less 
than 50% overlap to other ORFs were called using the CLC Genomics Workbench 
(CLC) ORF analysis tool as well as with an Integrated Services for Genomic 
Analysis (ISGA) pipeline which makes use of GLIMMER3 [301], BLAST, HMMer2 
[302] and other protein coding sequence and annotation software described by  
Hemmerich, et al. (2010) [303]. Similarity searches including nucleotide (BLASTn) 
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and Protein (BLASTp) BLAST analyses were performed on every ORF and ORFs 
were annotated as potential genes if they shared significant sequence similarity to 
known viral or cellular genes (BLAST E value ≤e-5) or contained a putative 
conserved domain as predicted by BLASTp. ORFs were numbered from left to right, 
with alphabetic sub-ordering used to indicate multiple potential fragments of larger 
APV ORFs. As published by Hendrickson et al., (2010) [7], an ORF was annotated 
as a whole gene if intact at its 5‘ end with at least 80% the length of its orthologue. 
An ORF intact at its 5‘ end but less than 80% of its orthologue length has been 
annotated as a truncated gene. Any ORF that has been disrupted at its 5‘ end has 
been annotated as a fragmented gene, which is not expected to be transcribed 
and/or translated into a functional gene product [7]. 
 
Promoters described by Afonso et al. (2000) [25] were predicted using CLC motif 
search tool and tandem repeats were identified using TandemRepeatsFinder [304]. 
Multiple sequence alignments were performed with progressiveMauve [305] and 
Base-By-Base v2 [306]. Dotplots were done in Jdotter [307]. 
 
4.2.3 Phylogenetic analysis 
 
Phylogenetic analyses were performed on representative amino acid sequences of 
DNA polymerase as well as on the concatenated amino acid sequences of 17 
conserved proteins from each ChPV species, as previously described [3]. 
 
The amino acid sequences of the DNA polymerase and the 17 conserved proteins, 
described by Gubser (2007) [3], from representative poxvirus species were obtained 
from Genbank. For the 17 conserved proteins, the individual sequences of each 
protein were first aligned using MUSCLE [308]. Gblocks.091b [309] was then used 
to remove any gaps or divergent blocks according to specified criteria [309]. All 17 
protein sequences for each virus were then extracted from the Gblocks output and 
concatenated manually. For the DNA polymerase and concatenated amino acid 
sequences, multiple sequence alignments were performed with MUSCLE [308]. An 
additional analysis was performed using the whole genome nucleotide sequences of 
CNPV, FPVUS, FeP2 and PEPV, which were aligned with ClustalW in Galaxy. 
Appropriate phylogenetic models were selected using ProtTest 2.4 [310], and 
phylogenetic analysis was performed in MEGA 5.10 [250] using both maximum 




4.2.4 Nucleotide sequence accession number 
 
The sequence of the South African Feral Pigeonpox virus (FeP2) has been 





The FeP2 genome was assembled into a contiguous sequence of 282,356bp 
(Genbank accession number KJ801920). Because the terminal hairpin loops were 
not sequenced, the left most nucleotide was arbitrarily nominated base 1. 
 
4.3.1 Phylogenetic analysis of FeP2 
 
Phylogenetic analysis was performed using the DNA polymerase gene, a 
concatenated amino acid sequence of 17 translated ORFs and the entire genomic 
sequence (see methods). All three analyses produced equivalent tree topologies 
(Fig. 4.1). FeP2 groups with FWPV (clade A) separately from CNPV (Clade B). 
Because of the limited number of whole APV genome sequences, it was not 

















Figure 4.1 Maximum likelihood phylogenetic trees based on the amino acid 
sequence alignment of A) the DNA polymerase genes and B) 17 
concatenated genes from selected poxviruses. Multiple sequence alignment 
was performed with MUSCLE and the appropriate phylogenetic model was 
selected using ProtTest 2.4. The maximum likelihood phylogenetic tree based on 
the JTT matrix-based model (121) with 100 bootstrap replicates was constructed in 
MEGA 5.10. Discrete Gamma distribution was used to model evolutionary rate 
differences among sites. The tree is drawn to scale, with branch lengths measured 
in the number of substitutions per site. All positions containing gaps and missing 











































4.3.2 Overall genetic comparison of FeP2 to FWPV and CNPV. 
 
The three genomic sequences of FeP2, FWPV and CNPV were compared for 
nucleotide percentage identity. FeP2 is more closely related to FWPV (84.0%) than 
to CNPV (63.4%). Dot plot analysis reveals a large deletion of 16kb in FeP2 
compared to FWPV (Fig. 4.2 A). Like the other APVs, FeP2 has an A/T rich 
genome, with 70.5% A+T content. 
 
4.3.3 Inverted terminal repeats (ITRs) 
 
The FeP2 genome, like most other poxviruses, contains two identical inverted 
repeated sequences at its termini (ITRs). These are 4682bp in length which are 
shorter than the ITRs of the other sequenced APVs (FPVUS: 9520bp, FP9: 10158bp 
and CNPV: 6491bp). Like FPVUS and CNPV, the A+T content within the two ITRs is 
lower than average at 64.8%. At the terminal ends of each ITR in FeP2 exists a 
257bp repeat region with 3.1 and 3.5 copies respectively of a 34bp and 55bp 
tandem repeat. The 34bp repeats occur between nt 7-111 and 282090-282279, and 
the 55bp repeats are found between nt 75-264 and 282243-282347. FPVUS 
contains a 1.7kb region with 42 copies of a 31-32bp tandem repeat (between nt198-
1853, and 286703-288340) [25]. CNPV contains at least 31, 9, and 7 copies of 17-, 
41-, and 48-bp tandem repeats respectively within the terminal regions of each ITR 
[24]. The repeated sequences are unique to the different APVs. Three intact ORFs, 
orthologous to fpv001 (fep001) and fpv002 (fep003) and to cnpv021 (fep002, 
fpv246), are present in the ITRs. 
 
4.3.4 Overall arrangement of ORFs in genome 
 
The genomic arrangement of ORFs in FeP2 is shown in Figure 4.3 and has been 
compared to FPVUS, FP9 and CNPV in Figure 4.4. Clearly, there is conservation 
amongst the 4 sequenced APVs, but, at the same time, there are major differences 
between them. Unlike the OPVs the APVs exhibit variation within the central core 
region, where blocks of APV genes have been inverted and/or transposed, 
suggesting that this genus is the most divergent of the ChPVs [3, 24, 25]. 
Comparison of gene orthologues indicate overall genomic synteny between FeP2 
and FPVUS and genomic organisation is similar to that of other sequenced ChPVs 
[10, 25, 246]. Table 4.1 lists all ORFs potentially coding for proteins of >30 amino 
acids for FeP2, and Figures 4.3 and 4.4 represent these graphically. 
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FeP2 contains 271 ORFs which have been annotated as putative genes. 
Orthologues of FPVUS genes as well as other genes have been determined (Table 
4.1, Fig. 4.3). These ORFs represent an approximate coding density of 82.5% and 
encode proteins between 34 and 1937 amino acids (Table 4.1). Of these 271 ORFs, 
11 have been annotated as truncated genes (Table 4.2). A further 36 of these ORFs 
are fragmented forms of 28 larger orthologous genes (Table 4.2). Therefore a total 
of 224 ORFs have been annotated as full length putative genes. 
 
Relative to the FPVUS genome, FeP2 has 36 deleted ORFs (Table 4.2). FeP2 
contains 34 inserted ORFs relative to FPVUS, comprising 12 fragments of larger 
genes, 2 truncated genes and 20 intact genes (Table 4.3). 5 of the intact genes do 
not have any functional orthologue in FPVUS (Table 4.1). Between FeP2 and 
FWPV, the most conserved ORF is the orthologue of fpv103 (fep105 and VACV 
F17R) which encodes the DNA binding virion core phosphoprotein and shares 100% 
amino acid identity amongst the three viruses.  
 
Figure 4.2 Dotplot comparisons of FeP2, FPVUS and CNPV genomic sequences. A) Dotplot 
comparing FPVUS (horizontal) and FeP2 (vertical). B) Dotplot comparing CNPV (horizontal) and 
FPVUS (vertical). C) Dotplot comparing CNPV (horizontal) and FeP2 (vertical). Dotplots were 
constructed using Jdotter (Brodie et al., 2004). Major deletions can be seen as breaks in the 
diagonal line. Lines perpendicular to the main diagonal in the top-right and bottom-left corners 
indicate the inverted terminal repeats (ITRs). The short diagonal lines, parallel to the main diagonal 























































































































































































































FeP2 lacks sequence similar to the REV observed in FPVUS and other APV strains 
[25, 292-297]. 
 
As described above, the FeP2 genome is closely related and syntenic to the FWPV 
genome overall (Fig. 4.4); however, differences in gene content are observed. Of 
particular note is the large deletion in FeP2 relative to FPVUS (Fig. 4.2A).The 
deleted region corresponds to the FPVUS genes fpv121 (cc-chemokine family), 
fpv122 (VACV B22R gene), fpv123 (VACV B22R gene), fpv124 (N1R/p28 family 
gene) and fpv125 (V-type Ig domain family gene). 
 
4.3.5 Conserved genes 
 
There are 181 genes that are conserved amongst the four sequenced APVs, which 
have been highlighted in blue in Figure 4.4. These include genes that lie within the 
more variable terminal regions of the genome. These APV core genes were defined 
as such if intact orthologues of the gene were present at least once in all five APV 
sequences. The 181 APV core genes include the 90 core genes conserved in all 
ChPVs which are involved in essential functions such as replication, transcription 
and virion assembly [3, 8]  (indicated in bold and italic in Table 4.1). There are an 
additional 91 genes conserved in all APVs with a variety of different functions 
(indicated in bold in Table 4.1).  
 
4.3.6 Gene families 
 
APVs contain extensive gene families, which vary greatly between different species. 
In CNPV, these comprise over 49% of the genome, whereas they encompass 38% 
of the FWPV genome [24, 25]. In CNPV and FWPV, these gene families account for 
much of the variation between the two genomes [24]. Intact members of gene 
families comprise 33% of the FeP2 genome. Table 4.4 summarises the differences 
in the number of intact gene family proteins found in the five sequenced APV 
genomes. FeP2 is noticeably different in its reduced number of ankyrin repeat 
proteins and C-type lectin gene families; and in the absences of genes encoding β-
NGF and IL-18 binding protein. 
100 
 















ORF Description/ putative function 
1 200 I fpv001 205 77.18 A40R C-type lectin family 
2 66 F cnpv021/fpv246 1585 5.61  
Hypothetical protein Aasi_1435 
[Candidatus Amoebophilus asiaticus 
5a2] 
3 222 I fpv002 222 91.03  Hypothetical protein 4a 46 F cnpv006/fpv002.5 182 14.75  Hypothetical protein 4b 38 F cnpv006/fpv002.5 182 9.74  Hypothetical protein 5 467 I cnpv320/fpv017 465 83.19  Ig-like domain protein 6 79 F cnpv309/fpv241 196 14.14 M1L Ankyrin repeat family 
7 410 I fpv006 418 84.25 C10L C4L/C10L-like gene family protein 
8 504 I cnpv015/fpv162 528 42.11 B4R Ankyrin repeat family 
9 40 F TVAG_011430 732 3.69  
Ankyrin repeat family [Trichomonas 
vaginalis G3] 
10 680 I fpv244 668 31.66  Ankyrin repeat family 11 355 I fpv010 355 84.51  Serpin family 12 293 I fpv011 278 74.4  α-SNAP 13 518 I fpv246 592 30.22   
14 178 I IL10 (Ficedula albicollisα) 177 28.26  Interleukin-10 
15 330 I fpv012 331 76.2  Ankyrin repeat family 16 403 I cnpv028/fpv240 362 34.87 B4R Ankyrin repeat family 
17 437 I fpv014 437 86.73  Ankyrin repeat family 18 170 I fpv015 177 75.71  Hypothetical protein 19 237 I fpv016 238 79.83  Hypothetical protein 20 245 I fpv017 245 76.92  V-type Ig domain 21 683 I fpv018 700 83.88  Ankyrin repeat family 22 97 I fpv019 104 56.25  Hypothetical protein 
23 189 I cnpv037 171 44.04  
Hypothetical protein (fragment in 
FPV) 
24 427 I fpv020 426 87.12 C10L C4L/C10L-like family 
25 331 I fpv021 320 78.25  G-protein-coupled receptor family 26 581 I fpv022 578 84.88  Ankyrin repeat family 27 434 I fpv023 434 90.32  Ankyrin repeat family 28 594 I fpv024 596 89.95  Ankyrin repeat family 29 203 I fpv025 203 86.7  Hypothetical protein 30 498 I cnpv044/fpv024 480 38.92 B4R Ankyrin repeat family 
31 67 F fpv026 436 10.78  Ankyrin repeat family 32 44 T fpv028 180 15  hypothetical protein 33 464 I cnpv046/fpv024 450 48.39  Ankyrin repeat family 34 126 I fpv029 124 89.68  Hypothetical protein 35 808 I fpv030 817 82.62  Alkaline phosphodiesterase 36 341 I fpv031 341 91.79  Ankyrin repeat family 37 44 F fpv034 415 7.45  Ankyrin repeat family 38 135 I fpv035 135 96.03  Hypothetical protein 39 164 I fpv037 162 68.29  Hypothetical protein 40 145 I fpv038 145 89.66 F2L dUTP pyrophosphatase 
41 175 I fpv039 175 81.14  Bcl-2 42 337 I fpv040 337 91.39  Serpin family 43 226 I fpv041 206 57.83  Hypothetical protein 44 564 I fpv043 564 89.89 A50R DNA ligase 
45 358 I fpv044 358 91.06  Serpin family 46 370 I fpv046 370 82.75 A44L Hydroxysteroid dehydrogenase 
47 576 I fpv047 612 74.39 A39R Semaphorin 
48 261 I fpv048 261 93.87  GNS1/SUR4 
49 154 I fpv049 154 94.81 A1L Late transcription factor VLTF2 
50 552 I fpv050 552 97.1 D13L 
Rifampicin resistance, N3L 
protein 
51 289 I fpv051 289 95.16 D12L mRNA capping enzyme 
52 637 I fpv052 637 95.6 D11L 
NPH-1 transcription termination 
factor 
53 225 I fpv053 225 95.56 D10L 
muT motif; gene expression 
regulation 
54 237 I fpv054 231 92.41 D9R muT motif 
55 274 I fpv055 275 64.13  V-type Ig Domain 
56 161 I fpv056 161 96.89 D7R RNA polymerase subunit RPO18 
57 633 I fpv057 633 98.58 D6R Early transcription factor VETFs 
58 791 I fpv058 791 97.98 D5R NTPase; DNA replication 
59 200 I fpv060 188 73.5  CC chemokine family 60 109 I fpv061 129 66.41  CC chemokine family 61 199 I cnpv232/fpv060 204 30.23  CC chemokine family 
62 218 I fpv062 218 97.71 D4R Uracil DNA glycosylase 
63a 93 T fpv063 400 39.91   
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63b 134 T fpv063 400 21.75   64 134 F fpv064 200 61.19  Glutathione peroxidase 65 110 I fpv065 111 80.18  Hypothetical protein 66 138 I fpv066 122 73.19  Hypothetical protein 67 93 I fpv067 90 87.1  HT motif family 68 131 I fpv068 133 66.2  Hypothetical protein 
69 268 I fpv069 270 92.59 D3R Virion protein 
70 273 I fpv070 273 84.98  T10 gene product 71 43 I cnpv095/fpv070.5 45 53.33  Hypothetical protein 72 287 I fpv071 289 88.93  Hypothetical protein 73 54 F cnpv098 80 27.71  Hypothetical protein 74 82 F fpv072 186 39.25  Beta-Nerve growth factor 75 106 T fpv073 174 37.93  Interleukin (IL18) binding protein 76 101 I fpv074 104 77.88  Hypothetical protein 77 187 I fpv075 199 82.41  N1R/p28 family 
78 125 I fpv077 125 95.2 G4L Gutaredoxin 
79 225 I fpv079 225 94.22 G2R Putative elongation factor 
80 103 I fpv078 103 92.23 G3L Hypothetical protein 
81 335 I fpv080 363 69.04  
Transforming Growth Factor β 
(TGF-B) 
82 627 I fpv081 626 94.42 G1L Metalloprotease 
83 682 I fpv082 682 93.84 I8R DNA/RNA helicase/NPH-11 
84 421 I fpv083 421 96.67 I7L Virion core proteinase 
85 391 I fpv084 390 94.37 I6L DNA-binding protein 
86 81 I fpv085 81 90.12 I5L IMV membrane protein 
87 183 I fpv086 183 86.89 J2R Thymidine kinase 
88 82 I fpv087 91 92.31  HT motif family 
89 291 I fpv088 290 94.85 I3L DNA binding phosphoprotein 
90 65 I fpv089 65 95.38 I2L Hypothetical protein 
91 311 I fpv090 311 98.39 I1L Virion protein 
92 34 I fpO3L 34 88.24 O3L Orthologue of vaccinia O3L & MC043.1L 
93 656 I fpv091 656 89.48 O1L Hypothetical protein 
94 131 I fpv092 131 93.13 E11L Hypothetical protein 
95 94 I fpv093 94 92.55 E10R Sulfhydryl oxidase ERV1 
96 988 I fpv094 988 92.42 E9L DNA polymerase 
97 282 I fpv095 272 89.36 E8R Hypothetical protein 
98 571 I fpv096 571 95.8 E6R Hypothetical protein 
99 1885 I fpv097 1912 85.45  VARV B22R family 100 1826 I fpv098 1802 95.47  VARV B22R family 101 1937 I fpv099 1949 84.66  VARV B22R family 
102 182 I fpv100 182 96.7 E4L RNA pol subunit RPO30 
103 717 I fpv101 717 92.33 E2L Hypothetical protein 
104 472 I fpv102 472 98.09 E1L 
Poly(A) polymerase large 
subunit, PAP-L 
105 114 I fpv103 114 100 F17R 
DNA binding virion core 
phosphoprotein 
106 210 I fpv104 210 81.43  Hypothetical protein 
107 149 I fpv105 148 95.97 F15L Hypothetical protein 
108 99 I fpv106 99 66  Conserved hypothetical protein 109 1780 I fpv107 1777 85.35  VARV B22R family 
110 377 I fpv108 377 94.69 F13L Virion envelope protein 
111 639 I fpv109 630 84.98 F12L Virion release protein 
112 142 I fpv110 451 75 F11L  
113 444 I fpv111 444 96.85 F10L 
SER/THR protein kinase (virus 
assembly) 
114 213 I fpv112 213 94.37 F9L Hypothetical protein 
115 66 I fpv113 66 95.45   116 183 I fpv114 183 92.35  HAL3 domain 117 143 F cnpv011/fpv246 586 8.53  Ankyrin repeat family 118 60 F cnpv004/fpv246 514 5.25   119 122 I fpv116 120 81.15  CC-chemokine family 
120 440 I fpv117 440 91.59 G5R Hypothetical protein 
121 63 I fpv118 63 96.83 G5.5R RNA pol subunit RPO7 
122 188 I fpv119 188 95.21 G6R Hypothetical protein 
123 343 I fpv120 343 96.5 G7L Virion core protein 
124 203 I cnpv012/fpv229 189 31.07  Hypothetical protein 125 239 I cnpv224 239 55.69  hypothetical protein 126 211 I cnpv170 212 81.6  Thymidylate Kinase 
127 260 I fpv126 260 98.85 G8R VLTF-1 
128 336 I fpv127 336 92.56 G9R Myristylated protein 
129 243 I fpv128 243 95.88 L1R Myristylated protein 
130 96 I fpv129 96 86.46 L2R Hypothetical protein 
131 301 I fpv130 301 93.69 L3L Hypothetical protein 
132 253 I fpv131 253 94.47 L4R DNA binding virion core VP8 
102 
 
133 129 I fpv132 129 93.8 L5R Putative membrane protein 
134 148 I fpv133 148 96.62 J1R Hypothetical protein 
135 308 I fpv134 308 94.81 J3R PolyA polymerase (PAPs) 
136 186 I fpv135 186 94.62 J4R RNA pol Subunit RPO22 
137 137 I fpv136 137 91.24 J5L Membrane protein 
138 1287 I fpv137 1287 96.81 J6R RNA pol Subunit RPO147 
139 166 I fpv138 166 94.58 H1L Protein tyrosine Phosphatase 
140 190 I fpv139 190 96.84 H2R Hypothetical protein 
141 333 I fpv140 327 87.39 H3L Virion env protein(p35) 
142 799 I fpv141 798 96.37 H4L 
RNA polymerase associated 
protein RAP94 
143 174 I fpv142 174 89.66 H5R VLTF-4 
144 316 I fpv143 316 96.2 H6R DNA topoisomerase 
145 152 I fpv144 152 92.11 H7R Putative 17 kDa protein 
146 103 I fpv145 103 84.47   
147 852 I fpv146 851 94.01 D1R 
mRNA capping enzyme, large 
subunit 
148 63 F fpv147 104 51.92  HT motif family 
149 140 I fpv148 139 90 D2L virion protein 




151 190 I fpv149 186 84.74  Hypothetical protein 152 284 I fpv150 276 81.69  N1R/p28 gene family protein 153 238 I fpv151 235 84.1  dCK 154 209 I fpv153 208 77.25  Hypothetical protein 155 410 I fpv155 408 85.85  N1R/p28 family 156 132 I fpv156 132 87.88  HT motif family 157 327 I fpv157 311 78.35  N1R/p28 family 158 464 I fpv158 464 95.04  Photolyase 159 246 I fpv159 241 83.74  N1R/p28 160 156 I fpv160 156 94.23  Hypothetical protein 161 149 I fpv161 157 83.44  N1R/p28 family 162 133 I cnpv210/fpv075 131 43.7  N1R/p28 family 163 45 I cnpv211/fpv161.5 54 36.36  Hypothetical protein 164 160 I cnpv212/fpv124 176 53.41  N1R/p28 family 165 591 I fpv162 603 78.31  Ankyrin repeat family 166 256 I fpv163 263 76.05  N1R/p28 family 167 46 F fpv162 603 3.32  Ankyrin repeat family 168 383 I fpv164 383 67.36  Hypothetical protein 
169 225 I fpv165 225 95.11 A2L Late transcription factor VLTF-3 
170 72 I fpv166 72 95.83 A2.5L Virus redox protein 
171 658 I fpv167 658 98.33 A3L Virion core protein P4b 
172 244 I fpv168 288 63.09 A4L Immunodominant virion protein 
173 169 I fpv169 167 97.04 A5R RNA pol subunit RP019 
174 374 I fpv170 375 94.39 A6L Hypothetical protein 
175 709 I fpv171 709 97.18 A7L 
Early transcription factor large 
subunit, VETF-L 
176 301 I fpv172 301 97.67 A8R 
Intermediate transcription factor 
VITF-3 
177 76 I fpv173 76 98.68 A9L Hypothetical protein 
178 891 I fpv174 891 96.07 A10L Virion core protein P4a 
179 272 I fpv175 274 96.35 A11R Hypothetical protein 
180 175 I fpv176 171 88 A12L Virion protein 
181 49 T fpv177 68 61.76  Hypothetical protein 
182 71 I fpv178 71 88.73 A13L Virion protein 
183 91 I fpv179 91 94.51 A14L Virion envelope protein 
184 53 I fpv179.1 54 98.11 a14.5 Virion envelope protein 
185 97 I fpv180 97 96.91 A15L Hypothetical protein 
186 369 I fpv181 369 91.87 A16L 
Putative mystirilated membrane 
protein 
187 198 I fpv182 198 97.98 A17L 
Phosphorylated virion membrane 
protein 
188 462 I fpv183 462 95.89 A18R 
DNA helicase (transcription 
elongation) 
189 88 I fpv184 88 93.18 A19L Hypothetical protein 
190 113 I fpv186 113 92.04 A21L Hypothetical protein 
191 432 I fpv185 433 92.84 A20R Processivity factor 
192 156 I fpv187 156 91.03 A22R Hypothetical protein 
193 383 I fpv188 383 94.26 A23R 
Intermediate transcription factor 
VITF-3 
194 1157 I fpv189 1161 97.76 A24R RNA pol subunit RPO132 
195 608 I fpv190 620 87.18 A25L A-type inclusion protein 
196 472 I fpv191 474 91.77 A26L A-type inclusion protein 
197 140 I fpv192 141 95.74 A28L Hypothetical protein 
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198 302 I fpv193 302 89.4 A29L RNA pol subunit RPO35 
199 74 I fpv194 74 97.3 A30L Hypothetical protein 
200 37 I fp9.194.1  81.58  A30.5L orthologue 201 113 I fpv195 113 91.15 A31R Hypothetical protein 
202 120 I fpv196 120 81.67  Hypothetical protein 
203 304 I fpv197 301 92.11 A32L Virion assembly protein 
204 173 I fpv198 173 92.49 A34R C-type lectin-like protein 
205 106 F fpv199 219 38.81  V-type Ig Domain 206a 39 F fpv200 265 10.94  V-type Ig domain 206b 58 F fpv200 265 17.36  V-type Ig domain 207 277 I fpv201 283 87.28  Hypothetical protein 208 285 I fpv203 285 83.51  Tyrosine protein kinase 209 342 I fpv204 342 90.64  Serpin family 210 220 I fpv205 218 82.27  Hypothetical protein 211 308 I fpv206 308 87.99  G-protein-coupled receptor family 212 92 I fpv207 100 77  Hypothetical protein 213 67 T CNPV279 169 13.64  Beta-NGF-like protein 214 213 I fpv208 (cnpv281) 214 40.19  Hypothetical protein 215 139 I fpv209 130 74.62  HT motif family 
216 123 I fpv211 125 80.95 C11R Epidermal Growth Factor-like protein 
217 303 I fpv212 303 93.01 B1R Serine/threonine protein kinase 
218 162 I fpv213 162 90.74  Hypothetical protein 219 125 I fpv214 124 76.98  Putative 13.7 kDa protein 220 74 I fpv215 74 94.59  Hypothetical protein 




222 294 I fpv216 296 84.46  Ankyrin repeat family 223 143 I Tanapox 67R 178 26.52  67R Tanapox host range protein 224 42 F fpv217 328 9.45  Hypothetical protein 225a 37 T fpv218 461 6.29  Ankyrin repeat family 225b 190 T fpv218 461 29.87  Ankyrin repeat family 225c 108 T fpv218 461 28.63  Ankyrin repeat family 226 440 I fpv219 434 84.2  Ankyrin repeat family 227 183 I fpv221 183 88.52 A47L A47L homolog 
228 747 I fpv222 747 82.89  Ankyrin repeat family 229 44 F fpv223 141 21.99  Ankyrin repeat family 
230 106 F cnpv298/fpv223-225 571 8.58  Ankyrin repeat family 
231 293 I fpv226 292 88.74 B1R Serine/threonine protein kinase 
232 361 I fpv227 361 88.92  Ankyrin repeat family 233a 83 F fpv228 525 12.38  Ankyrin repeat family 233b 39 F fpv228 525 5.33  Ankyrin repeat family 233c 101 F fpv228 525 14.29  Ankyrin repeat family 




500 21.37   
235 503 I cnpv301/fpv233 527 37.13  Ankyrin repeat family 236 185 I fpv229 180 80  Hypothetical A47L-like protein 
237a 51 F cnpv303/fpv230-231 256 2.5  Ankyrin repeat family 
237b 140 F cnpv303/fpv230-231 256 15  Ankyrin repeat family 
237c 132 F cnpv303/fpv230-231 256 11.16  Ankyrin repeat family 
238 481 I fpv232 482 85.68  Ankyrin repeat family 239 502 I fpv233 512 85.55  Ankyrin repeat family 240a 80 F fpv234 428 15.89  Ankyrin repeat family 240b 57 F fpv234 428 9.81  Ankyrin repeat family 240c 41 F fpv234 428 7.01  Ankyrin repeat family 241 279 I fpv236 280 76.79  N1R/p28 family 242 122 I fpv237 67 26.83  Hypothetical protein 243 72 F fpv239 163 31.9 A40R C-type lectin family 
244 411 I fpv240 410 79.08  Ankyrin repeat family 245 209 I cnpv313 218 51.14  Ig domain protein 
246 628 I cnpv314/fpv242-243 584 50.94  Ankyrin repeat family 




































253 122 I fpv247 124 82.26  Efc family 254 149 I fpv248 151 78.15  N1R/p28 family 255 107 I fpv249 105 61.4  Hypothetical protein 256 124 I fpv258 123 68 A40R C-type lectin family 
257 222 I fpv259 222 91.44  Hypothetical protein 
258 66 F Aasi_1435/ Cnpv021 1585 2.27  
Hypothetical protein Aasi_1435 
[Candidatus Amoebophilus asiaticus 
5a2] 
259 200 I fpv260 205  A40R C-type lectin family 
Bold and Italic: The 90 core genes conserved in all ChPVs which are involved in essential functions such as replication, transcription and 
virion assembly. Bold: An additional 88 genes conserved in all avipoxviruses. Gene status is depicted as “I” for intact genes, “F” for 
fragmented genes, “T” for truncated genes and “a” where the gene is absent from the genome. α best BlastP hit (Where the best BlastP 



















Table 4.2. Deletions and disruptions in FeP2 
relative to FPVUS. Putative functions for the 
deleted genes have been given where possible 
FeP2 Function 
Deleted genes  
fpv003 C-type lectin family 
fpv004 hypothetical protein 
fpv005 Efc family 
fpv007 hypothetical protein 
fpv008 C-type lectin family 
fpv009 hypothetical protein 
fpv013 hypothetical protein 
fpv027 G-protein coupled receptor family 
fpv032 Dnase II 
fpv033 α-SNAP 
fpv036 hypothetical protein 
fpv042 hypothetical protein 
fpv045 hypothetical protein 
fpv072 β-NGF 
fpv073 IL-18 binding protein 
fpv115 Ankyrin repeat family 
fpv121 CC-chemokine family 
fpv122 B22R 
fpv123 B22R 
fpv124 N1R/p28 family 
fpv125 V-type Ig Domain 
fpv152 HT-motif 
fpv154 hypothetical protein 
fpv210 hypothetical protein 
fpv220 hypothetical protein 
fpv224 Ankyrin repeat family 
fpv225 hypothetical protein 
fpv238 hypothetical protein 
fpv250 US ORF2 
fpv251 Serpin 
fpv252 hypothetical protein 
fpv253 C-type lectin family 
fpv254 hypothetical protein 
fpv255 C4L/C10L-like family 
fpv256 Efc family 
fpv257 hypothetical protein 
Disrupted genes  
fpv026 fragmented ankyrin repeat 
fpv028 truncated hypothetical protein 
fpv034 fragmented ankyrin repeat 
fpv063 truncated hypothetical protein 
fpv064 fragmented glutathione peroxidase 
fpv072 fragmented β-NGF 
fpv073 truncated IL-18 binding protein 
fpv162.2 Fragmented ankyrin repeat 
fpv177 truncated hypothetical protein 
fpv199 fragmented V-Type Ig Domain 
fpv200 fragmented V-Type Ig Domain 
fpv217 fragmented hypothetical protein 
fpv218 truncated ankyrin repeat 
fpv223 fragmented ankyrin repeat 
fpv228 fragmented ankyrin repeat 
fpv234 fragmented ankyrin repeat 
fpv239 fragmented C-type lectin 
fpv245 fragmented ankyrin repeat 
Table 4.3. Insertions in FeP2 relative to FPVUS. 
Inserted genes have been listed if they are present in 
FeP2 in an unexpected site as predicted by genomic 
synteny with the FPVUS. Where no homology to 
FPVUS genes is present, the name of the best 
BlastP hit has been used. 
FeP2 Function 
Inserted genes  
Fragmented cnpv021 ankyrin repeat 
Fragmented cnpv006 hypothetical protein 
cnpv320 Ig Domain protein 
Fragmented cnpv309 ankyrin repeat 
cnpv015 ankyrin repeat 
Fragmented Trichomonas vaginalis ankyrin repeat 
fpv244 ankyrin repeat 
fpv246 ankyrin repeat 
IL-10 (Ficedula albicollis) IL-10 
cnpv028 ankyrin repeat 
cnpv037 hypothetical protein 
cnpv044 ankyrin repeat 
cnpv046 ankyrin repeat 
cnpv232 CC-chemokine-like protein 
cnpv095 hypothetical protein 
Fragmented cnpv098 hypothetical protein 
fp03L vaccinia 03L ortholog 
Fragmented cnpv011 ankyrin repeat 
Fragmented cnpv004 ankyrin repeat 
cnpv012 hypothetical protein 
cnpv224 hypothetical protein 
cnpv170 thymidilate kinase 
Fragmented E. Bacterium hypothetical 
cnpv210 N1R/p28-like protein 
cnpv211 hypothetical protein 
cnpv212 N1R/p28-like protein 
Truncated cnpv279 beta-NGF protein 
Fragmented protein (X. tropicalis) hypothetical 
Tanapox 67R Host Range Protein 
Fragmented O.tsutsugamushi str ankyrin repeat 
cnpv301 ankyrin repeat 
cnpv313 Ig Domain protein 
Fragmented cnpv320 Ig Domain protein 
Truncated cnpv014 Ig Domain protein 






























































































































































































































































































































4.3.7 Gene Translocations and Duplications 
 
Analysis of the FeP2 genome revealed several occurances of gene duplication and 
translocation relative to FWPV (Table 4.1, Fig. 4.4). In some instances the position 
of the gene was closer to that observed in CNPV than FWPV. A second copy of the 
ankyrin repeat family gene, fpv244 orthologue (fep010; cnpv009) is found in the 
equivalent place in the left hand region of FeP2, between nucleotides 15367-13325.  
 
4.3.8 Disrupted and Deleted Genes 
 
Relative to FPVUS, FeP2 contains 5 truncated FPVUS genes and the fragmented 
forms of 13 FPVUS orthologues (Table 4.2). FeP2 contains truncated or fragmented 
remains of ORFs with similarity to CNPV (Table 4.3). Relative to the FPVUS 
genome, FeP2 has 36 deleted ORFs (Table 4.2) that are absent from any potential 
coding regions of its genome. 
 
4.3.9 Inserted genes 
 
Relative to FWPV, the FeP2 genome contains several inserted genes (Table 4.3). 
FeP2 contains an orthologue of a TMPK (fep126, cnpv170; VACV A48R) (Table 4.3) 
and a putative IL-10 gene (fep014) with limited similarity to the CNPV orthologue 
(22.05% aa identity) (Fig. 4.5). The amino acid identities between avian IL-10 genes 
and the CNPV IL-10 orthologue (18.7- 22.7%) is lower than that for the FeP2 
Table 4.4. A summary of the numbers of intact gene family proteins in 
FeP2, FPVUS, FP9, CNPV and VACV. 
 
 FeP2 FPVUS FP9 CNPV VACV 
Ankyrin repeat proteins 26 31 22 51 17 
B22R 4 6 5 6 1 
N1R/p28 11 10 8 26 ? 
C4L/C10L 2 3 3 3 3 
CC chemokine 4 4 4 5 2 
C-type Lectin 4 9 6 11 2 
G protein-coupled receptor gene family 2 3 2 4 ? 
HT Motif 4 6 6 5 - 
Ig-like domain protein 4 5 4 9 3 
Serpin  4 5 5 5 2 
Efc family 1 3 2 2 - 
TGF-β 1 1 1 5 - 
β-NGF 0 2 2 2 - 
interleukin 18 (IL-18)-binding protein 0 1 1 3 1 
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orthologue (22.3-28.3%). The FeP2 and CNPV IL-10 genes are most similar to that 
of a Collared Flycatcher (Ficedula albicollis) sharing 28.3% and 22.7% amino acid 
identity respectively (Fig. 4.5). FWPV does not encode an IL-10 gene [25].  
 
FeP2 encodes a homologue of tanapox virus (TANV) and YLDV 67R which are 
orthologues of VACV C7L (fep223). Based on MUSCLE alignments of several 
poxvirus C7L orthologues, TANV and YLDV 67R orthologues share 97.19% amino 
acid identity. FeP2 shares 26.0% amino acid identity with TANV 67R and 25.4% 
with YLDV 67R. The FeP2 gene contains putative C7/F8A protein family conserved 
domains (PFAM accession: pfam03287, E-value: 7.09e-24) which are conserved 





4.3.10 Comparison of FeP2 to FWPV with respect to attenuation and 
lineage specific mutations 
 
In order to determine lineage specific mutations, Laidlaw and Skinner (2004) 
determined the sequence of HP1 (European strain), the virulent parent of FP9, at all 
loci where FP9 differed from FPVUS (American strain) [27]. Here we compared 
nucleotide changes in FeP2 at 43 genomic positions influencing the amino acid 
composition of 25 ORFs of European and American strains as previously identified 
[27]. In 15 places, FeP2 was the same as HP1 (European lineage) and in 18 places, 
FeP2 was the same as FPVUS (American lineage). FeP2 differs from both HP1 and 
FPVUS in 10 places. 
 
 
Figure 4.5 Pairwise alignment table comparing the amino acid sequences of 
avipoxvirus Interleukin 10 (IL-10) orthologues with selected avian IL-10 genes. 





The genome sequence of a novel South African APV, FeP2 has been determined 
and is significantly different from that of CNPV (approx. 63% identity) and FWPV 
(approx. 85% identity). In OPVs, the internal region of different species share at 
least 96% identity when compared at the nucleotide level, while different strains 
from the same species share at least 99% nucleotide sequence identity [311]. These 
identities have been listed as criteria for establishing poxvirus taxonomy [312]. 
Therefore, according to the identity between the FeP2 and FPVUS genomes (85% 
nucleotide identity), as well as the differences in phylogenetics and growth 
characteristics between these two viruses (chapter 2 and 3), one can conclude that 
FeP2 is a separate species of APV.  
 
Laidlaw and Skinner (2004) [27] identified geographical lineage-specific mutations 
which distinguished European FWPVs, FP9 and HP1 from the American strain 
FPVUS. A comparison of FeP2 with the published FWPV sequences at these sites 
shows that FeP2 shares lineage-specific mutations with both HP1 and FPVUS. 
FeP2 is no more closely related to either the American or the European virus, 
suggesting that FeP2 originates from a common ancestor that diverged relatively 
recently from a FWPV-like progenitor which was more distantly related to the CNPV-
like progenitor. It is important to note that the divergence between APV species is 
comparable to that between some poxvirus genera and the different species within 
the OPV genus are highly similar. 
 
FeP2 is most closely related to FWPV. Despite this, relative to FWPV, the FeP2 
genome contains several genes that are more closely related to CNPV. FeP2 
encodes 16 intact CNPV orthologues (Table 4.3), four of which are not in FWPV, 
including a TMPK protein (cnpv170, fep126) (Table 4.1 and Table 4.3). The 
remainder are more similar to CNPV orthologues but are present in FWPV. Rather 
than being acquired through horizontal gene transfer or recombination, these genes 
are most probably from a common ancestor. Their existence suggests that FeP2 
diverged prior to the present day FWPV, somewhere between the CNPV and FWPV 
branches. Several of the CNPV-like genes exist as gene fragments (Table 4.3), 
which is indicative of their gradual loss through progressive mutation, 




There are several instances of gene duplication and translocation in FeP2 relative to 
FWPV (Fig. 4.4). Most of these involve genes containing ankyrin repeats. Virulent 
FWPV contains 31 ankyrin repeat containing genes and attenuated FP9 contains 22 
of these genes. It is postulated that loss of these genes may be responsible for the 
attenuation of the virus [25, 27]. FeP2 contains 26 ankyrin repeat-containing genes 
(Table 4.1; Table 4.4). Thus the reduced numbers of intact ankyrin repeat genes 
observed in FeP2 compared to FWPV would suggest that this virus is less virulent. 
On the other hand, the expansion of the number of ankyrin repeat genes in certain 
APV strains could represent the forming of adaptive genomic accordions, similar to 
that of the K3L gene in OPV, the formation of which has been described to play an 
adaptive role in these viruses [313]. 
 
The most striking difference between FeP2 and FWPV is a large deletion of ~16kb 
from the central, usually conserved, region of the genome. ORFs corresponding to 
fpv121 (cc-chemokine family), fpv122 and fpv123 (VAR B22R family), fpv124 
(N1R/p28 family) and fpv125 (V-type Ig domain gene family) are deleted in FeP2 at 
this site. The existence of gene fragments and insertions on the borders of this 
deletion, as well as in the equivalent regions in FWPV, suggests that this is a 
―hotspot‖ of genetic change, the mechanism of which is uncertain.  
 
CC chemokines attract immune cells to sites of infection [314]. MCV encodes a CC 
chemokine-like protein (MC148R) which antagonises host CC and CXC chemokines 
[315]. Similarly, APV encode several copies of CC chemokine-like genes which may 
function as antagonists or agonists of the CC chemokines to modify the host 
response to viral infection [25][25][25]. The loss of the CC-chemokine orthologue in 
FeP2 (corresponding to fpv121) may affect the ability of FeP2 to inhibit the action of 
host CC chemokines. VACV B22R is a member of the serine protease inhibitor 
family (serpins), which regulate immune responses and cell death by acting as 
decoys for their target proteinases. VACV B22R (SPI-1) plays a role in the reduction 
of the host immune response to the virus, and the rabbitpox orthologue of B22R 
inhibits apoptosis [41, 316]. Studies with VACV have shown that deletion of B22R 
attenuates VACV and increases its safety without reducing immunogenicity [41]. 
The deletion of two of these genes in FeP2 may have a similar effect. The FPVUS 
genes, fpv124 and fpv125, encoding the Rabbit fibroma virus N1R/Ectromelia virus 
p28 (N1R/p28) gene family protein and a V-type Ig domain family protein 
respectively are deleted in FP9 as well as in FeP2 [27]. APV immunoglobulin (Ig) 
domain genes have potential roles in immunomodulation [24] and N1R/p28 genes 
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are implicated in host range and viral virulence [25]. The five FPVUS genes that are 
deleted from the central region of FeP2 are all involved in viral host range and 
virulence, and their loss may indicate that FeP2 is more attenuated than FPVUS. 
This is supported by the fact that the attenuated FWPV strain, FP9, lacks two of 
these genes (fpv124 and fpv125) as a result of attenation (passage)-specific 
mutations [27]. 
 
Relative to the FPVUS genome, FeP2 has 36 deleted ORFs (Table 4.2). Most of the 
genes deleted are members of multi-gene families, the disruption of which has been 
implicated in the attenuation of poxviruses [27], however there are several other 
deletions of significant ORFs. Of interest, the orthologue of fpv032 encoding a 
DNase II has been deleted in FeP2. In FWPV, fpv032 represents the large subunit 
of cellular DNase II [25, 317] and cellular DNase II is thought to function in DNA 
catabolism during apoptosis [318, 319]. Additionally, the orthologue of fpv033 
encoding one of the two  α-SNAP genes present in FWPV, is absent from FeP2. 
Eukaryotic α-type soluble NSF attachment proteins (α-SNAP) are involved in 
vesicular transport through the Golgi apparatus and for exocytosis [320, 321]. The 
fpv033 gene has been shown to be conserved in FWPV strains but non-essential to 
viral replication and it is thought to be involved in virus-host interactions [322]. 
Although the fpv033 gene orthologue has been deleted in FeP2, a second α-SNAP-
like gene (fep012, fpv011) exists in the genome which exhibits 34% amino acid 
identity with fpv033. 
 
FWPV contains two genes with homology to cellular β-nerve growth factor (β-NGF) 
(fpv072 and fpv076). In FeP2, the orthologue of fpv076 is completely deleted and 
the orthologue of fpv072 (fep074) is fragmented (Table 4.2). An additional β-NGF-
like gene is observed in a truncated form in FeP2 (fep213) (Table 4.3). This is most 
similar to the CNPV gene cnpv279, which exists as a fragment in FWPV [24]. The 
FeP2 ORF, fep213 is truncated to 67 amino acids by the introduction of a premature 
stop codon, where the intact cnpv279 orthologue is 169 amino acids. It is unknown 
whether this protein would be functional in FeP2. β-NGF has proinflammatory 
properties and is produced by fibroblasts and keratinocytes in response to injury 
[323-328]. FWPV encoded β-NGF is thought to be involved in promoting survival in 
infected cells and could have a role in inhibiting antiviral immune responses in the 




FeP2 (fep126) contains an orthologue of TMPK (cnpv170; VACV A48R), which is 
absent in FWPV [25]. This is the only difference found with respect to the 
complement of nucleotide metabolism genes. Interestingly, despite being within the 
conserved central region of the genome, the TMPK gene orthologues occur within a 
region of FeP2 that is highly variable compared to FWPV. In addition, the CNPV 
orthologue insertions that occur within this particular variable region in FeP2 occur in 
different sites across the CNPV genome. The higher than average amino acid 
identity shared between FeP2 and the CNPV TMPK (81.6%) suggests that this 
TMPK gene is necessary and conserved in these viruses. CNPV and FeP2 are the 
only poxvirus species outside of the OPV genus to contain a TMPK homologue. 
VACV encodes TMPK (A48R) that is 42% identical to human TMPK [329]. TMPK 
catalyzes an important step in the biosynthesis of (deoxy) thymidine triphosphate 
and is essential for cell metabolism [330]. The presence of this gene in CNPV and 
FeP2 may affect cell tropism in these viruses compared to FWPV [24]. 
 
FeP2 encodes a putative IL-10 gene. Putative orthologues of IL-10 are also found in 
ORF virus, BPSV [9], LSDV [187] and YLDV [188]. IL-10 is a cytokine that has both 
immunostimulatory and immunosuppressive functions [186] and the ORF virus IL-10 
orthologue has been shown to be immunomodulatory in function [189, 190, 331]. 
The IL-10 gene encoded by  FeP2 contains two functional domains of the IL-10 
superfamily (pfam00726, e-value = 2.40e-14 and smart00188, e value= 2.43e-13) 
and may also be involved immune evasion.  
 
FeP2 encodes a gene with homology to TANV and YLDV 67R (26.0% amino acid 
identity) which are orthologues of VACV C7L and not found in FWPV or CNPV. The 
poxvirus C7L family of host range genes functions by mediating poxvirus host range 
and antagonising the host defence system [332]. VACV C7L orthologues are found 
in all OPV and most mammalian poxviruses, with the exception of molluscum 
contagiosum virus and parapoxviruses [333]. This is the first report of a C7L-like 
gene in APVs. It is possible that this gene has been retained by FeP2 from the last 
common ancestor between avian and mammalian poxviruses although homologous 
recombination with another poxvirus cannot be ruled out. In mammalian cells, C7L 
has been shown to inhibit apoptosis [276], antagonise the anti-viral effects of type I 
IFNs and Interferon Regulatory Factor 1 (IRF-1) [334, 335]  and can antagonize the 
dsRNA-activated protein kinase (PKR) pathway by inhibiting the phosphorylation of 
eIF2a [336]. It has previously been suggested that C7L orthologues are an important 
adaptation of mammalian poxviruses for replication in mammalian hosts [334]. The 
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presence of C7L orthologues in FeP2 confounds these previous observations but 
the function of this gene in this APV remains to be determined. YLDV 67L shows 
only 28-30% identity to the VACV C7L protein but, despite its limited amino acid 
identity, has been shown to function equivalently in supporting VACV replication in 
mammalian hosts [333]. 
 
The genome sequence of FeP2 has added greatly to the limited repository of 
genomic information available for the APV genus. In the comparison of FeP2 to 
existing sequences, FWPV and CNPV, we have established insights into African 
APV evolution. Although FeP2 is more closely related to FWPV, the presence of 
whole or disrupted genes with similarity to CNPV genes that are absent in FWPV, 
suggests that FeP2 originates from the common ancestor of CNPV and FWPV. The 
presence of an intact gene in CNPV and FeP2 where the FWPV counterpart is 
fragmented into two ORFs further supports this theory as fragmented genes 
represent the gradual loss of genetic information during the process of virus 
evolution. Additional sequences of APV genomes would help to define APV 
evolution as a whole. 
 
The ongoing search for an ideal vaccine vector makes this work relevant. Future 
work could focus on how this APV differs from the well characterized FWPV and 
CNPV with respect to immune activation and foreign gene expression. Microarray 
analysis which looks at gene expression changes induced by the different viruses in 
a model system will be beneficial to determine how differences in APV genomes 
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Many different poxviruses are available as potential vaccine vectors. In addition to 
being highly immunogenic, poxviruses such as MVA, LSDV and APVs are host 
restricted and/or attenuated. MVA, an Orthopoxvirus, was derived from vaccinia 
virus Ankara, which was passaged over 570 times in chicken embryo fibroblasts 
resulting in attenuation and severe restriction of host range, as a result of numerous 
genomic deletions rendering it unable to replicate in most mammalian cells [281, 
337]. LSDV is a capripoxvirus, permissive only to ruminants [338]. APVs are host 
restricted to cells of avian origin [45, 275].  
 
MVA is a successful vaccine vector against a variety of pathogens and malignancies 
[70, 339]. LSDV has been proposed as a novel vaccine vector for different human 
and animal pathogens, including HIV and rabies [338]. APVs have been used 
effectively as vaccine vectors against a number of mammalian and human 
pathogens [76]. Poxvirus vaccine vectors have been shown to be an important 
component of heterologous prime-boost strategies to induce HIV responses in 
clinical trials including planned efficacy trials [340, 341]. 
 
Recent studies of different vaccines including yellow fever vaccine and influenza 
vaccine have revealed early host gene signatures which are capable of predicting 
the subsequent vaccine-induced adaptive immune response [342-345]. Host-range 
restricted poxviruses have been shown to successfully activate the host immune 
system [85, 86] and evidence exists to indicate that each virus does this in a 
different way, with an accompanying different pattern of gene expression [87-91]. 
The poxviruses ALVAC (based on CNPV), MVA and NYVAC (a vaccinia virus with 
specific deletions) produce distinct innate immune profiles, characterised by different 
induction of pro-inflammatory and antiviral cytokines and chemokines in both rhesus 
monkeys and human PBMCs [93].  
 
It has been shown that in non-permissive cells, FWPV proceeds further into the 
poxvirus life cycle than CNPV [271], and that heterologous HIV gag/pol and env 
genes are more efficiently expressed by FWPV than CNPV in vitro due to longer 
transgene expression and more balanced cytokine induction [346]. However, the 
only successful HIV-1 vaccine clinical trial to date (31.2% protection from HIV-1 
infection) has been the Thai RV144 trial involving priming with a CNPV (ALVAC) 
vector expressing HIV-1 gp120/Gag-Pro and boosting with a recombinant 
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glycoprotein 120 subunit, AIDSVAX RW [60]. More head to head comparisons of 
poxvirus-vectored vaccines would help to establish which candidate would be 
suitable to achieve the desired vaccine-induced response to achieve protection 
against pathogens and cancers. 
 
Innate immunity is critical for directing the adaptive immune response to antigen and 
influences the magnitude and quality of the long-lived, protective immune responses 
to pathogens or vaccines [347]. The identification of innate immune signatures that 
can predict the consequent adaptive immune response is beneficial in the 
development and rational design of new vaccine candidates. Chemokines induce 
the migration of immune effector cells to the site of infection. IL-8 (CXCL8) induction 
causes the recruitment of neutrophils, whereas MIP-1α and MIP-1β recruit NK cells, 
macrophages and immature DCs. IP-10 (CXCL10) causes the migration of activated 
T cells into tissue [348]. Clearly the innate immune response is important in the 
induction of an adaptive immune response. Systems biology evaluates the complex 
interactions within a biological system, and is an approach which can be enormously 
valuable in studying the interplay between virus (or vaccine) and host. Application of 
the systems biology approach to vaccine development (―systems vaccinology‖) and 
establishment of innate immune signatures has proven useful in predicting the 
immunogenicity of the highly effective yellow fever vaccine (YF-17D) [342], seasonal 
influenza vaccines [343] and the immunogenic but inefficacious Merck Ad5/HIV 
vaccine [344]. Post hoc systems analysis of the Merck Ad5/HIV vaccine indicated 
both that innate immune reponses are able to predict immunogenicity of the vaccine, 
and that the existence of pre-exisiting neutralizing antibodies to Ad5 attenuate the 
innate immune response to MRKAd5/HIV, suggesting that the enhanced HIV 
acquisition in pre-immune individuals in the Step trial may be a result of poor innate 
activation rather than increased immune activation as previously hypothesized [344]. 
A better understanding of the mechanisms underlying the optimal innate immune 
responses would aid rational vaccine development.  
 
Type I IFNs (IFNα/β) are expressed rapidly in response to viral infection. Type I 
IFNs in turn activate many ISGs which exert various antiviral effector functions. The 
effect of type I IFNs on poxvirus-induced immune responses is complex and poorly 
understood. Co-administration of IFN-α with VACV resulted in a decrease in cell 
mediated immunity whereas IFN-α enhanced antigen-specific T-cell proliferation and 
cytotoxic T lymphocyte responses when co-administered with FWPV [110]. 
Conversely, type I IFN is not necessary for the induction of adaptive immunity to 
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FWPV-encoded antigen [111]. A balance is necessary for vaccination purposes, 
where enough type I IFNs are produced to activate the immune system, yet not 
enough to inhibit viral DNA replication and gene expression before antigen 
presentation can occur [96]. This is corroborated by Johnson et al (2012) [349], who 
compared rAd5, rAd28 and rAd35. Here they showed that the specific IFN-α 
induction by rAd28 and rAd35 significantly lowered the immunogenicity of these 
vectors compared to rAd5 which did not induce IFN-α expression [349]. The effect of 
type I IFN responses on different vaccines requires delineation of innate immune 
signatures and how they determine subsequent adaptive responses. 
 
Microarray analyses performed in vitro have been used to investigate the effects of 
VACV [90], MVA [87] and NYVAC [89] infection on HeLa cell gene expression. 
Gene expression profiles in human monocyte derived dendritic cells (MDDCs) have 
also been generated with MVA, NYVAC [88] and ALVAC [91]. Furthermore, a 
comparison of the closely related VACV-derived vectors NYVAC and MVA revealed 
significant differences in antigen production and host gene dysregulation in cell 
culture [276]. Consequently it was speculated that genetically diverse poxvirus 
strains would induce significant differences in host gene expression. The interaction 
of poxviruses with the host is not just dependent on the actual cell infected by the 
virus but also on the factors secreted by those infected cells and their effects on the 
surrounding cells. Although in vitro expression studies have provided useful 
information, gene expression profiles performed in cell culture may not accurately 
reflect the changes in the system that occurs as a result of infection in vivo. A recent 
study in Rhesus Macaques has shown that the CNPV-based vector, ALVAC, 
induced distinct cytokine and chemokine levels compared to the vaccinia virus-
based vectors MVA and NYVAC and that multiple subsets of PBMCs are likely to 
contribute to the overall response to different poxviruses [93].  
 
Here we investigate and compare the effects of the capripoxvirus LSDV, the 
orthopoxvirus MVA, and the four APVs; CNPV, FWPV, FeP2 and PEPV on host 
gene expression profiles in the spleens of BALB/c mice. The spleen is one of the 
major peripheral lymphoid organs and functions to collect antigen from the blood 
and present it to migratory lymphocytes, thereby playing a role in the induction of the 
adaptive immune response [350]. Comparative analysis of the gene expression 
profiles in mouse spleens by microarray will yield valuable information on the ability 
of different host restricted poxviruses to alter mammalian cell pathways on a whole 
organism level. This has relevance for both human and veterinary vaccines. 
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5.2 Materials and methods 
5.2.1 Viruses 
 
FeP2 was from a Feral Pigeon (Columba livia), isolated as described in chapter 2, 
section 2.2.1. PEPV seedstock was kindly obtained from Olivia Carulei a fellow PhD 
student at University of Cape Town, originally isolated by D. Kow and Prof. K 
Dumbell [71]. MVA and wild type CNPV were obtained from Prof. K. Dumbell‘s 
collection housed at the University of Cape Town and were originally from Prof. A. 
Mayr (Veterinary Faculty, University of Munich, Munich, Germany). The FWPV 
vaccine is DCEP 25 modified strain (Sanofi Merial, Duluth, GA, USA) obtained from 
a licensed veterinarian and LSDV is a vaccine strain, Herbivac® (Ceva), 
manufactured by Deltamune (Pretoria, South Africa).  
 
Virus isolates were grown and titrated on the CAMs of embryonated 10-11 day old 
(MVA, CNPV, FWPV) or 7 day old (LSDV) SPF White Leghorn chicken eggs, which 
were obtained from Avifarms (Pty) Ltd (Lyttelton, South Africa), using a method 
described previously (chapter 2, section 2.2.2). Titrations were performed on CAMs 
for APVs and MVA. Titration of LSDV was performed by immunostaining on Madin 
Darby bovine kidney (MDBK) cells by Dr. Z. Ginbot. 
 
5.2.2 Virus infection of mice 
 
Mouse work was performed by Rodney Lucas in the University of Cape Town, 
Health Sciences Faculty Research Animal Facility. Seven week old naive female 
BALB/c mice were randomly divided into groups of three and each mouse was 
inoculated intravenously (i.v.) with  105 pfu/100ul poxvirus, diluted in PBS or mock 
infected with PBS alone or egg extract (100μl). The egg extract was made from 
uninfected CAMs, following the same extraction and purification procedure as the 
virus samples above. We compared the gene expression profiles of the groups of 
mice that were mock-infected with egg extract and PBS. For each different virus, 
three groups of three mice each were inoculated. At 24 hours post infection, the 
mice were sacrificed by cervical dislocation without anaesthesia and the spleens 







5.2.3 RNA extraction 
 
Mouse spleens were removed from RNAlater and the three spleens in each group 
were pooled and homogenized thoroughly, using a TissueRuptor (Qiagen), in 
TRIzol® reagent (Life Technologies, Carlsbad, CA, USA). Total RNA was isolated 
using TRIzol® Plus RNA Purification Kit (Life Technologies, Carlsbad, CA, USA) 
with On-column PureLink® DNase treatment according to the manufacturer‘s 
instructions. RNA was resuspended in RNase free water and quality checked using 
the Nanodrop ND1000 (Thermoscientific, Waltham, MA, USA) and the Agilent 
Bioanalyzer Nano Assay (Agilent, Santa Clara, CA, USA). Olivia Carulei assisted 
with the RNA extractions. 
 
5.2.4 Microarray and data analysis 
 
mRNA hybridization was performed by IMGM Laboratories GmbH (Martinsried, DE) 
with the Affymetrix GeneChip Mouse Gene 2.0 ST array (Affymetrix, Santa Clara, 
CA, USA). Data analysis was performed in R [351], using packages from the 
Bioconductor suite (http://www.bioconductor.org), and CRAN 
(http://cran.rproject.org). All R code is available in appendix 3. Dr Armin Deffur 
provided bioinformatics support and input. Probe level data from .CEL files was 
normalised using the Robust Multi-array Averaging (RMA) method [352] obtained as 
part of the ―affy‖ package [353] from Bioconductor, resulting in log2 transformed 
values. Boxplots, scatterplots and histogram outputs of the normalised data were 
obtained and checked for consistency (not shown). Data was annotated using the 
Mouse Gene ST 2.0 annotation data package from Bioconductor. Non-specific 
filtering was performed using the Genefilter package [354]. This step included an 
intensity filter which filtered the data set such that the intensity of each gene should 
be >log2 (100) in at least 20% of the samples. Secondly, a variance filter was 
applied such that the interquartile range of log2-intensities should be at least 0.5. 
 
Differential gene expression was determined using a linear model approach using 
the R package, Limma [355]. A heatmap was made using heatmap.2 from the 
CRAN package gplots [356], and depicted the unsupervised hierarchical clustering 
based on the genes with p-value < 0.05 and log2 fold change (FC) above or below 
cutoff (±1). Venn diagrams were made using Venny [357] available at 
http://bioinfogp.cnb.csic.es/tools/venny/index.html. Gene ontology (GO) enrichment 
was performed using the R package clusterProfiler [358]. For gene ontology 
120 
 
analysis, all genes with an adjusted p-value of ≤ 0.05, irrespective of fold change, 
were used to ensure that no information was lost by the arbitrary designation of a 
fold change cut off. This was done to show the full effect on pathways by the 
different viruses. Functional analysis was performed using Database for Annotation, 
Visualization and Integrated Discovery (DAVID) v6.7 web-based tools 
(www.david.-abcc.-ncifcrf.-gov/-tools.-jsp). Quantitative real time PCR (RT-PCR) 
was performed on selected genes to validate microarray findings (data not shown). 
 
Histone transcripts 
Previous studies have found that increased detection of histone genes by poxvirus 
infection is described as an experimental artefact due to the de novo 




5.3.1 Comparison of the host responses to different poxviruses 
 
We compared the differential host gene expression induced by six host-restricted 
poxviruses, MVA, LSDV, FWPV, CNPV, FeP2 and PEPV, in the spleens of BALB/c 
mice at 24h post infection. Transcripts with an adjusted p-value < 0.05 were 
described as up regulated if they had a log2 FC of ≥1, or down regulated if they had 
a log2 FC of ≤-1. A summary of the number of up and down regulated genes is given 
in Table 5.1. Full gene lists are given in appendix 4, Tables a1 and a2. Several 
histone transcripts (39 in total) were down regulated in response to virus infection 
and, because any interpretation of these transcripts would be speculative, these 
have been excluded from further analysis. 
 
Unsupervised hierarchical clustering based on the genes with p-value < 0.05 and 
log2 FC above or below cutoff (>1, <-1) showed that each virus induced a unique 
overall response (Fig. 5.1). Venn diagrams highlight the number of differences and 
similarities in the up- and down regulated genes between the viruses (Fig. 5.2). 
Each virus modulated a different number of genes, with varying numbers of genes in 
common (Fig. 5.2). Figures 5.2 A and B show the differences in up- (A) and (B) 
down regulated transcripts between FWPV, CNPV, MVA and LSDV respectively. 
Similarly, figures 5.2C and D represent the differences in gene expression between 
the four APVs analysed. When only the APVs were compared FeP2 up regulated 17 
genes in common with all four APVs, two in common with CNPV and one in 
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common with PEPV. PEPV up regulated 43 genes in common with CNPV and 7 in 
common with FWPV. FWPV up regulated 166 unique genes and 198 in common 
with CNPV. CNPV up regulated 19 unique genes. There were only 3 genes down 
regulated in all four APVs tested. FeP2 had no other genes down regulated. PEPV 
shared 15 down regulated genes with CNPV and FWPV, and one with CNPV only. 
FWPV had 28 unique down regulated genes and 16 in common with just CNPV. 
CNPV had 12 unique genes down regulated. 
 
The Venn diagrams comparing FWPV, CNPV, MVA and LSDV indicate that the 
majority of up regulated genes are shared amongst these 4 viruses (Fig. 5.2). The 
down regulated genes however, appear largely unique, especially for LSDV and 
MVA (Fig. 5.2). FWPV and CNPV down regulate a smaller number of genes in 
comparison to LSDV and MVA. Comparison of APV-induced up- and down 
regulated genes shows that FeP2 and PEPV induce significantly less change in host 
gene expression than FWPV and CNPV (Fig. 5.2). FeP2 induced the lowest 
response (Fig. 5.2, Table 5.1). For all six viruses, more genes were up regulated 
than down regulated (Table 5.1).  
 
The differences in the enrichment of genes associated with specific GO terms are 
displayed in Figure 5.3. This analysis indicates that while PEPV, CNPV, FWPV, 
MVA and LSDV enrich several common GO terms (eg: biological process), FeP2 
fails to do so. FeP2 however up regulates genes that are associated with GO terms 
that are not enriched in the other 5 viruses, including several GO terms related with 
development, regulation of response to stimulus and defence response (Fig. 5.3). 
Although five of the viruses up regulated genes associated with the same GO terms 



















Table 5.1. Summary of the number of significantly up- and down regulated 
transcripts with adjusted p-value < 0.05. Genes are described as up regulated if they 
had a fold change of ≥2, or down regulated if they had a fold change of ≤-2. These 
included genes that are not annotated and therefore do not have an Entrez ID. The 
numbers of genes without annotation are indicated in brackets. 
 
 
Up regulated FC>2 Down regulated FC<-2 
MVA 299 (42NA) 177 (86NA) 
LSDV 463 (111NA) 85 (11NA) 
FWPV 433 (101NA) 62 (28NA) 
CNPV 280 (31NA) 47 (11NA) 
FeP2 20 (1NA) 3 (0NA) 
PEPV 68 (6NA) 19 (2NA) 
Figure 5.1. Heatmap comparing the differential expression induced in mouse spleens in 
response to FeP2, PEPV, LSDV, MVA, CNPV and FWPV. Only genes (with p-value<0.05) with 
log2 fold change induction above or below the cutoff (±1) as compared to the mock infected control 
are shown. Unsupervised hierarchical clustering of the samples is represented by dendograms. 
















Figure 5.2. Venn diagrams showing the overlap between the differentially up regulated (A) and 
down regulated (B) transcripts induced by CNPV, FWPV, MVA and LSDV and the up regulated 
(C) and down regulated (D) transcripts induced by the four avipoxviruses. For each diagram, the 
circles represent the number of differently expressed transcripts regulated by each virus (p value ≤ 
0.05, log2 fold change of ≥ ±1). The numbers in the intersections of each circle represents the number 














Figure 5.3. Biological theme comparison comparing the significantly enriched (p-value≤0.05) Gene 
Ontology (GO) terms  in CNPV, FeP2, FWPV, LSDV, MVA and PEPV. The above graph is organised by 
the number of genes (indicated by the size of the dot) assigned to each GO term and by the significance of 
the association (p-value) (indicated by the colour of the dot). 
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5.3.2 Immunity and host defence response-related genes 
 
Selected up regulated genes involved in the immune response are listed in Table 
5.2. (Full list of up regulated genes is given in appendix 4). Seventeen of these 
genes are uniquely up regulated by LSDV. RIG-I (Ddx58) senses viral nucleic acid 
[361], Cebpb is important for macrophage function [362] and control of inflammatory 
responses [363], Tap1 and Tap2 genes are involved in antigen presentation to MHC 
class 1 molecules [364], Ifitm3 and Ifi203 are ISGs, c-Myc and Mif are transcription 
factors and Adar is  an RNA editing enzyme. There are 8 genes induced by CNPV, 
FWPV and MVA, which are not up regulated in LSDV-infected mice. Two of these 
include the cytidine deaminase, Apobec1, which can edit viral nucleic acid and can 
thereby limit viral replication [365], and caspase 1 (Casp1), which is associated with 
pyroptosis (Table 5.2). 
 
Twenty six genes involved in the host immune/defence response were up regulated 
only in APV -infected mouse spleens (Table 5.2). The only APV - specific gene that 
was up regulated by all four APVs was the macrophage receptor with collagenous 
structure (Marco) gene which has been shown to suppress early inflammatory 
responses to virus infection [366]. There were, however, 9 additional genes which 
were up regulated by both CNPV and FWPV that were not induced by the other 
viruses. These included the chemokine Ccl6 which promotes immune cell activation 
and recruitment [367] and the immunoglobulin heavy chain genes, Ighg (IgG) and 
Ighg3 (IgG3) (Table 5.2). Amongst these 26 APV-specific genes, 14 were 
exclusively up regulated by FWPV. The Nod-like receptor, NLR, Nod1, which has 
been shown to be augmented in response to virus-induced production of type I IFNs 
[368] was exclusively up regulated by FWPV. Two genes were uniquely up 
regulated in CNPV-infected mice including the immunoglobulin heavy chain gene, 
Ighm (IgM) and lymphocyte antigen 96 (Ly96) (Table 5.2). 
 
Four genes were up regulated by LSDV and MVA that were not induced by the 
APVs in mice (Table 5.2), namely the Moloney Leukemia Virus 10 (Mov10) gene, 
hematopoietic SH2 domain containing protein (Hsh2d), poly (ADP-ribose) 
polymerase family, member 11 (Parp11)  and schlafen 8 (Slfn8). No genes were 
uniquely up regulated in response to MVA infection (Table 5.2). PePV and FeP2 





Table 5.2. Selection of up regulated genes in mouse spleens in response to CNPV, FeP2, FWPV, 
LSDV, MVA and PEPV. Differences in Log2 Fold Changes (between each virus and the control) are 
depicted. 
Symbol Name Entrez MVA LSDV CNPV FWPV PEPV FeP2 
GENES INDUCED BY LSDV ALONE. 
Oas1b 2'-5' oligoadenylate synthetase 1B 23961 - 1.6 - - - - 
Adar adenosine deaminase, RNA-specific 56417 - 1 - - - - 
Cebpb CCAAT/enhancer binding protein (C/EBP), beta 12608 - 1 - - - - 
Ddx58 
(RIG-1) 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 230073 - 1.3 - - - - 
Grn granulin 14824 - 1.1 - - - - 
Gvin1 GTPase, very large interferon inducible 1 74558 - 1.5 - - - - 
Gm17757 GTPase, very large interferon inducible 1 pseudogene 1004178
29 
- 1.5 - - - - 
H2-T24 histocompatibility 2, T region locus 24 15042 - 1.2 - - - - 
Ifi203 interferon activated gene 203 15950 - 1.1 - - - - 
Ifitm3 interferon induced transmembrane protein 3 66141 - 1.4 - - - - 
Ifi27l2a interferon, alpha-inducible protein 27 like 2A 76933 - 1.9 - - - - 
Ly6i lymphocyte antigen 6 complex, locus I 57248 - 1 - - - - 
Mif macrophage migration inhibitory factor 17319 - 1.1 - - - - 
Myc myelocytomatosis oncogene 17869 - 1.1 - - - - 
Nlrc5 NLR family, CARD domain containing 5 434341 - 1.8 - - - - 
Slfn2 schlafen 2 20556 - 1.1 - - - - 
Stat1 signal transducer and activator of transcription 1 20846 - 1.4 - - - - 
Tap1 transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) 21354 - 1.1 - - - - 
Tap2 transporter 2, ATP-binding cassette, sub-family B (MDR/TAP) 21355 - 1 - - - - 
Trim25 tripartite motif-containing 25 217069 - 1 - - - - 
Trim34b tripartite motif-containing 34B 434218 - 1.1 - - - - 
GENES INDUCED BY CNPV, FWPV AND MVA ONLY, AND NOT LSDV. 
Casp1 caspase 1 12362 1.1 - 1.2 1.1 - - 
Clec4a2 C-type lectin domain family 4, member a2 26888 1.2 - 1.5 1.1 - - 
Ifi205 interferon activated gene 205 226695 1.4 - 1.6 1.8 - - 
Prdx1 peroxiredoxin 1 18477 1 - 1 1.2 - - 
Pnpt1 polyribonucleotide nucleotidyltransferase 1 71701 1.1 - 1.1 1.4 - - 
Scimp SLP adaptor and CSK interacting membrane protein 327957 1.2 - 1.2 1.5 - - 
GENES INDUCED BY AVIPOXVIRUSES ONLY (CNPV, FWPV, FEP2 AND/ OR PEPV) 
Anxa1 annexin A1 16952 - - 1.6 1.8 - - 
Apobec1 apolipoprotein B mRNA editing enzyme, catalytic 
polypeptide 1 
11810 - - 1.2 1.2 - - 
Ccl6 chemokine (C-C motif) ligand 6 20305 - - 1.3 1.3 - - 
Ear2 eosinophil-associated, ribonuclease A family, member 2 13587 - - 1.3 1.5 - - 
Hsbp1 heat shock factor binding protein 1 68196 - - 1.2 1.2 - - 
Ighg Immunoglobulin heavy chain (gamma polypeptide) 380794 - - 1.5 1.6 - - 
Ighg3 Immunoglobulin heavy constant gamma 3 380795 - - 1.3 1.2 - - 
Lilrb3 leukocyte immunoglobulin-like receptor, subfamily B (with 
TM and ITIM domains), member 3 
18733 - - 1.1 1 - - 
Marco macrophage receptor with collagenous structure 17167 - - 1 - 1.5 1.5 
Pf4 platelet factor 4 56744 - - 1.2 1.1 - - 
Pram1 PML-RAR alpha-regulated adaptor molecule 1 378460 - - 1.1 1.1 - - 
Psma1 proteasome (prosome, macropain) subunit, alpha type 1 26440 - - 1.1 1.3 - - 
GENES INDUCED BY FWPV ONLY. 
Aif1 allograft inflammatory factor 1 11629 - - - 1.1 - - 
Anxa2 annexin A2 12306 - - - 1.1 - - 
Ddx18 DEAD (Asp-Glu-Ala-Asp) box polypeptide 18 66942 - - - 1.1 - - 
Dcn decorin 13179 - - - 1.5 - - 
Fgl2 fibrinogen-like protein 2 14190 - - - 1.2 - - 
Gsdmd gasdermin D 69146 - - - 1.2 - - 
Myd88 myeloid differentiation primary response gene 88 17874 - - - 1.2 - - 
Nos2 nitric oxide synthase 2, inducible 18126 - - - 1.1 - - 
Nod1 nucleotide-binding oligomerization domain containing 1 107607 - - - 1 - - 
Pdcd5 programmed cell death 5 56330 - - - 1.2 - - 
Psmc6 proteasome (prosome, macropain) 26S subunit, ATPase, 6 67089 - - - 1 - - 
Prmt1 protein arginine N-methyltransferase 1 15469 - - - 1 - - 
Serpinb6b serine (or cysteine) peptidase inhibitor, clade B, member 6b 20708 - - - 1.2 - - 
GENES INDUCED BY CNPV ONLY. 
Ctsl cathepsin L 13039 - - 1.1 - - - 
Ighm immunoglobulin heavy constant mu 16019 - - 1.1 - - - 
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Ly96 lymphocyte antigen 96 17087 - - 1.2 - - - 
Pomp proteasome maturation protein 66537 - - 1 - - - 
GENES INDUCED BY LSDV AND MVA, BUT NOT BY THE AVIPOXVIRUSES 
 
Hsh2d hematopoietic SH2 domain containing 209488 1.1 1.4 - - - - 
Mov10 Moloney leukemia virus 10 17454 1.1 1.5 - - - - 
Parp11 poly (ADP-ribose) polymerase family, member 11 101187 1 1.4 - - - - 
Slfn8 schlafen 8 276950 1.2 1.5 - - - - 
OTHER 
Oas1a 2'-5' oligoadenylate synthetase 1A 246730 1.5 2.7 1.6 1.4 - - 
Oas1g 2'-5' oligoadenylate synthetase 1G 23960 2.3 3.9 2.5 2.3 - - 
Oas2 2'-5' oligoadenylate synthetase 2 246728 2.1 3.4 2 1.6 - - 
Oas3 2'-5' oligoadenylate synthetase 3 246727 1.1 2.6 1.3 1 - - 
Oasl1 2'-5' oligoadenylate synthetase-like 1 231655 2.6 3.5 2.4 2.5 - - 
Oasl2 2'-5' oligoadenylate synthetase-like 2 23962 2 3.4 2 2 - - 
Amica1 adhesion molecule, interacts with CXADR antigen 1 270152 - 1.1 - 1.1 - - 
Angptl4 angiopoietin-like 4 57875 1.1 1.5 - 1.6 1.1 - 
Asb13 ankyrin repeat and SOCS box-containing 13 142688 1.2 1 1.1 1.3 - - 
Anxa4 annexin A4 11746 1.8 1.9 1.7 2.1 1.1 - 
Apol9b apolipoprotein L 9b 71898 2.3 2.7 2.6 2.4 - - 
Bst2 bone marrow stromal cell antigen 2 69550 2.3 3 2.1 2.2 - - 
Casp4 caspase 4, apoptosis-related cysteine peptidase 12363 1.9 1.6 1.9 2 - - 
Ctsc cathepsin C 13032 1.1 1.1 - 1.1 - - 
Cd274 CD274 antigen 60533 1.9 2.3 1.6 2.1 1.2 - 
Cd5l CD5 antigen-like 11801 1.2 1.5 1.4 1.1 - - 
Cd69 CD69 antigen 12515 1.8 1.8 1.5 1.7 - - 
Ccl2 
(MCP1) 
chemokine (C-C motif) ligand 2 20296 3.5 3.3 2.9 3.3 2.8 - 
Ccl3 (MIP-
1α) 
chemokine (C-C motif) ligand 3 20302 2 2.1 2.3 2 1.4 - 
Ccl7 chemokine (C-C motif) ligand 7 20306 3 2.9 2.6 2.9 2.7 1.5 
Ccr5 chemokine (C-C motif) receptor 5 12774 1.1 1.5 1.3 1.3 - - 
Ccrl2 chemokine (C-C motif) receptor-like 2 54199 - 1.5 1.2 1.4 - - 
Cxcl10 (IP-
10) 
chemokine (C-X-C motif) ligand 10 15945 2.7 3 2.2 2.8 1.7 - 
Cxcl11 (I-
TAC) 
chemokine (C-X-C motif) ligand 11 56066 4.5 4.4 3.4 4.3 1.5 - 
Cxcl9 
(MIG) 
chemokine (C-X-C motif) ligand 9 17329 2.1 2.3 - 1.8 - - 
Chi3l3 chitinase 3-like 3 12655 - 1.2 1.4 1.6 - - 
Csf2rb2 colony stimulating factor 2 receptor, beta 2, low-affinity 
(granulocyte-macrophage) 
12984 - 1.5 - 1.7 - - 
C1qa complement component 1, q subcomponent, alpha 
polypeptide 
12259 - 1.1 1 - - - 
C2 complement component 2 (within H-2S) 12263 1.5 1.8 1.7 1.6 1 - 
Cfb complement factor B 14962 2.2 2.6 1.6 2 1 - 
Cdkn1a 
(P21) 
cyclin-dependent kinase inhibitor 1A  12575 1.7 2 1.5 2 1.2 - 
Cstb cystatin B 13014 1.4 1 1.5 1.5 - - 
Cst7 cystatin F (leukocystatin) 13011 1.2 1.4 1.1 1.4 - - 
Cmpk2 cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial 22169 1.3 2 1.3 1.3 - - 
Cycs cytochrome c, somatic 13063 - 1.1 - 1.1 - - 
Ctla2a cytotoxic T lymphocyte-associated protein 2 alpha 13024 1.1 1 1.1 1.3 - 1.4 
Ddx60 DEAD (Asp-Glu-Ala-Asp) box polypeptide 60 234311 1.7 2.6 1.5 1.4 - - 
Dhx58 
(LGP2) 
DEXH (Asp-Glu-X-His) box polypeptide 58 80861 1.7 2.5 1.6 1.5 - - 
Dram1 DNA-damage regulated autophagy modulator 1 71712 1.2 1.4 - 1.3 - - 
Ddit4 DNA-damage-inducible transcript 4 74747 1.2 1.2 1.8 1.3 1.4 - 
Eif2ak2 
(PKR) 
eukaryotic translation initiation factor 2-alpha kinase 2 19106 1.1 2.1 1.1 1.1 - - 
Daxx Fas death domain-associated protein 13163 2 2.3 1.7 1.9 - - 
Fcgr1 Fc receptor, IgG, high affinity I 14129 2.4 2.6 2.4 2.6 1.4 - 
Fcgr4 Fc receptor, IgG, low affinity IV 246256 2.5 3.6 2.8 2.9 1.8 - 
Fpr1 formyl peptide receptor 1 14293 1.3 1.1 1.4 1.4 - - 
Fpr2 formyl peptide receptor 2 14289 1.8 1.5 1.7 1.9 - - 
Glipr2 GLI pathogenesis-related 2 384009 1.4 1.5 1.1 1.5 - - 
Gp49a glycoprotein 49 A 14727 2.6 2.4 2.7 2.7 1.9 2 
Gca grancalcin 227960 1.2 1.3 1.4 1.6 - - 
Gzma granzyme A 14938 1.8 1.8 2.2 2 - - 
Gzmb granzyme B 14939 3.7 4.7 4.1 4.2 2.4 - 
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Gadd45b growth arrest and DNA-damage-inducible 45 beta 17873 1.3 1.5 1.2 1.5 - - 
Gbp1 guanylate binding protein 1 14468 2.1 2.7 1.6 2.5 - - 
Gbp11 guanylate binding protein 11 634650 3.9 4.5 2.9 4.2 1.6 - 
Gbp2 guanylate binding protein 2 14469 2.3 2.8 1.5 2.7 - - 
Gbp3 guanylate binding protein 3 55932 1.6 1.8 1.2 1.6 - - 
Gbp4 guanylate binding protein 4 17472 2.1 2.7 1.3 2.4 - - 
Gbp5 guanylate binding protein 5 229898 2 2.8 1.3 2.2 1.1 - 
Gbp7 guanylate binding protein 7 229900 1.6 2.2 1.2 1.7 - - 
Gbp10 guanylate-binding protein 10 626578 2.1 3.2 1.3 1.9 - - 
Gbp8 guanylate-binding protein 8 76074 1.3 1.4 1.4 2.1 - - 
Gbp9 guanylate-binding protein 9 236573 1.2 1.9 1 1.3 - - 
Hp haptoglobin 15439 1.2 1.8 1.7 1.9 1.3 1.3 
Hspa1b heat shock protein 1B 15511 2.3 2.9 2.4 2.5 - - 
H2-Q4 histocompatibility 2, Q region locus 4 15015 1 1.2 - 1.2 - - 
H2-Q6 histocompatibility 2, Q region locus 6 110557 1 1 - 1.1 - - 
H2-T22 histocompatibility 2, T region locus 22 15039 1 1.3 - - - - 
H2-T23 histocompatibility 2, T region locus 23 15040 1 1.3 - 1 - - 
Irgm1 immunity-related GTPase family M member 1 15944 1.4 2.3 1.1 1.4 - - 
Irgm2 immunity-related GTPase family M member 2 54396 1 1.7 - 1.2 - - 
Irg1 immunoresponsive gene 1 16365 2.6 2.5 1.9 2.5 1.6 - 
Ifi202b interferon activated gene 202B 26388 2.4 2.6 2.1 2.2 - - 
Ifi204 interferon activated gene 204 15951 3.3 4 3.2 3.9 - - 
Igtp interferon gamma induced GTPase 16145 1.4 2.2 1 1.8 - - 
Ifitm6 interferon induced transmembrane protein 6 213002 1.8 1.9 2.4 2.3 1.6 1.5 
Ifih1 
(MDA5) 
interferon induced with helicase C domain 1 71586 1.3 2.1 1.2 1.2 - - 
Iigp1 interferon inducible GTPase 1 60440 1.7 2.9 1.2 1.9 - - 
Irf1 interferon regulatory factor 1 16362 - 1.3 - 1.1 - - 
Irf7 interferon regulatory factor 7 54123 1.7 2.9 1.7 1.1 - - 
Ifi35 interferon-induced protein 35 70110 1.1 1.5 1.1 1.2 - - 
Ifi44 interferon-induced protein 44 99899 2 2.5 1.8 1.6 - - 
Ifi44l interferon-induced protein 44 like 15061 2.1 2.9 2 2 - - 
Ifit1 interferon-induced protein with tetratricopeptide repeats 1 15957 2.2 3.3 2 1.7 - - 
Ifit2 interferon-induced protein with tetratricopeptide repeats 2 15958 1.8 2.5 1.8 1.7 - - 
Il1a interleukin 1 alpha 16175 1.9 2 2.2 2.3 1.8 - 
Il1f9 interleukin 1 family, member 9 215257 1.3 1.6 1.7 1.8 1.2 1 
Il1rn interleukin 1 receptor antagonist 16181 1.3 1.1 - 1.2 - - 
Il12rb1 interleukin 12 receptor, beta 1 16161 2 2.4 1.7 2.1 1.1 - 
Il12rb2 interleukin 12 receptor, beta 2 16162 1.2 1.3 1.3 1.3 - - 
Il15 interleukin 15 16168 1.1 1.3 1.2 1 - - 
Il15ra interleukin 15 receptor, alpha chain 16169 1.8 1.9 1.5 1.8 1.2 - 
Il18bp interleukin 18 binding protein 16068 1.2 1.7 1.3 1.5 - - 
Il2ra interleukin 2 receptor, alpha chain 16184 1.1 1.2 - 1.3 1.1 - 
Il33 interleukin 33 77125 - 1 - 1.1 - - 
Isg15 ISG15 ubiquitin-like modifier 1000388
82 
1.6 2.2 1.5 1.4 - - 
Klrk1 killer cell lectin-like receptor subfamily K, member 1 27007 1.5 1.7 1.6 1.5 - - 
Lgals9 lectin, galactose binding, soluble 9 16859 1.2 1.6 1.1 1.2 - - 
Lgals3bp lectin, galactoside-binding, soluble, 3 binding protein 19039 1.2 1.7 1.1 - - - 
Lilrb4 leukocyte immunoglobulin-like receptor, subfamily B, 
member 4 
14728 1.6 1.5 1.7 1.7 1.1 - 
Lcn2 lipocalin 2 16819 1.4 1.6 2.2 2.2 1.4 1.7 
Ly6a lymphocyte antigen 6 complex, locus A 110454 1.7 1.9 1.2 1.3 - - 
Ly6c1 lymphocyte antigen 6 complex, locus C1 17067 1.8 2.2 1.9 1.9 - - 
Ly6c2 lymphocyte antigen 6 complex, locus C2 1000415
46 
1.3 1.6 1.3 1.1 - - 
Ly6g lymphocyte antigen 6 complex, locus G 546644 - 1.7 2.5 2.2 - - 
Msr1 macrophage scavenger receptor 1 20288 2.3 2 2 2.2 1.4 1.1 
Mmp13 matrix metallopeptidase 13 17386 2.7 2.6 2.4 2.4 1.5 - 
Mmp19 matrix metallopeptidase 19 58223 1.9 2 2 2 1.5 1.2 
Mmp25 matrix metallopeptidase 25 240047 - 1 - 1.1 - - 
Mmp8 matrix metallopeptidase 8 17394 2.7 3 3.1 3.4 2.5 2.8 
Ms4a4a membrane-spanning 4-domains, subfamily A, member 4A 666907 2.6 2.7 2.6 2.5 1.5 1.1 
Ms4a4c membrane-spanning 4-domains, subfamily A, member 4C 64380 1.2 1.5 1.2 1 - - 
Ms4a4d membrane-spanning 4-domains, subfamily A, member 4D 66607 1.6 1.5 1.6 1.8 - - 
Ms4a6c membrane-spanning 4-domains, subfamily A, member 6C 73656 1.1 1.1 1.2 1.2 - - 
Ms4a6d membrane-spanning 4-domains, subfamily A, member 6D 68774 3.2 3.5 3.1 3.3 - - 
Ms4a7 membrane-spanning 4-domains, subfamily A, member 7 109225 1.7 1.4 2 1.9 1.4 - 
Mlkl mixed lineage kinase domain-like 74568 2.1 2.7 2 2.3 - - 
Mnda myeloid cell nuclear differentiation antigen 381308 1.8 1.8 1.6 1.7 - - 
Mndal myeloid nuclear differentiation antigen like 1E+08 1.1 1.3 1.1 1.2 - - 
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Mx1 myxovirus (influenza virus) resistance 1 17857 3.2 3.9 3 2.8 - - 
Mx2 myxovirus (influenza virus) resistance 2 17858 2.7 3.7 2.1 2.2 - - 
Nampt nicotinamide phosphoribosyltransferase 59027 1.7 1.9 1.5 2 - - 
Nmi N-myc (and STAT) interactor 64685 1.3 1.6 1.1 1.5 - - 
Prf1 perforin 1 (pore forming protein) 18646 1.2 1.4 1.1 1.2 - - 
Phf11a PHD finger protein 11A 219131 1.2 1.4 1.1 1.1 - - 
Phf11b PHD finger protein 11B 236451 2 1.8 1.7 1.8 - - 
Phf11c PHD finger protein 11C 628705 2 2.4 1.7 1.7 - - 
Phf11d PHD finger protein 11D 219132 2.4 2.9 2.4 2.4 1.1 - 
Plac8 placenta-specific 8 231507 1.3 1.7 - 1.3 - - 
Parp10 poly (ADP-ribose) polymerase family, member 10 671535 1.2 1.5 - 1.2 - - 
Parp12 poly (ADP-ribose) polymerase family, member 12 243771 1.5 2.5 1.3 1.6 - - 
Parp14 poly (ADP-ribose) polymerase family, member 14 547253 1.1 1.7 - 1 - - 
Parp9 poly (ADP-ribose) polymerase family, member 9 80285 1.3 1.9 1.1 1.2 - - 
Psme1 proteasome (prosome, macropain) 28 subunit, alpha 19186 - 1.1 - 1 - - 
Psma7 proteasome (prosome, macropain) subunit, alpha type 7 26444 - 1.1 - 1.1 - - 
Psmb10 proteasome (prosome, macropain) subunit, beta type 10 19171 1.1 1.4 - 1.3 - - 
Psmb8 proteasome (prosome, macropain) subunit, beta type 8 (large 
multifunctional peptidase 7) 
16913 - 1.4 - 1.1 - - 
Pyhin1 pyrin and HIN domain family, member 1 236312 1.7 1.8 1.5 1.4 - - 
Pydc3 pyrin domain containing 3 1000334
59 
1.9 2.4 1.7 1.5 - - 
Pydc4 pyrin domain containing 4 623121 2.9 3.4 2.2 1.9 - - 
Ppa1 pyrophosphatase (inorganic) 1 67895 1.3 2.1 - 1.5 - - 
Pdk4 pyruvate dehydrogenase kinase, isoenzyme 4 27273 1.5 1.1 1.7 1.4 1.8 1.8 
Rtp4 receptor transporter protein 4 67775 1.4 2.2 1.2 1.1 - - 
Retnlg resistin like gamma 245195 1.1 1.3 1.5 1.6 1.4 1.6 
Rnf19b ring finger protein 19B 75234 - 1.2 - 1.1 - - 
Rnf213 ring finger protein 213 672511 1.4 2.2 1 1 - - 
Slfn1 schlafen 1 20555 1.8 1.9 1.3 1.5 - - 
Slfn3 schlafen 3 20557 1.3 1.7 1.5 1.7 - - 
Slfn4 schlafen 4 20558 1.9 3 2 1.8 - - 
Slfn5 schlafen 5 327978 1.5 2.4 1.4 1.1 - - 
Slfn9 schlafen 9 237886 1.5 2.4 1.4 1.7 - - 
Serpina3f serine (or cysteine) peptidase inhibitor, clade A, member 3F 238393 1.9 2.7 1.3 2.2 1.3 - 
Serpinb9 serine (or cysteine) peptidase inhibitor, clade B, member 9 20723 1.3 1.1 1.1 1.4 - - 
Serpinb9b serine (or cysteine) peptidase inhibitor, clade B, member 9b 20706 1.2 1 1.1 - - - 
Serpine1 serine (or cysteine) peptidase inhibitor, clade E, member 1 18787 1.1 - - 1 - - 
Stat2 signal transducer and activator of transcription 2 20847 1.4 1.9 1.2 1.5 - - 
Slamf8 SLAM family member 8 74748 - 1.1 - 1.2 - - 
Slc15a3 solute carrier family 15, member 3 65221 - 1.3 - 1.1 - - 
Slc25a22 solute carrier family 25 (mitochondrial carrier, glutamate), 
member 22 
68267 - 1.2 1 1.2 - - 
Socs1 suppressor of cytokine signaling 1 12703 1.6 2.2 - 1.9 - - 
Socs2 suppressor of cytokine signaling 2 216233 1 1.4 - 1.8 - - 
Tgtp1 T cell specific GTPase 1 21822 - 1.4 - 1.1 - - 
Tgtp2 T cell specific GTPase 2 1.00E+08 1.6 2.7 - 1.5 - - 
Trex1 three prime repair exonuclease 1 22040 - 1.2 - 1 - - 
Timp1 tissue inhibitor of metalloproteinase 1 21857 2.8 2.9 2.4 2.9 1.8 1.6 
Tlr13 toll-like receptor 13 279572 1.4 1 1.7 1.5 1 - 
Tlr3 toll-like receptor 3 142980 1 1.4 1.2 1.1 - - 
Tlr7 toll-like receptor 7 170743 1.1 1.2 1.2 - - - 
Tlr8 toll-like receptor 8 170744 1.1 1.1 1.3 1 - - 
Trafd1 TRAF type zinc finger domain containing 1 231712 1.1 1.6 1 1.1 - - 
Trem3 triggering receptor expressed on myeloid cells 3 58218 1.1 1.4 1.2 1.5 - - 
Trim12c tripartite motif-containing 12C 319236 - 1.5 1.2 1.3 - - 
Trim21 tripartite motif-containing 21 20821 1.1 1.3 - 1.4 - - 
Trim30a tripartite motif-containing 30A 20128 1.3 2.1 - 1.1 - - 
Trim30c tripartite motif-containing 30C 434219 2.6 3.4 2.5 2.2 - - 
Trim30d tripartite motif-containing 30D 209387 3.1 3.5 3.4 2.7 1.4 - 
Wars tryptophanyl-tRNA synthetase 22375 1.1 1.6 - 1.4 - - 
Tnfsf10 tumor necrosis factor (ligand) superfamily, member 10 22035 2 2.3 2 1.9 - - 
Usp18 ubiquitin specific peptidase 18 24110 2.2 3.1 2 1.8 - - 
Zbp1 Z-DNA binding protein 1 58203 1.9 2.7 1.3 1.6 - - 
Italics : Genes induced by LSDV alone. 
Italics and underlined:  Genes induced by CNPV, FWPV and MVA only, and not LSDV. 
Bold: Genes induced by Avipoxviruses only (CNPV, FWPV, FeP2 and/ or PEPV) 
Bold and Italics: Genes induced by FWPV only. 
Bold and underlined: Genes induced by CNPV only. 
Underlined: Genes induced by LSDV and MVA, but not by the Avipoxviruses 
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Selected down regulated genes involved in the immune response are listed in Table 
5.3. Full lists of down regulated genes in response to each virus are given in 
appendix 4. MVA and LSDV induced the down regulation of several genes that were 
not affected in APV-infected spleens. These included three forms of the chemokine 
CCL21 (Ccl21a, Ccl21b, Ccl21c) which are potent chemoattractants for lymphocytes 
and dendritic cells [369] (Table 5.3). Furthermore, MVA and LSDV down regulate 
the high affinity IgM and IgA Fc (Fragment, crystallizable) receptor Fcamr. Fcamr is 
the receptor for the Fc fragment of immunoglobulins IgA and IgM [370]. Interestingly, 
MVA, LSDV, FWPV and CNPV all down regulate the gene encoding the murine 
homolog for DC-specific ICAM-3–grabbing nonintegrin (DC SIGN) (Cd209a), and 
MVA and LSDV down regulate an additional DC SIGN homolog, CD209b (SIGNR1) 
(Table 5.3). LSDV uniquely down regulates CD59a, which is the primary regulator of 
complement membrane attack in mouse [371] and CD7 which is expressed on T- 
and NK cells, and on cells in the early stages of T, B, and myeloid cell differentiation 
[372]. LSDV also uniquely down regulates the immunoglobulin kappa chain complex 
(IgK) amongst other immune related genes (Table 5.3). TLR11 is down regulated by 
MVA alone (Table 5.3). 
 
While many of the immunity related genes listed in Table 5.2 are regulated in some 
way by Type I IFNs, in order to characterise and compare the differences in the 
Type I IFN-regulated responses between MVA, LSDV, FWPV, CNPV, FeP2 and 
PEPV at 24hrs, we analysed a selection of genes known to be involved in the IFN 
response [373-375] (Fig. 5.4). This figure clearly shows that LSDV induces the 
greatest IFN response compared to the other viruses (Fig. 5.4). 
 
MVA, FWPV and CNPV all up regulate the protease caspase 1 whereas LSDV does 
not (Fig. 5.4). MVA, FWPV, CNPV and LSDV significantly up regulated caspase 4 
(casp 4) (historically called caspase 11 in the mouse) (Table 5.2). The SA APVs, 
FeP2 and PEPV do not regulate any caspase genes. 
 
The up- and down regulated genes involved in B cell and T cell responses induced 
by the viruses in this study were compared (Fig. 5.5). Fig. 5.5A highlights the 
regulated genes that are involved in the T cell response. FeP2 and PEPV regulated 
only one gene each involved in this response, Ctla2a and MHC class I gene, H2-M2, 
respectively. The other four viruses differentially regulated several MHC class I 
genes amongst others (Fig. 5.5A). As highlighted in Table 2, the APVs CNPV and 
FWPV exclusively up regulate immunoglobulin heavy chain genes, (Ighg (IgG) and 
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Ighg3 (IgG3)) with CNPV inducing a third, Ighm (IgM) (Fig.5B). LSDV down 
regulates the immunoglobulin kappa (IgK) chain complex (Fig. 5.5B). In addition to 
these, the poxviruses differentially regulate genes for Fc receptors and complement 
genes (Fig. 5.5B).  
 
Here we compared the gene expression induced by each of the 6 poxviruses at 
24hrs to selected correlates of protection and molecular signatures from previously 
published studies (Table 5.4). The induction of multiple PRRs has been shown to 
activate different immune pathways and thereby induce a more polyvalent immune 
response [376, 377]. We identified differential expression of several genes involved 
in pathogen recognition (Table 5.4). Several genes are common to the innate and 
adaptive immune responses induced by the poxviruses analysed here and other 





In this study, we compared the gene expression profiles in mouse spleens after 
infection with poxviruses from 3 different genera. Although in vitro expression 
studies have provided useful information, gene expression profiles performed in cell 
culture may not accurately reflect the changes that occur as result of infection in 
vivo. We have therefore made use of a mouse model to delineate the host 
responses to host-restricted poxviruses in a whole organism. Here we show that six 
host-restricted poxviruses produce different gene expression profiles (Fig. 5.1), 
including GO term enrichment (Fig. 5.3) and genes responsible for immune 
responses (Table 5.2). These distinct profiles indicate potentially significant 





Table 5.3. Selection of down regulated genes in mouse spleens in response to MVA, LSDV, CNPV, 
FWPV, FeP2 and PEPV. Differences in Log2 Fold Changes (between each virus and the control) are 
depicted. 
Symbol Name Entrez MVA LSDV CNPV FWPV PEPV FeP2 
GENES DOWN REGULATED BY LSDV ALONE 
Adamdec1 ADAM-like, decysin 1 58860 - -1.1 - - - - 
Cd59a CD59a antigen 12509 - -1.2 - - - - 
Cd7 CD7 antigen 12516 - -1.1 - - - - 
Esm1 endothelial cell-specific molecule 1 71690 - -1.1 - - - - 
Igfbp3 insulin-like growth factor binding protein 3 16009 - -1 - - - - 
Igk immunoglobulin kappa chain complex 243469 - -1 - - - - 
Lilra5 leukocyte immunoglobulin-like receptor, subfamily A 
(with TM domain), member 5 
232801 - -1.1 - - - - 
Prkcg protein kinase C, gamma 18752 - -1 - - - - 
GENES DOWN REGULATED BY MVA ALONE 
Ctsf cathepsin F 56464 -1.1 - - - - - 
Depdc1a DEP domain containing 1a 76131 -1.1 - - - - - 
Diap3 diaphanous homolog 3 (Drosophila) 56419 -1.1 - - - - - 
Hmmr 
(CD168) 
hyaluronan mediated motility receptor (RHAMM) 15366 -1 - - - - - 
Tlr11 toll-like receptor 11 239081 -1 - - - - - 
GENES INDUCED BY LSDV AND MVA, BUT NOT BY CNPV AND FWPV 
Ccl21a chemokine (C-C motif) ligand 21A (serine) 18829 -1.3 -1.7 - - - - 
Ccl21b chemokine (C-C motif) ligand 21B (leucine) 100042493 -1.2 -1.7 - - - - 
Ccl21c chemokine (C-C motif) ligand 21C (leucine) 65956 -1.2 -1.6 - - - - 
Kel Kell blood group 23925 -1.5 -1.5 - - - - 
Slc12a2 solute carrier family 12, member 2 20496 -1 -1 - - - - 
Timd4 T cell immunoglobulin and mucin domain containing 
4 
276891 -1.1 -1.3 - - - - 
GENES INDUCED BY CNPV, FWPV AND MVA ONLY, AND NOT LSDV. 
Tspan33 tetraspanin 33 232670 -1.6 - -1.3 -1.1 - - 
OTHER 
Abca9 ATP-binding cassette, sub-family A (ABC1), member 9 217262 -1.3 -1.5 - -1.1 - - 
Aplnr apelin receptor 23796 -1.4 -1.5 -1.2 -1.2 - - 
Cd209a CD209a antigen 170786 -1.7 -2.2 -1.1 -1.5 - - 
Cd209b CD209b antigen 69165 -1.2 -1.3 - - - - 
Cldn13 claudin 13 57255 -1.5 -1.2 -1.1 - - - 
Emr4 EGF-like module containing, mucin-like, hormone 
receptor-like sequence 4 
52614 -1.4 -1.8 -1.1 -1.5 -1.3 - 
Fcamr Fc receptor, IgA, IgM, high affinity 64435 -1.1 - -1.5 - - - 
Fcer2a Fc receptor, IgE, low affinity II, alpha polypeptide 14128 -2.6 -3 -2.4 -2.5 -2.2 -1.3 
H2-M2 histocompatibility 2, M region locus 2 14990 -1 -1.4 -1 -1 -1.1 - 
Hs3st2 heparan sulfate (glucosamine) 3-O-sulfotransferase 2 195646 -1.4 -1.3 -1 -1 - - 
Ifi27l1 interferon, alpha-inducible protein 27 like 1 52668 -1.4 -1.3 - - - - 
Mgst3 microsomal glutathione S-transferase 3 66447 -1.6 -1 - -1 - - 
Slc16a10 solute carrier family 16 (monocarboxylic acid 
transporters), member 10 
72472 -1.4 - - -1.1 - - 
Slc2a4 solute carrier family 2 (facilitated glucose 
transporter), member 4 
20528 -1.7 -1 - -1.1 - - 
Slc38a5 solute carrier family 38, member 5 209837 -1.4 -1.2 -1 - - - 
Slc6a20a solute carrier family 6 (neurotransmitter 
transporter), member 20A 
102680 -1.4 -1.3 -1 -1 - - 
Tfrc transferrin receptor 22042 -1.2 - - - - - 
Tspan8 tetraspanin 8 216350 -1.4 - - -1 - - 
Italics : Genes induced by LSDV alone. 
Bold: Genes induced by MVA alone 
Underlined: Genes induced by LSDV and MVA, but not by avipoxviruses 



























































































































































































































































































































































































Figure 5.5A). T-cell specific responses and 5B) B-cell specific responses up- or down regulated in 
mouse spleens in response to CNPV, FeP2, FWPV, LSDV, MVA and PEPV. The log2 fold changes of 
significantly differentially expressed (p value ≤ 0.05) genes involved in the respective types of responses 
are compared. A value of 0 indicates that no change was observed compared to mock-infected mouse 
spleens. A positive value depicts up regulated genes and a negative value depicts down regulated genes.  
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Table 5.4. Comparison of early poxvirus-induced immune responses to selected innate molecular signatures of existing vaccine vectors. Differences in Log2 
Fold Changes (between each virus and the control) are depicted. 
  description MVA LSDV CNPV FWPV PEPV FeP2 Evidence References 
INNATE IMMUNE RESPONSE 
Pathogen recognition  
Tlr13 toll-like receptor 13 1.4 1.0 1.7 1.5 1.0 -    
Tlr3 toll-like receptor 3 1 1.4 1.2 1.1 - - Merck Ad5/HIV [344] 
Tlr7 toll-like receptor 7 1.1 1.2 1.2 - - - YF-17D,  LAIV [342, 343] 
Tlr8 toll-like receptor 8 1.1 1.1 1.3 1.0 - - Merck Ad5/HIV [344] 
Tlr11 toll-like receptor 11 -1.0 - - - - -    
Ddx58 (RIG-I) RIG-I-like receptor - 1.3 - - - - YF-17D [342] 
Cd209a (DC SIGN) CD209a antigen -1.7 -2.2 -1.1 -1.5 - -    
Cd209b (DC SIGN) CD209b antigen -1.2 -1.3 - - - -    
Ifih1 (MDA5) RIG-I-like receptor 1.3 2.1 1.2 1.2 - - YF-17D [342] 
Zbp1 (DAI) cytoplasmic double-stranded DNA sensor 1.9 2.7 1.3 1.6 - -    
Dhx58 (LGP2) RIG-I-like receptor 1.7 2.5 1.6 1.5 - - YF-17D [342] 
Eif2ak2 (PKR) eukaryotic translation initiation factor 2-alpha kinase 2 (protein kinase R) 1.1 2.1 1.1 1.1 - - YF-17D [342] 
Genes associated with the innate immune response of viral vectors  
Cxcl10 (IP-10) chemokine (C-X-C motif) ligand 10 2.7 3 2.2 2.8 1.7 - Significantly upregulated in response to YF-17D,  
Merck Ad5/HIV, TIV 
[344] 
Mx1 myxovirus (influenza virus) resistance 1 3.2 3.9 3 2.8 - - YF-17D [342] 
Il-1α interleukin 1 alpha 1.9 2 2.2 2.3 1.8 - Significantly upregulated in response to YF-17D  
Isg15 ISG15 ubiquitin-like modifier 1.6 2.2 1.5 1.4 - - Merck Ad5/HIV [344] 
Stat1 signal transducer and activator of transcription 1 - 1.4 - - - - YF-17D,  Merck Ad5/HIV, LAIV [342-344] 
Cxcl11 (I-TAC) chemokine (C-X-C motif) ligand 11 4.5 4.4 3.4 4.3 1.5 - Merck Ad5/HIV [344] 
Ccr5 chemokine (C-C motif) receptor 5 1.1 1.5 1.3 1.3 - - Merck Ad5/HIV [344] 
Gbp7 guanylate binding protein 7 1.6 2.2 1.2 1.7 - - Merck Ad5/HIV [344] 
Irf1 interferon regulatory factor 1 - 1.3 - 1.1 - - Merck Ad5/HIV [344] 
Stat2 signal transducer and activator of transcription 2 1.4 1.9 1.2 1.5 - - LAIV [343] 
Irf7 interferon regulatory factor 7 1.7 2.9 1.7 1.1 - - LAIV [343] 
Casp1 caspase 1 1.1 - 1.2 1.1 - -    
ADAPTIVE IMMUNE RESPONSE  
B cell related responses  
Ighg Immunoglobulin heavy chain (gamma polypeptide) - - 1.5 1.6 - -    
Ighg3 Immunoglobulin heavy constant gamma 3 - - 1.3 1.2 - - TIV, correlated with decreased risk of HIV-1 
infection in the RV144 trial ALVAC-HIV(vCP1521) 
[378] 
Ighm immunoglobulin heavy constant mu - - 1.1 - - - positively correllates with antibody response to 
TIV 
[343] 
Igk immunoglobulin kappa chain complex - -1.0 - - - - positively correllates with antibody response to 
TIV 
[343] 
T cell related responses  
Gzmb granzyme B 3.7 4.7 4.1 4.2 2.4 - expressed by CD8+ T cells in response to YF-
17D 
[342] 
Ccr5 chemokine (C-C motif) receptor 5 1.1 1.5 1.3 1.3 - - expressed by CD8+ T cells in response to YF-
17D 
[342] 
Ccl2 (MCP1) chemokine (C-C motif) ligand 2 3.5 3.3 2.9 3.3 2.8 - predicted the magnitude of the CD8+ T cell 
response to Merck Ad5/HIV 
[344] 




Previous in vitro studies with VACV, MVA and NYVAC have resulted in more down 
regulated genes than up regulated genes [87-90]; however, this was not  the case in 
other poxviruses, including CPV [92], MXPV [92] or ALVAC [91]. Unlike our study 
done in a mouse model all these studies were done in cell culture. We show that 
fewer genes are down regulated than up regulated in response to in vivo infection at 
24hrs (Table 5.1) and that distinct differences exist between the genes that are 
down regulated in response to the six viruses. A list of selected down regulated 
genes known to be involved in the immune response is given in Table 5.3. All genes 
that are down regulated in response to infection of mice are listed in appendix 4. For 
each poxvirus tested several mouse genes dysregulated are not yet annotated 
suggesting biological roles for unannotated genes and highlighting the importance of 
further functional analysis and annotation of the mouse genome. 
 
Contrary to in vitro studies, MVA caused more transcripts to be up regulated than 
down regulated in mouse spleens. However, MVA infection resulted in a greater 
number of down regulated transcripts compared to LSDV, FWPV and CNPV. MVA 
caused the down regulation of several genes involved in pyruvate metabolism and 
cell division. VACV is known to inhibit the synthesis and reduce the stability of host 
RNA [379, 380] and the down regulation of cellular genes by MVA, both in mice and 
in vitro [87] may represent a similar process. Interestingly, MVA specifically down 
regulates murine-only TLR11, which recognises uropathogenic bacteria [381] and a 
profilin-like molecule from the protozoan parasite Toxoplasma gondii [382]. TLR11 
has been shown to be reduced in response to conditions of stress [383]. 
 
MVA and LSDV induced the down regulation of several genes that were not affected 
by the APVs tested. These included three forms of the chemokine CCL21 (Ccl21a, 
Ccl21b, Ccl21c) which are potent chemoattractants for lymphocytes and dendritic 
cells [369] (Table 5.3). VACV A41L encodes a chemokine binding protein which 
binds and inhibits CCL21 [384]. VACV and MVA deletion mutants lacking the A41L 
gene, induce stronger virus-specific CD8+ T-cell responses [384, 385]. LSDV does 
not have a homolog of the A41L gene; there must be other mechanisms that 
mammalian poxviruses have evolved to evade the effects of CCL21, which is clearly 
important for the host in clearing poxvirus infection. In selecting/designing a vaccine 
vector it would be desirable to use a virus which lacks A41L and does not down 
regulate CCL21 if a strong CD8+ T cell response is required. Interestingly, MVA, 
LSDV, FWPV and CNPV all down regulated the gene encoding the murine homolog 
for DC-specific ICAM-3–grabbing nonintegrin (DC SIGN) (Cd209a). Furthermore 
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MVA, LSDV and FWPV down regulated an additional DC SIGN homolog, CD209b 
(SIGNR1) (Table 5.3). DC-SIGN is a C-type lectin surface receptor found on 
dendritic cells (DCs) that interacts with intracellular adhesion molecule-3 (ICAM-3) to 
facilitate the clustering of DCs and T-cells necessary for T-cell activation [386]. 
Down regulation of DC-SIGN has been observed in response to infection with 
human herpesvirus 6 [386].  
 
All six viruses down regulated the Fcer2a gene which encodes the IgE FC receptor 
alpha polypeptide. Fc receptors bind to antibodies on infected cells stimulating 
antibody-mediated phagocytosis or antibody-dependent cell-mediated cytotoxicity 
(ADCC). The Fc epsilon receptor II, unlike the other FC receptors is a c-type lectin 
and exists in two forms, with the alpha form (Fcer2a) functioning in B cells as an 
adhesion molecule [387, 388]. Most poxviruses encode several c-type lectin-like 
molecules [24, 25, 67] which are important, either in the host control of infection 
(and the virally encoded c-type lectin proteins act as decoys) or for virus processes. 
The LSDV genome lacks a recognisable c-type lectin homolog [187]. It is not clear 
how poxviruses down regulate Fcer2a and whether this is an advantage or 
disadvantage for a vaccine vector. On the one hand the vector would not be cleared 
in an ADCC manner; however, down regulation of Fcer2a may also limit the desired 
(ADCC) response to a foreign gene product. 
 
LSDV caused the most significant response in mice compared to the other 
poxviruses, both in terms of the number of up regulated genes and the magnitude 
and breadth of the type I IFN response (Fig. 5.5). According to unsupervised 
hierarchical clustering (Fig. 5.1), LSDV clustered independently from the APVs and 
MVA. LSDV up regulated genes involved in the antigen processing and presentation 
pathway (H2-T24, Tap1 and Tap2). Furthermore, LSDV uniquely up regulated the 
gene encoding macrophage migration inhibitory factor (Mif), which is important in 
both macrophage function and T-cell immunity [389], and Ddx58, otherwise known 
as RIG-I (retinoic acid-inducible gene 1), which recognises viral RNA, activating 
downstream signalling pathways that facilitate type I IFN production [390]. The up 
regulation of RIG-I may, in part, be responsible for the increased type I IFN 
response seen in LSDV-infected mice. Another one of the many genes uniquely up 
regulated by LSDV was the transcription factor (Myc) that promotes growth, 
proliferation and apoptosis [391]. Myc has been shown to be up regulated in 
response to infection with NYVAC and MVA in HeLa cells [89]. The absence of Myc 
up regulation in mouse spleens by MVA was surprising. 
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Both LSDV and MVA up regulated a cellular homolog of Moloney Leukemia Virus 10 
(Mov10), which has been shown to inhibit retrovirus replication [392]. Mov10 
overexpression can reduce the infectivity of human immunodeficiency virus type 1 
(HIV-1), simian immunodeficiency virus, and murine leukemia virus [392]. It 
specifically interacts with the nucleocapsid domain of HIV Gag [392], which may 
have implications for vaccine vectors encoding Gag proteins. APVs may therefore 
be better vectors than MVA or LSDV for the expression of Gag. 
 
Amongst the four APVs analysed here, FWPV induced the strongest host response 
in mice whereas FeP2 infection resulted in remarkably little change in host gene 
expression. The vast difference in the host responses between APVs is expected 
between CNPV and FWPV, as on a genomic level, these viruses are significantly 
divergent with amino acid identity between ORF homologues (55-74%) being similar 
to that observed between different ChPV genera [24, 24]. It was suprising to see 
differences between the host responses induced by FeP2 and PEPV which share 
94.4% nucleotide identity with each other and 85.3% and 84.0% nucleotide identity 
with FWPV respectively (The PEPV sequence is to be presented in Olivia Carulei‘s 
PhD dissertation). Since APVs are restricted to only avian hosts, one would expect 
to observe fewer differences in mammalian host responses induced by them as it is 
highly likely that their proteins are not as functional in mammalian cells as those of 
MVA and LSDV. Here we show that three relatively closely related APVs (FWPV, 
FeP2 and PEPV) induce significant differences in gene expression in the host. 
Unsupervised hierarchical clustering differentiates between the observed responses 
to the four APVs, grouping CNPV and MVA together and FWPV in a separate 
cluster (more closely related to CNPV and MVA than to LSDV) (Fig. 5.1). FeP2 and 
PEPV group together in a cluster that is separate from the other four viruses (Fig. 
5.1). This grouping is quite different from phylogenetic relationships established by 
DNA sequence comparisons (chapter 4, Fig. 4.1).  
 
CNPV and FWPV induce the up regulation of two immunoglobulin genes (Ighg and 
Ighg3 (IgG3)) with CNPV up regulating a third, Ighm (Fig. 5.5B). Antibodies of the 
same epitope specificity but of a different subclass can have different antibody 
effector functions [378]. In a recent comparison of the immune responses resulting 
from the partially effective clinical RV144 HIV-1 trial and the ineffective VAX003 trial, 
it was shown that HIV-1–specific IgG3 antibodies distinguished the outcomes of the 
two HIV-1 vaccine trials (RV144 and VAX003) and correlated with decreased risk of 
HIV-1 infection in the RV144 trial. It is suggested that the CNPV, ALVAC-HIV 
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(vCP1521) prime component of RV144 may have stimulated different antibody 
subclasses, specifically IgG3, compared to the protein-only vaccine (VAX003) [378]. 
The up regulation of IgG3 specifically by FWPV and CNPV in vivo, suggests that 
these two APV vectors may be involved in stimulation of the clinically important IgG3 
antibody subclass. Up regulation of IgG3 was not detected in ALVAC-infected 
monocyte derived dendritic cells (MDDCs) [91]; this potentially significant finding is 
an example of the importance of in vivo testing.  
 
CNPV infection induces the unique up regulation of immunoglobulin heavy constant 
mu (Ighm). Ighm is the gene encoding the heavy chain of IgM. IgM is the first 
antibody isotype induced in response to infection or vaccination [393]. IgM 
antibodies are multi-faceted in their antimicrobial function and are involved in direct 
neutralization by particle agglutination, complement activation, enhancement of 
phagocytosis and the generation of the adaptive immune response [394]. There are 
two classes of IgM, natural (innate) IgM, and immune (adaptive/induced) IgM [393]. 
Induced IgM is produced primarily by spleen and lymph node B-2 cells, following 
antigenic exposure [395]. Vaccine induced IgM has been shown to contribute to the 
early control of Rabies virus [394] and induced, but not natural IgM protects against 
West Nile virus [395]. IgM has been proposed for use as a vaccine adjuvant [396] 
and its up regulation by a vector backbone may be beneficial to vaccine efficacy. 
 
The fact that LSDV uniquely down regulates the immunoglobulin (light chain) kappa 
chain complex (IgK) and the absence of any up regulation of immunoglobulin genes 
suggests that this virus may be a poor inducer of an antibody response. However, 
several LSDV-based vaccines have been shown to induce vaccine insert-specific 
antibody responses [338, 397, 398].  
 
Type I IFN responses have been highlighted in previous studies investigating host 
gene expression changes in response to different host-restricted poxviruses [88, 
91]. Type I IFN induces an extensive range of ISGs with various anti-viral functions 
(reviewed here: [108]). Poxviruses, in turn, encode several immunoregulatory 
proteins, which counteract these host anti-viral responses [156]. Upon passage 
without immune pressure, during the process of attenuation of vaccines, genes 
associated with immunoregulation and host range become deleted or mutated, as 
they serve no function to the virus. Previous studies have shown that in vitro MVA 
infection causes increased innate system activation compared to vaccinia virus 
Western Reserve (VACV-WR) [87, 90]. Attenuated poxviruses, which have lost the 
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function of several important immunomodulatory proteins, tend to cause increased 
stimulation of the host innate immune response. This is confirmed by the study in 
which the adaptive and memory responses induced by the HIV vaccine candidate 
NYVAC-C were enhanced following removal of the Type I and II IFN decoy 
receptors encoded by the VACV B8R and/or B19R genes [157]. Similarly, in the 
MVA-based HIV vaccine candidate MVA-B the deletion of the genes C6L and K7R, 
coding for inhibitors of IFN signalling, improved the resulting adaptive and memory 
immune responses [158].  
 
In concurrence with previous studies of poxvirus-induced host responses [91][88], 
Type I IFN responses were initiated by MVA, LSDV, CNPV and FWPV, with LSDV 
inducing the strongest response in mice (Fig. 5.4), followed by CNPV and FWPV, 
with MVA inducing a relatively low IFN response. FeP2 and PEPV induced very little 
ISG expression. As seen in ALVAC-induced gene expression in human MDDC‘s 
[91], numerous IFN responsive genes and downstream signalling molecules were 
up regulated despite the lack of meaningful IFN-β or IFN-α induction. It is possible 
that the peak of IFN-β or IFN-α levels was missed at 24 hours post infection in which 
case the experiment should be repeated at earlier time points. Alternatively, altered 
IFN-β or IFN-α levels may not have been detected due to the relatively small 
increase in these proteins compared to the amplified levels of ISGs. The observed 
enhanced type I IFN-specific and other immune responses elicited by LSDV, FWPV 
and CNPV compared to MVA may be due to the absence of virus-encoded 
immunomodulators in these viruses which could still be present in MVA.  
 
Comparison of the two attenuated VACV strains, NYVAC and MVA showed MVA to 
induce a stronger IFN response than NYVAC, as a result of the loss of more IFN-
antagonists during its passage in CEFs [44, 67, 87, 89]. Interestingly, although 
LSDV is host-restricted to cells of mammalian origin (bovine) and FWPV and CNPV 
to avian cells, LSDV induces a stronger IFN response in mice. Either LSDV host-
range proteins are unable to subvert host responses in non-permissive hosts, or, 
genes encoding such proteins have been deleted/mutated during attenuation of the 
vaccine. Our results suggest that LSDV is more immunogenic than FWPV and 
CNPV in mice. It is not known whether this greater IFN-response induced by LSDV 
in comparison to APVs would lead to enhanced clearance of the virus and a 
decreased immune response to transgenes, or whether the increased IFN response 
would result in an improved immune response to the transgene, should LSDV be 
used as a vaccine vector.  
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TLRs are important regulators of the innate immune system. Poxviruses are 
recognized by a number of different PRRs with innate immune sensing patterns 
differing considerably between species and even between different derivatives of the 
same parent species (VACV, MVA and NYVAC) [96]. Several studies have 
implicated different TLRs required for innate recognition of poxviruses. Recombinant 
FWPV is recognised in a TLR7 and TLR9-dependent manner in DCs; binding to 
both TLRs results in type I IFN production. [101]. Innate immune recognition of 
VACV is mediated by TLR2 [99] and TLR2 and TLR6 are important for MVA 
recognition and subsequent cytokine production [95]. Conversely, TLR3 activation 
has been shown to contribute to VACV pathogenesis [102] demonstrating that 
activation of TLRs in poxvirus infection may have a dual role, acting to initiate the 
host response to infection and as an important mediator of poxvirus pathogenicity.  
 
In our mouse spleen study we show that TLR13, TLR3 and TLR8 are up regulated 
by four poxviruses analysed (CNPV, FWPV, MVA and LSDV). In addition, TLR7 is 
up regulated by CNPV, MVA and LSDV but not by FWPV (Table 5.2). TLR13 is a 
murine intracellular receptor that is predominantly expressed in splenic DC‘s and 
macrophages and activates both a MyD88- and TAK1-dependent TLR signalling 
pathway to activate NF-κB, and induces type I IFN through IRF7. TLR13 has been 
shown to be involved in the recognition of vesicular stomatitis virus [399], but not of 
poxviruses. TLR7 and 8 both recognise ssRNA [400][401] but have functional 
differences. TLR7 is more effective at inducing IFN and IFN-regulated molecules, 
and conversely, TLR8 is more effective at inducing proinflammatory cytokines and 
chemokines, such as TNF-α, IL-12, and MIP-1 [402]. Up regulation of TLR3, which 
detects double stranded RNA, has been observed in response to MVA, but not 
NYVAC infection of MDDCs [88]. Due to the implication of the involvement of the 
poxvirus gene A52R in TLR signalling and its absence in MVA, this gene was 
highlighted as potentially responsible for the up regulation of TLR3 [88]. To date, no 
homolog of this gene has been found in any sequenced APVs [24, 25]; however, 
several homologs of this gene exist in the LSDV genome [187]. This suggests that 
either the LSDV genes are not functional in mice or that the absence of an A52R 
homolog is not solely responsible for the up regulation of TLR3. IFNs have been 
shown to up regulate TLR gene expression in viral infections [98]. Here we have 
established that CNPV, FWPV, MVA and LSDV all induce significant type I IFN 




The important role played by TLRs in both the innate and adaptive immune 
responses to pathogens is undisputed. TLRs activate signalling pathways to induce 
appropriate immune system effector responses. Specifically, TLR3, TLR4, TLR7, 
TLR8 and TLR9 induce antiviral responses by inducing type I IFN responses [97].  
 
MVA, FWPV and CNPV all up regulate the protease caspase 1 whereas LSDV does 
not (Fig. 5.4). Eukaryotic cells can undergo several distinct programs of cell death, 
producing different morphological and physiological outcomes. Caspase 1 
dependent programmed cell death (pyroptosis), unlike apoptosis, is a pro-
inflammatory process that has recently been recognised as important for the control 
of microbial infections [138]. Caspase 1 is activated in large oligomeric complexes, 
inflammasomes [403], which assemble in response to the sensing of PAMPs 
(microbial/viral) [404] or danger or stress signals termed danger-associated 
molecular patterns (DAMPs) [405, 406]. The up regulated transcription of caspase 1 
by MVA, FWPV and CNPV suggests that pyroptosis is taking place in response to 
infection with these viruses. All of MVA, FWPV, CNPV and LSDV also significantly 
up regulated caspase 4 (casp 4) (historically called caspase 11 in the mouse). 
Caspase 4 expression is necessary for the maturation of the proproteins of IL-1b 
and IL-18 (proIL-1b, proIL-18) and plays an important role in the activation of 
caspase-1 in inflammasome complexes, and therefore inflammation [407]. The 
correlation of caspase up regulation with either apoptosis or pyroptosis is still to be 
assessed. 
 
Application of the systems biology approach to vaccines and determination of innate 
immune signatures has proven useful in predicting the immunogenicity of the highly 
effective yellow fever vaccine (YF-17D) [342], the seasonal influenza vaccines [343] 
and the immunogenic but inefficacious Merck Ad5/HIV vaccine [344]. A better 
understanding of the mechanisms underlying the optimal innate immune responses 
would aid rational vaccine development. Here we compared selected key gene 
signatures involved in the early immune responses of several vaccine vectors and 
the host gene expression changes induced by the 6 poxviruses. Several of the 
innate immune signatures observed in tested vaccines, including YF-17D, Merck 
Ad5/HIV, LAIV (live attenuated influenza vaccine) and TIV (trivalent influenza 
vaccine), were common to one or more of the poxviruses investigated here. The 
gene encoding monocyte chemotactic protein 1 (MCP1) (Ccl2) was up regulated by 
5 out of the 6 poxviruses (MVA, LSDV, CNPV, FWPV and PEPV). This gene was 
positively correlated with the CD8+ T cell response to Merck Ad5/HIV 
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vaccination1[344]. Immunoglobulin genes, Ighm (up regulated by CNPV) and IgK 
(down regulated by LSDV) were positively correlated with the antibody response to 
TIV influenza vaccination [343]. This suggests that the different poxviruses could be 
associated with different levels of antibody induction during the adaptive immune 
response. Based on our data we speculate that LSDV may be more suitable for a T-
cell vaccine and CNPV more suitable for the induction of an antibody response. This 
reflects the published data on LSDV [408] and CNPV [378]. 
 
Microarray analyses can provide important information regarding the effect of 
different clinically relevant viruses on host gene expression. One limitation of 
microarray data analysis is that as of yet there are no standardised methods of 
statistical analysis. It has been demonstrated previously that fold change 
designations and p-value cutoffs can significantly alter microarray interpretation 
[409]. Here we have chosen stringent fold change and p-value cutoffs (log2FC ±1, 
adjusted p-value<0.05) in line with similar studies [87-90], in order to avoid false 
discovery and inaccurate biological inferences. We concede that in doing so, some 
smaller changes in gene expression may have been overlooked. Further work 
should entail investigating gene dysregulation at different times post infection. Also, 
innate immune signatures should be directly correlated with subsequent adaptive 
responses. Correlation of gene expression data with biological or clinical findings 
would be most informative. 
 
The findings presented here indicate that six, genetically diverse host-restricted 
poxviruses, CNPV, FWPV, FeP2, PEPV, MVA and LSDV, produce qualitatively and 
quantitatively distinct host responses in an in vivo mouse model. This suggests 
potentially important biological differences in response to infection, especially 
because small changes in gene expression may produce disproportionate results in 
biological systems. Since the innate immune system plays a fundamental role in 
controlling adaptive immune responses [345, 347] these differences may affect the 













In this study, we have tested the hypothesis that there are novel South African APVs 
that could be developed as vaccine vectors.  
 
Preliminary characterisation of 8 novel South African APV isolates was performed 
(chapter 2). For the first time, information is available on the APVs that are 
circulating in South African birds. Although the phylogenetic analysis of highly 
conserved genetic regions indicates that the SA APVs are closely related to each 
other, variation in growth characteristics on CAMs suggests that many of our novel 
APVs differ significantly. 
 
When grown on chick CAMs, FeP2 produced white, variably-sized pocks and 
caused a substantial amount of membrane thickening (chapter 2, Fig. 2.2) with 
pronounced immune infiltration and angiogenesis of the mesoderm (chapter 2, Fig 
2.3). This growth phenotype was markedly different from that observed for FWPV 
(vaccine strain DCEP 25), which produced less membrane thickening and red, 
haemorrhagic pocks, and CNPV (wild type) which caused no obvious membrane 
thickening and produced small, yellow pocks (chapter 2, Table 2.2 and 2.3, Fig. 2.2). 
Therefore, according to growth phenotype on CAMs, we concluded that FeP2 was 
different from both CNPV and FWPV. In addition, according to phylogenetic 
analysis, FeP2 grouped separately from CNPV and FWPV (in subclade A3c). 
Moreover, FeP2 grouped differently according to which conserved genetic region 
was analysed (chapter 2, Fig 2.4-2.7). This suggested that there would be significant 
differences in the less conserved regions of the FeP2 genome. Preliminary attempts 
to grow the novel SA APVs in primary CEF cells suggested that FeP2 and not the 
other virises would grow in cell culture. From these results we chose FeP2 for 
further characterisation.  
 
The full genome sequence of FeP2 was determined (chapter 4) and shown to be 
significantly different from that of CNPV (approx. 63% identity) and FWPV (approx. 
85% identity). Based on DNA similarity of the FeP2 and FWPV genomes, as well as 
the differences in phylogenetics and growth characteristics between these two 




The most striking difference between FeP2 and FWPV is a large deletion of ~16kb 
from the central, usually conserved, region of the genome. ORFs corresponding to 
fpv121 (cc-chemokine family), fpv122 and fpv123 (VAR B22R family), fpv124 
(N1R/p28 family) and fpv125 (V-type Ig domain gene family) are deleted in FeP2 at 
this site. The five FPVUS genes that are deleted from the central region of FeP2 are 
all involved in viral host range and virulence, and their loss may indicate that FeP2 is 
more attenuated than FPVUS. This is supported by the fact that the attenuated 
FWPV strain, FP9, lacks two of these genes (fpv124 and fpv125) as a result of 
attenuation (passage)-specific mutations [27].  
 
In addition to this large deletion relative to the FPVUS genome, FeP2 has 36 
deleted ORFs, most of which are members of multi-gene families, the disruption of 
which has been implicated in the attenuation of poxviruses [27]. In light of these 
―attenuation‖- specific mutations, it is interesting that FeP2 has retained cellular and 
host range genes, such as C7L (fep223) and IL-10 (fep014). To have been kept 
intact, these genes must confer some advantage to the virus. The poxvirus C7L 
family of host range genes functions by mediating poxvirus host range and 
antagonising the host defence system [332]. VACV C7L orthologues are found in all 
OPVs and most mammalian poxviruses, with the exception of molluscum 
contagiosum virus and parapoxviruses [333]. C7L-like genes are not found in the 
sequenced CNPV or FWPV genomes. IL-10 is a cytokine that has both 
immunostimulatory and immunosuppressive functions [186], and other pox IL-10 
orthologues have been shown to be immunomodulatory in function [189, 190, 331]. 
Putative orthologues of IL-10 are also found in ORF virus, BPSV [9], LSDV [187] 
and YLDV [188]. CNPV encodes an IL-10 orthologue with limited similarity to that of 
FeP2 (22.05% aa identity) and FWPV does not encode an IL-10 gene [25]. The 
function and benefit of either of these genes in FeP2 is unknown, although it is likely 
that they would have immunomodulatory function in the infected host. 
 
While it is interesting that FeP2 produces a more inflammatory response on chick 
CAMs than CNPV and FWPV, this may be a result of a lack of immunomodulatory 
genes in FeP2 and reduced suppression of the host response to this virus. Several 
differences between the genomes of FeP2 and the relatively closely related FWPV 
exist which could account for the differences in phenotype observed on chick CAMs. 
One possible explanation is that FWPV contains two genes with homology to 
cellular β-nerve growth factor (β-NGF) (fpv072 and fpv076). FWPV encoded β-NGF 
is thought to be involved in promoting survival in infected cells and could have a role 
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in inhibiting antiviral immune responses in the host [25]. FeP2 encodes a severely 
truncated β-NGF gene homologue, which is unlikely to be functional. The β-NGF 
genes in FWPV could be responsible for the reduced inflammation observed in 
FWPV-infected CAMs in comparison to that of FeP2.  
 
It would be beneficial to thoroughly understand the behaviour of any candidate 
vaccine vector both in vitro and in vivo. To this end, we examined the in vitro growth 
kinetics and morphogenesis of FeP2 in permissive and non-permissive cells and 
compared these to other viruses, including MVA, FWPV, CNPV and PEPV. CEF 
cells were shown to be permissive for FeP2 and the avipoxvirus exhibited complete 
morphogenesis following a similar sequence of events to other APVs in vitro [71]. 
Conversely, productive growth of FeP2 is inhibited in HeLa cells and morphogenesis 
was severely restricted. The morphogenesis of FeP2 in Hela cells was similar to the 
morphogenesis of CNPV observed in mammalian cell lines [271]. Investigation of 
FeP2 growth in additional human cell lines and foreign gene expression experiments 
would be useful to determine whether or not this virus could proceed far enough in 
its life cycle to sufficiently express transgenes within human cells. 
 
Both permissive and non-permissive cells infected with all the viruses analysed 
(FeP2, MVA, FWPV, CNPV and PEPV) failed to undergo apoptosis (chapter 3). 
However, for all viruses, CPE was observed (not shown) indicating that the cells are 
dying by some other process. In mouse spleens, we show that MVA, FWPV and 
CNPV up regulate caspase 1, which is involved in pyroptosis and not apoptosis. 
Taken together, these results could indicate that these viruses may induce other 
programmes of cell death, such as pyroptosis and necrosis, which are not observed 
by apoptosis-specific assays.  
 
The apoptosis assays performed in chapter 3 do indicate that the five viruses all 
inhibit apoptosis, since inhibition of camptothecin-induced apoptosis is observed. 
Poxviruses encode several modulators of apoptosis (reviewed in chapter 1, section 
1.4.4) but it is difficult to speculate which gene or genes could be responsible for the 
inhibition observed. Since all the viruses inhibit apoptosis it is unlikely that either the 
large internal deletion in the FeP2 genome, nor the insertion of the VACV C7L gene, 
could be solely responsible for phenotype observed. The observed inhibition of 
apoptosis could well result from a combination of gene products. 
The comparison of host responses produced by different poxvirus vectors would aid 
in the assessment and rational design of improved vaccines. Host-range restricted 
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poxviruses have been shown to successfully activate the host immune system. In 
order to investigate the ability of different poxviruses to interact with the mammalian 
host, we compared host gene expression profiles in the spleens of BALB/c mice in 
response to infection (105 pfu/mouse). The findings presented here indicate that six, 
genetically diverse host-restricted poxviruses, CNPV, FWPV, FeP2, PEPV, MVA 
and LSDV, produce qualitatively and quantitatively distinct host responses in an in 
vivo mouse model.  
 
The differences in host gene expression likely occur through several mechanisms, 
including viral recognition, tropism and host immune response modulation. Although 
host-restricted poxviruses are unable to complete their replication cycle in 
mammalian cells, these viruses are able to express large amounts of their genome, 
allowing for the expression of immunomodulatory proteins which may shape the 
host immune response and subsequent gene expression changes in the mouse 
spleen. It is likely that the addition of a transgene encoding foreign antigen could 
affect host responses to a poxvirus-vectored vaccine candidate. Zhang et al (2007) 
showed that the inclusion of a gag/pro/env expression cassette into MVA and CNPV 
altered apoptosis kinetics in infected cells, as compared to cells infected with 
corresponding empty vectors [136]. 
 
Interestingly, South African APVs, FeP2 and PEPV, produced the smallest response 
in the mouse spleens. Even compared to PEPV, FeP2 infection resulted in 
remarkably little change in host gene expression. Since APVs are restricted to avian 
hosts, one would expect to observe fewer differences between the mammalian host 
responses induced by them compared to those induced by MVA and LSDV. Here 
we show that three relatively closely related APVs (FWPV, FeP2 and PEPV) induce 
significant differences in gene expression in the host.  
 
It remains to be determined whether or not an increased vector-specific innate 
immune response would be beneficial for a poxvirus-based vaccine. Although MVA- 
and CNPV-vectored vaccine candidates have been shown to be immunogenic in 
clinical trials [60, 410], these responses have been limited and require further 
improvement. MVA virus-specific immunogenicity has been shown to be significantly 
reduced compared to that of VACV Western Reserve (VACV WR) [411]. Host 
transcriptional responses in HeLa cells following VACV WR infection was markedly 
different to that observed after MVA infection [87, 90]. Following VACV WR 
infection, only 37 host genes were upregulated in HeLa Cells, whereas 163 were 
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upregulated in response to MVA infection [87, 90]. It is possible that the reduced 
host response to infection correlates positively with the improved immunogenicity of 
VACV WR compared to MVA, although this has not been directly determined. 
Alternatively, while MVA is known to induce a poor immune response against itself, 
it can induce strong immune responses to encoded heterologous antigen [412]. 
Whether or not host gene expression changes correlate to adaptive responses to 
heterologous antigen remains to be delineated. 
 
FP9 has been shown to be a more immunogenic recombinant vaccine vector than 
the Webster FPV-M strain [413]. Passage-specific, attenuation mutations are 
thought to be responsible for the difference in immunogenicity between these two 
viruses [414]. Unlike FP9, the genome sequence and passage history of the FWPV-
DCEP 25 strain used in this study is unknown. Due to its limited ability to replicate in 
CEFs (chapter 3), one can assume that it is not an attenuated, or tissue culture-
adapted strain of FWPV. Therefore it is possible that the FWPV strain assessed 
here would not be as immunogenic as FP9; however, without genomic sequence 
information and further investigation, this is purely speculative.  
 
In another study of FWPV, complete redundancy has been shown for type I IFNs in 
the generation of adaptive immunity to FWPV-encoded antigen [111]. In addition 
type I IFNs do not affect the formation of an antibody response to CNPV [415]. 
While type I IFN responses are important for the induction of the immune response 
to virus infection, they may decrease the immunogenicity of viral-vectored vaccines 
by promoting anti-viral responses and subsequent viral clearance [96]. In our study, 
we show that all viruses analysed, except PEPV and FeP2, induced strong type I 
IFN responses (chapter 5). It would be interesting to determine what effect the type I 
IFN responses (or lack thereof) have on the immunogenicity of these viruses.  
 
One could speculate that the inability of FeP2 to induce a response at 24hrs in mice 
could be related to the apparent inefficiency of FeP2 to enter and proceed to late 
stages of morphogenesis in HeLa cells. CNPV has been shown to be similarly 
restricted in human cells [271]. Since this experiment was only performed at one 
time point, it is possible that the FeP2 (and PEPV) response could occur at an 
earlier or later time point and was missed at 24hrs. Investigation at further time 




It is of great interest and significance that CNPV and FWPV induce the up regulation 
of the two immunoglobulin genes Ighg and Ighg3 (IgG3) (chapter 5, Fig. 5.5B). This 
result supports the finding that the CNPV, ALVAC-HIV (vCP1521) prime component 
of RV144 may be responsible for stimulating HIV-1–specific IgG3 antibodies which 
correlated with decreased risk of HIV-1 infection in the RV144 trial. The up 
regulation of an additional immunoglobulin (Ig) gene, Ig heavy constant mu (Ighm), 
by CNPV, suggests that this virus may be a good candidate for the induction of an 
antibody response. Conversely, LSDV, which uniquely down regulates the Ig (light 
chain) kappa chain complex (IgK) and fails to up regulate any Ig genes, may be a 
poor inducer of an antibody response. However, several LSDV-based vaccines have 
been shown to induce vaccine insert-specific antibody responses [338, 397, 398]. 
Further studies, which directly correlate innate immune signatures with subsequent 
adaptive responses, are required.  
 
The main aims of this study were to characterise South African APVs and to 
investigate the potential of one of these viruses for use as a vaccine vector 
candidate. Although FeP2 failed to induce a significant innate immune response at 
24hrs in the mouse spleen, further investigation is required to determine whether an 
immune response can be induced in response to FeP2-encoded antigen. On one 
hand, it is possible that this virus simply does not enter mammalian cells sufficiently 
enough to produce a response. However, morphogenesis of FeP2 in HeLa cells was 
similar to that of CNPV in human cells [271]. Furthermore, FeP2 was shown to 
actively inhibit apoptosis in these cells. It would therefore be important to establish 
the gene expression changes induced by FeP2 infection at different time points and 
to determine whether or not FeP2 could efficiently express a transgene in 
mammalian cells, and whether or not the insertion of a transgene would influence 
the innate immune response in vivo. These experiments are underway in our 
laboratory.  
 
While it is too early to categorically state whether or not FeP2 would make a good 
candidate vaccine vector we are able to draw the following conclusions: FeP2 can 
be grown in CEFs, which will allow for the production of a recombinant virus. No 
evidence of FeP2 entry into the nucleus was observed, in permissive or non-
permissive cells, and therefore a strictly cytoplasmic site of replication is concluded. 
FeP2 also exhibits several aspects of attenuation when compared to other APV 
strains. Taken together, these characteristics confer a potential significant safety 
advantage to this virus. In addition, FeP2 exhibits similar growth kinetics and 
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morphogenesis to CNPV and FWPV in human cells, and all three viruses inhibit 
apoptosis in these cells to a similar degree. The failure to induce a significant innate 
immune response in vivo is surprising; however, this may be an advantage to a 
potential vaccine vector as the vector will not be cleared quickly. Further studies to 










































Composition of reagents 
 
1.1 McIlvains Buffer  pH 7.4 
Solution A: 1.8mM citric acid (2.1g citric acid in 100ml dH2O) 
Solution B: 0.36mM Na2HPO4.12H2O (7.2g Na2HPO4.12H2O in 100ml dH2O) 
Add 18.17ml Solution A and 1.83ml Solution B and make up to 1L with dH2O. 
 





Dilute in 800ml dH2O. Adjust pH to 7.4 and make up to a volume of 1L with 
dH2O. 
1x solution made up with 25ml 10X PBS added to 250ml dH2O  
 
1.3 PBS + Penicillan/Streptomycin and Fungin (PSF) 
1x PBS containing the following: 
500U/ml penicillin 
100µg/ml streptomycin 
1µg/ml fungin  
 
1.4 Physiological saline 
0.85% w/v NaCl 
0.85g NaCl  
Made up to a final volume of 100 ml dH2O 
 
1.5 TE Buffer pH 9.0 
10mM Tris-HCL 
1mM EDTA 
Made up in 400ml dH2O, adjust pH to 9 and make up to 500ml with dH2O. 
 
1.6 Lysis buffer 
10% N-lauryl sarcosinate 
50 mM Tris pH7.8 
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200 mM β-mercaptoethanol 
 
1.7  1x Tris-borate-EDTA (TBE) buffer 
89mM Tris (269g) 
89mM Boric Acid (137.6g) 
2mM EDTA (18.63g) 
Made up to 25L with dH2O 
 
1.8 10% buffered formalin 
37–40 % Formaldehyde  
35.03 M NaH2PO4.H20  
21.84 M Na2HPO4 (anhydrous)  



























Customized bioinformatics pipeline for the pre-processing and assembly of 

























Full lists of up- and down regulated genes in mouse spleens in response to 
modified vaccinia Ankara (MVA), lumpy skin disease virus (LSDV),  canarypox 
virus (CNPV), fowlpox virus (FWPV),  pigeonpox (FeP2) and penguinpox virus 
(PEPV).  
 
Table a1. Full list of annotated up regulated genes in mouse spleens in response to CNPV, FeP2, FWPV, LSDV, MVA and 
PEPV. Differences in Log2 Fold Changes (between each virus and the control) are depicted. 
Symbol Name Entrez MVA LSDV CNPV FWPV PEPV FeP2 
1500012F01Rik RIKEN cDNA 1500012F01 gene 68949 1.2 1.1 1.5 1.6 - - 
1500012F01Rik RIKEN cDNA 1500012F01 gene 68949 - 1 - - - - 
2610524H06Rik RIKEN cDNA 2610524H06 gene 330173 - - 1.1 1.2 - - 
3110062M04Rik RIKEN cDNA 3110062M04 gene 78412 1.2 1.7 1.5 1.4 - - 
3830406C13Rik RIKEN cDNA 3830406C13 gene 218734 - - 1 - - - 
4933412E12Rik RIKEN cDNA 4933412E12 gene 71086 - 1 - 1 - - 
9330175E14Rik RIKEN cDNA 9330175E14 gene 320377 - 1.1 - 1.1 - - 
A530040E14Rik RIKEN cDNA A530040E14 gene 621875 1.1 - - - - - 
A530064D06Rik RIKEN cDNA A530064D06 gene 328830 2 1.8 2.2 1.9 1.2 - 
Abracl ABRA C-terminal like 73112 - - - 1 - - 
Abtb2 ankyrin repeat and BTB (POZ) domain containing 
2 
99382 - 1.1 - 1.1 - - 
Adamts1 a disintegrin-like and metallopeptidase (reprolysin 
type) with thrombospondin type 1 motif, 1 
11504 - 1.1 - - - - 
Adar adenosine deaminase, RNA-specific 56417 - 1 - - - - 
AI607873 expressed sequence AI607873 226691 1.8 2 1.8 1.6 1.1 - 
Aif1 allograft inflammatory factor 1 11629 - - - 1.1 - - 
Akr1b10 aldo-keto reductase family 1, member B10 (aldose 
reductase) 
67861 - - 1.1 1.1 - - 
Alox12 arachidonate 12-lipoxygenase 11684 - - 1 1.2 - - 
Alpl alkaline phosphatase, liver/bone/kidney 11647 1.3 1.3 1 1.2 - - 
Amica1 adhesion molecule, interacts with CXADR antigen 
1 
270152 - 1.1 - 1.1 - - 
Angptl4 angiopoietin-like 4 57875 1.1 1.5 - 1.6 1.1 - 
Anxa1 annexin A1 16952 - - 1.6 1.8 - - 
Anxa2 annexin A2 12306 - - - 1.1 - - 
Anxa4 annexin A4 11746 1.8 1.9 1.7 2.1 1.1 - 
Aoah acyloxyacyl hydrolase 27052 - - 1.1 - - - 
Apobec1 apolipoprotein B mRNA editing enzyme, catalytic 
polypeptide 1 
11810 - - 1.2 1.2 - - 
Apod apolipoprotein D 11815 1.5 1.3 1.5 1.4 - - 
Apol9b apolipoprotein L 9b 71898 2.3 2.7 2.6 2.4 - - 
Asb13 ankyrin repeat and SOCS box-containing 13 142688 1.2 1 1.1 1.3 - - 
Asprv1 aspartic peptidase, retroviral-like 1 67855 1.2 1.1 1.2 1.3 - - 
Atf3 activating transcription factor 3 11910 1.3 1.4 1.2 1.4 1.1 - 
Atp10a ATPase, class V, type 10A 11982 1.1 1.2 - 1.1 - - 
Atp8b1 ATPase, class I, type 8B, member 1 54670 1 1.3 1 1.3 - - 
Atp8b4 ATPase, class I, type 8B, member 4 241633 - 1.4 - - - - 
AW011738 expressed sequence AW011738 100382 1.1 1.7 1 1 - - 
AW112010 expressed sequence AW112010 107350 2 1.8 1.4 1.8 - - 
B430306N03Rik RIKEN cDNA B430306N03 gene 320148 1.2 1.4 1.3 1.5 - - 
B4galt4 UDP-Gal:betaGlcNAc beta 1,4-
galactosyltransferase, polypeptide 4 
56375 - 1.1 - - - - 
B4galt5 UDP-Gal:betaGlcNAc beta 1,4-
galactosyltransferase, polypeptide 5 
56336 - 1 - - - - 
BC023105 cDNA sequence BC023105 667597 1.3 1.5 1.3 1.4 1.1 - 
BC094916 cDNA sequence BC094916 545384 1.2 1.8 - - - - 
BC147527 cDNA sequence BC147527 625360 1.2 1.5 - - - - 
Bst2 bone marrow stromal cell antigen 2 69550 2.3 3 2.1 2.2 - - 
C1qa complement component 1, q subcomponent, alpha 
polypeptide 
12259 - 1.1 1 - - - 
C2 complement component 2 (within H-2S) 12263 1.5 1.8 1.7 1.6 1 - 
Cacnb3 calcium channel, voltage-dependent, beta 3 
subunit 
12297 - 1.2 - 1.1 - - 
Car13 carbonic anhydrase 13 71934 1 1.2 1.1 1.1 - - 
Casp1 caspase 1 12362 1.1 - 1.2 1.1 - - 
Casp4 caspase 4, apoptosis-related cysteine peptidase 12363 1.9 1.6 1.9 2 - - 
Ccdc53 coiled-coil domain containing 53 67282 - - - 1 - - 
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Ccl2 chemokine (C-C motif) ligand 2 20296 3.5 3.3 2.9 3.3 2.8 - 
Ccl3 chemokine (C-C motif) ligand 3 20302 2 2.1 2.3 2 1.4 - 
Ccl6 chemokine (C-C motif) ligand 6 20305 - - 1.3 1.3 - - 
Ccl7 chemokine (C-C motif) ligand 7 20306 3 2.9 2.6 2.9 2.7 1.5 
Ccr5 chemokine (C-C motif) receptor 5 12774 1.1 1.5 1.3 1.3 - - 
Ccrl2 chemokine (C-C motif) receptor-like 2 54199 - 1.5 1.2 1.4 - - 
Cd274 CD274 antigen 60533 1.9 2.3 1.6 2.1 1.2 - 
Cd5l CD5 antigen-like 11801 1.2 1.5 1.4 1.1 - - 
Cd69 CD69 antigen 12515 1.8 1.8 1.5 1.7 - - 
Cdkn1a cyclin-dependent kinase inhibitor 1A (P21) 12575 1.7 2 1.5 2 1.2 - 
Cebpb CCAAT/enhancer binding protein (C/EBP), beta 12608 - 1 - - - - 
Cfb complement factor B 14962 2.2 2.6 1.6 2 1 - 
Chi3l3 chitinase 3-like 3 12655 - 1.2 1.4 1.6 - - 
Chic1 cysteine-rich hydrophobic domain 1 12212 1.1 1.4 1 - - - 
Clec4a2 C-type lectin domain family 4, member a2 26888 1.2 - 1.5 1.1 - - 
Cmpk2 cytidine monophosphate (UMP-CMP) kinase 2, 
mitochondrial 
22169 1.3 2 1.3 1.3 - - 
Cndp2 CNDP dipeptidase 2 (metallopeptidase M20 
family) 
66054 1.2 1.4 1.1 1.4 - - 
Col4a2 collagen, type IV, alpha 2 12827 - 1.1 - - - - 
Cp ceruloplasmin 12870 1.6 1.7 1.6 1.8 1.2 - 
Csf2rb2 colony stimulating factor 2 receptor, beta 2, low-
affinity (granulocyte-macrophage) 
12984 - 1.5 - 1.7 - - 
Csprs component of Sp100-rs 114564 1.3 - - - - - 
Csprs component of Sp100-rs 114564 1.5 1.2 - - - - 
Csprs component of Sp100-rs 114564 1.5 1.2 - - - - 
Cst7 cystatin F (leukocystatin) 13011 1.2 1.4 1.1 1.4 - - 
Cstb cystatin B 13014 1.4 1 1.5 1.5 - - 
Ctla2a cytotoxic T lymphocyte-associated protein 2 alpha 13024 1.1 1 1.1 1.3 - 1.4 
Ctsc cathepsin C 13032 1.1 1.1 - 1.1 - - 
Ctsl cathepsin L 13039 - - 1.1 - - - 
Cxcl10 chemokine (C-X-C motif) ligand 10 15945 2.7 3 2.2 2.8 1.7 - 
Cxcl11 chemokine (C-X-C motif) ligand 11 56066 4.5 4.4 3.4 4.3 1.5 - 
Cxcl9 chemokine (C-X-C motif) ligand 9 17329 2.1 2.3 - 1.8 - - 
Cycs cytochrome c, somatic 13063 - 1.1 - 1.1 - - 
Cycs cytochrome c, somatic 13063 - 1.1 - 1.1 - - 
Cycs cytochrome c, somatic 13063 - 1.2 - 1.2 - - 
Daxx Fas death domain-associated protein 13163 2 2.3 1.7 1.9 - - 
Dcn decorin 13179 - - - 1.5 - - 
Ddit4 DNA-damage-inducible transcript 4 74747 1.2 1.2 1.8 1.3 1.4 - 
Ddx18 DEAD (Asp-Glu-Ala-Asp) box polypeptide 18 66942 - - - 1.1 - - 
Ddx58 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 230073 - 1.3 - - - - 
Ddx60 DEAD (Asp-Glu-Ala-Asp) box polypeptide 60 234311 1.7 2.6 1.5 1.4 - - 
Dhx58 DEXH (Asp-Glu-X-His) box polypeptide 58 80861 1.7 2.5 1.6 1.5 - - 
Dram1 DNA-damage regulated autophagy modulator 1 71712 1.2 1.4 - 1.3 - - 
Dtx3l deltex 3-like (Drosophila) 209200 1 1.5 - - - - 
Dusp28 dual specificity phosphatase 28 67446 - 1 - - - - 
Ear2 eosinophil-associated, ribonuclease A family, 
member 2 
13587 - - 1.3 1.5 - - 
Eif2ak2 eukaryotic translation initiation factor 2-alpha 
kinase 2 
19106 1.1 2.1 1.1 1.1 - - 
Emp1 epithelial membrane protein 1 13730 - - - 1.1 - - 
Epsti1 epithelial stromal interaction 1 (breast) 108670 - 1.4 - - - - 
F830016B08Rik RIKEN cDNA F830016B08 gene 240328 1.5 2.5 1.9 1.9 1.2 - 
Fam136a family with sequence similarity 136, member A 66488 - 1.1 - 1.3 - - 
Fam26f family with sequence similarity 26, member F 215900 1.5 1.9 1.1 1.8 - - 
Fbxw17 F-box and WD-40 domain protein 17 109082 - 1.2 - 1 - - 
Fcgr1 Fc receptor, IgG, high affinity I 14129 2.4 2.6 2.4 2.6 1.4 - 
Fcgr4 Fc receptor, IgG, low affinity IV 246256 2.5 3.6 2.8 2.9 1.8 - 
Fgl2 fibrinogen-like protein 2 14190 - - - 1.2 - - 
Folh1 folate hydrolase 1 53320 3.1 2.7 3 2.8 2.1 1.9 
Fpr1 formyl peptide receptor 1 14293 1.3 1.1 1.4 1.4 - - 
Fpr2 formyl peptide receptor 2 14289 1.8 1.5 1.7 1.9 - - 
Fscn1 fascin homolog 1, actin bundling protein 
(Strongylocentrotus purpuratus) 
14086 1.2 1.6 - 1 - - 
G530011O06Rik RIKEN cDNA G530011O06 gene 654820 2.5 1.7 1.8 - - - 
Gadd45b growth arrest and DNA-damage-inducible 45 beta 17873 1.3 1.5 1.2 1.5 - - 
Gatm glycine amidinotransferase (L-arginine:glycine 
amidinotransferase) 
67092 1.2 1.3 1.3 1.4 - - 
Gbp1 guanylate binding protein 1 14468 2.1 2.7 1.6 2.5 - - 
Gbp10 guanylate-binding protein 10 626578 2.1 3.2 1.3 1.9 - - 
Gbp11 guanylate binding protein 11 634650 3.9 4.5 2.9 4.2 1.6 - 
Gbp2 guanylate binding protein 2 14469 2.3 2.8 1.5 2.7 - - 
Gbp3 guanylate binding protein 3 55932 1.6 1.8 1.2 1.6 - - 
Gbp4 guanylate binding protein 4 17472 2.1 2.7 1.3 2.4 - - 
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Gbp5 guanylate binding protein 5 229898 2 2.8 1.3 2.2 1.1 - 
Gbp7 guanylate binding protein 7 229900 1.6 2.2 1.2 1.7 - - 
Gbp8 guanylate-binding protein 8 76074 1.3 1.4 1.4 2.1 - - 
Gbp9 guanylate-binding protein 9 236573 1.2 1.9 1 1.3 - - 




86 1 1.6 - 1 - - 
Gla galactosidase, alpha 11605 1.6 1.8 1.6 1.7 1.1 - 
Glipr2 GLI pathogenesis-related 2 384009 1.4 1.5 1.1 1.5 - - 
Gm10495 predicted gene 10495 1005046
11 - - - 1.3 - - 
Gm11772 predicted gene 11772 1005039
12 1.6 2.2 1.7 1.7 - - 
Gm12185 predicted gene 12185 620913 2 2.6 1.3 2.1 - - 
Gm12250 predicted gene 12250 631323 1.7 2.9 1.1 1.8 - - 
Gm13157 predicted gene 13157 1000416
77 - - - 1.1 - - 
Gm14446 predicted gene 14446 667373 3.3 3.4 2.3 2.5 - - 
Gm15056 predicted gene 15056 1005040
14 3.8 3.8 3.4 3.7 2.5 1.6 
Gm17757 GTPase, very large interferon inducible 1 
pseudogene 
1004178
29 - 1.4 - - - - 
Gm17757 GTPase, very large interferon inducible 1 
pseudogene 
1004178
29 - 1.5 - - - - 
Gm1966 predicted gene 1966 434223 1 1.5 - - - - 
Gm19705 predicted gene, 19705 1005034
60 1.5 1.4 1.3 1.5 - - 
Gm19763 predicted gene, 19763 1005035
48 - - - 1 - - 
Gm20134 predicted gene, 20134 1005042
51 1.7 1.5 1.2 1.3 - - 
Gm20559 predicted gene, 20559 330256 - 1.1 - - - - 
Gm4070 predicted gene 4070 1000428
56 - 1.5 - - - - 
Gm4841 predicted gene 4841 225594 1.8 2.1 2 2.1 2 - 
Gm4841 predicted gene 4841 225594 2.5 3 2.4 2.8 2.3 - 
Gm4951 predicted gene 4951 240327 1.5 2.7 1.3 1.5 - - 
Gm5431 predicted gene 5431 432555 2.6 3.1 2.4 2.3 - - 
Gm6548 eukaryotic translation elongation factor 1 alpha 1 
pseudogene 
625054 - 1.4 - - - - 
Gm6904 predicted gene 6904 628693 1.4 1.9 - - - - 
Gm7609 predicted pseudogene 7609 665378 1.4 1.2 - - - - 
Gm7609 predicted pseudogene 7609 665378 - 1.5 - - - - 
Gm8979 very large inducible GTPase 1 pseudogene 668108 - 1.1 - - - - 
Gm8989 very large inducible GTPase 1 pseudogene 668128 - 1.1 - - - - 
Gm8995 predicted gene 8995 668139 - 1.1 - - - - 
Gmppb GDP-mannose pyrophosphorylase B 331026 - 1.1 - - - - 
Gnb4 guanine nucleotide binding protein (G protein), 
beta 4 
14696 - 1.2 - - - - 
Gng12 guanine nucleotide binding protein (G protein), 
gamma 12 
14701 - - - 1.1 - - 
Gnl3 guanine nucleotide binding protein-like 3 
(nucleolar) 
30877 - - - 1.1 - - 
Gnpnat1 glucosamine-phosphate N-acetyltransferase 1 54342 1.1 - - 1 - - 
Gp49a glycoprotein 49 A 14727 2.6 2.4 2.7 2.7 1.9 2 
Gpr128 G protein-coupled receptor 128 239853 1.2 1.4 - 1.2 - - 
Grn granulin 14824 - 1.1 - - - - 
Gsdmd gasdermin D 69146 - - - 1.2 - - 
Gvin1 GTPase, very large interferon inducible 1 74558 - 1.5 - - - - 
Gzma granzyme A 14938 1.8 1.8 2.2 2 - - 
Gzmb granzyme B 14939 3.7 4.7 4.1 4.2 2.4 - 
H2-Q4 histocompatibility 2, Q region locus 4 15015 1 1.2 - 1.2 - - 
H2-Q6 histocompatibility 2, Q region locus 6 110557 1 1 - 1.1 - - 
H2-T22 histocompatibility 2, T region locus 22 15039 1 1.3 - - - - 
H2-T23 histocompatibility 2, T region locus 23 15040 1 1.3 - 1 - - 
H2-T24 histocompatibility 2, T region locus 24 15042 - 1.2 - - - - 
Hdc histidine decarboxylase 15186 - 1.4 1.2 1.5 - - 
Helz2 helicase with zinc finger 2, transcriptional 
coactivator 
229003 1.1 1.5 - - - - 
Herc6 hect domain and RLD 6 67138 1.3 1.9 1.1 1.1 - - 
Hk3 hexokinase 3 212032 1.5 2 1.7 2 1.2 - 
Hmgcs2 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 
2 
15360 1.3 1.1 2.1 1.7 1.8 2.2 
Hnrnph2 heterogeneous nuclear ribonucleoprotein H2 56258 - - - 1.1 - - 
Hp haptoglobin 15439 1.2 1.8 1.7 1.9 1.3 1.3 
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Hpse heparanase 15442 - 1.1 - - - - 
Hsbp1 heat shock factor binding protein 1 68196 - - 1.2 1.2 - - 
Hsh2d hematopoietic SH2 domain containing 209488 1.1 1.4 - - - - 
Hspa1b heat shock protein 1B 15511 2.3 2.9 2.4 2.5 - - 
Ifi202b interferon activated gene 202B 26388 2.4 2.6 2.1 2.2 - - 
Ifi203 interferon activated gene 203 15950 - 1.1 - - - - 
Ifi204 interferon activated gene 204 15951 3.3 4 3.2 3.9 - - 
Ifi205 interferon activated gene 205 226695 1.4 - 1.6 1.8 - - 
Ifi27l2a interferon, alpha-inducible protein 27 like 2A 76933 - 1.9 - - - - 
Ifi35 interferon-induced protein 35 70110 1.1 1.5 1.1 1.2 - - 
Ifi44 interferon-induced protein 44 99899 2 2.5 1.8 1.6 - - 
Ifi44l interferon-induced protein 44 like 15061 2.1 2.9 2 2 - - 
Ifih1 interferon induced with helicase C domain 1 71586 1.3 2.1 1.2 1.2 - - 
Ifit1 interferon-induced protein with tetratricopeptide 
repeats 1 
15957 2.2 3.3 2 1.7 - - 
Ifit2 interferon-induced protein with tetratricopeptide 
repeats 2 
15958 1.8 2.5 1.8 1.7 - - 
Ifitm3 interferon induced transmembrane protein 3 66141 - 1.4 - - - - 
Ifitm6 interferon induced transmembrane protein 6 213002 1.8 1.9 2.4 2.3 1.6 1.5 
Ighg Immunoglobulin heavy chain (gamma polypeptide) 380794 - - 1.5 1.6 - - 
Ighg3 Immunoglobulin heavy constant gamma 3 380795 - - 1.3 1.2 - - 
Ighm immunoglobulin heavy constant mu 16019 - - 1.1 - - - 
Igtp interferon gamma induced GTPase 16145 1.4 2.2 1 1.8 - - 
Iigp1 interferon inducible GTPase 1 60440 1.7 2.9 1.2 1.9 - - 
Il12rb1 interleukin 12 receptor, beta 1 16161 2 2.4 1.7 2.1 1.1 - 
Il12rb2 interleukin 12 receptor, beta 2 16162 1.2 1.3 1.3 1.3 - - 
Il15 interleukin 15 16168 1.1 1.3 1.2 1 - - 
Il15ra interleukin 15 receptor, alpha chain 16169 1.8 1.9 1.5 1.8 1.2 - 
Il18bp interleukin 18 binding protein 16068 1.2 1.7 1.3 1.5 - - 
Il1a interleukin 1 alpha 16175 1.9 2 2.2 2.3 1.8 - 
Il1f9 interleukin 1 family, member 9 215257 1.3 1.6 1.7 1.8 1.2 1 
Il1rn interleukin 1 receptor antagonist 16181 1.3 1.1 - 1.2 - - 
Il2ra interleukin 2 receptor, alpha chain 16184 1.1 1.2 - 1.3 1.1 - 
Il33 interleukin 33 77125 - 1 - 1.1 - - 
Irf1 interferon regulatory factor 1 16362 - 1.3 - 1.1 - - 
Irf7 interferon regulatory factor 7 54123 1.7 2.9 1.7 1.1 - - 
Irg1 immunoresponsive gene 1 16365 2.6 2.5 1.9 2.5 1.6 - 
Irgm1 immunity-related GTPase family M member 1 15944 1.4 2.3 1.1 1.4 - - 
Irgm2 immunity-related GTPase family M member 2 54396 1 1.7 - 1.2 - - 
Isg15 ISG15 ubiquitin-like modifier 1000388
82 1.6 2.2 1.5 1.4 - - 
Jhdm1d jumonji C domain-containing histone demethylase 
1 homolog D (S. cerevisiae) 
338523 1.1 1.6 1.1 1.1 - - 
Kcne4 potassium voltage-gated channel, Isk-related 
subfamily, gene 4 
57814 1.2 1.4 0 1.3 - - 
Klk1 kallikrein 1 16612 - - 1.3 1 - - 
Klrk1 killer cell lectin-like receptor subfamily K, member 
1 
27007 1.5 1.7 1.6 1.5 - - 
Lap3 leucine aminopeptidase 3 66988 1.1 1.5 1 1.5 - - 
Lcn2 lipocalin 2 16819 1.4 1.6 2.2 2.2 1.4 1.7 
Lgals3bp lectin, galactoside-binding, soluble, 3 binding 
protein 
19039 1.2 1.7 1.1 - - - 
Lgals3bp lectin, galactoside-binding, soluble, 3 binding 
protein 
19039 - 1.5 - - - - 
Lgals9 lectin, galactose binding, soluble 9 16859 1.2 1.6 1.1 1.2 - - 
Lgmn legumain 19141 1.3 1.2 1.4 1.4 - - 
Lilrb3 leukocyte immunoglobulin-like receptor, subfamily 
B (with TM and ITIM domains), member 3 
18733 - - 1.1 1 - - 
Lilrb4 leukocyte immunoglobulin-like receptor, subfamily 
B, member 4 
14728 1.6 1.5 1.7 1.7 1.1 - 
Lipg lipase, endothelial 16891 2.4 2.8 2.4 2.5 1.8 1.5 
Lrrc16a leucine rich repeat containing 16A 68732 - 1.2 - - - - 
Lrrc61 leucine rich repeat containing 61 243371 1.8 1.4 1.8 2.1 1.3 - 
Ltv1 LTV1 homolog (S. cerevisiae) 353258 - - - 1.1 - - 
Ly6a lymphocyte antigen 6 complex, locus A 110454 1.7 1.9 1.2 1.3 - - 
Ly6c1 lymphocyte antigen 6 complex, locus C1 17067 1.8 2.2 1.9 1.9 - - 
Ly6c2 lymphocyte antigen 6 complex, locus C2 1000415
46 1.3 1.6 1.3 1.1 - - 
Ly6g lymphocyte antigen 6 complex, locus G 546644 - 1.7 2.5 2.2 - - 
Ly6i lymphocyte antigen 6 complex, locus I 57248 - 1 - - - - 
Ly96 lymphocyte antigen 96 17087 - - 1.2 - - - 
Lyrm2 LYR motif containing 2 108755 - - - 1 - - 
Marco macrophage receptor with collagenous structure 17167 - - 1 - 1.5 1.5 
Mcee methylmalonyl CoA epimerase 73724 - - 1.1 - - - 
Med10 mediator of RNA polymerase II transcription, 28077 - - - 1.1 - - 
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subunit 10 homolog (NUT2, S. cerevisiae) 
Med11 mediator of RNA polymerase II transcription, 
subunit 11 homolog (S. cerevisiae) 
66172 - - - 1.1 - - 
Med4 mediator of RNA polymerase II transcription, 
subunit 4 homolog (yeast) 
67381 - - - 1 - - 
Mid1 midline 1 17318 1.3 1.4 - - - - 
Mif macrophage migration inhibitory factor 17319 - 1.1 - - - - 
Mir1949 microRNA 1949 1003167
00 - 1.2 - - - - 
Mitd1 MIT, microtubule interacting and transport, domain 
containing 1 
69028 1.2 1.4 1.1 1.2 - - 
Mki67ip Mki67 (FHA domain) interacting nucleolar 
phosphoprotein 
67949 - - 0 1.2 - - 
Mlkl mixed lineage kinase domain-like 74568 2.1 2.7 2 2.3 - - 
Mmp13 matrix metallopeptidase 13 17386 2.7 2.6 2.4 2.4 1.5 - 
Mmp19 matrix metallopeptidase 19 58223 1.9 2 2 2 1.5 1.2 
Mmp25 matrix metallopeptidase 25 240047 - 1 - 1.1 - - 
Mmp8 matrix metallopeptidase 8 17394 2.7 3 3.1 3.4 2.5 2.8 
Mnda myeloid cell nuclear differentiation antigen 381308 1.8 1.8 1.6 1.7 - - 
Mndal myeloid nuclear differentiation antigen like 1000404
62 1.1 1.3 1.1 1.2 - - 
Mov10 Moloney leukemia virus 10 17454 1.1 1.5 - - - - 
Mreg melanoregulin 381269 - 1.1 - 1.1 - - 
Mrpl42 mitochondrial ribosomal protein L42 67270 - - 1.1 1.2 - - 
Mrpl54 mitochondrial ribosomal protein L54 66047 - 1 - - - - 
Ms4a4a membrane-spanning 4-domains, subfamily A, 
member 4A 
666907 2.6 2.7 2.6 2.5 1.5 1.1 
Ms4a4c membrane-spanning 4-domains, subfamily A, 
member 4C 
64380 1.2 1.5 1.2 1 - - 
Ms4a4d membrane-spanning 4-domains, subfamily A, 
member 4D 
66607 1.6 1.5 1.6 1.8 - - 
Ms4a6c membrane-spanning 4-domains, subfamily A, 
member 6C 
73656 1.1 1.1 1.2 1.2 - - 
Ms4a6d membrane-spanning 4-domains, subfamily A, 
member 6D 
68774 3.2 3.5 3.1 3.3 - - 
Ms4a7 membrane-spanning 4-domains, subfamily A, 
member 7 
109225 1.7 1.4 2 1.9 1.4 - 
Msr1 macrophage scavenger receptor 1 20288 2.3 2 2 2.2 1.4 1.1 
Mvp major vault protein 78388 - 1.3 - 1 - - 
Mx1 myxovirus (influenza virus) resistance 1 17857 3.2 3.9 3 2.8 - - 
Mx2 myxovirus (influenza virus) resistance 2 17858 2.7 3.7 2.1 2.2 - - 
Myc myelocytomatosis oncogene 17869 - 1.1 - - - - 
Myd88 myeloid differentiation primary response gene 88 17874 - - - 1.2 - - 
N4bp1 NEDD4 binding protein 1 80750 - 1 - - - - 
Naa25 N(alpha)-acetyltransferase 25, NatB auxiliary 
subunit 
231713 - 1.2 - 1 - - 
Nampt nicotinamide phosphoribosyltransferase 59027 1.7 1.9 1.5 2 - - 
Nlrc5 NLR family, CARD domain containing 5 434341 - 1.8 - - - - 
Nmi N-myc (and STAT) interactor 64685 1.3 1.6 1.1 1.5 - - 
Nod1 nucleotide-binding oligomerization domain 
containing 1 
107607 - - - 1 - - 
Nol8 nucleolar protein 8 70930 - - - 1 - - 
Nop56 NOP56 ribonucleoprotein 67134 - - - 1.4 - - 
Nos2 nitric oxide synthase 2, inducible 18126 - - - 1.1 - - 
Oas1a 2'-5' oligoadenylate synthetase 1A 246730 1.5 2.7 1.6 1.4 - - 
Oas1b 2'-5' oligoadenylate synthetase 1B 23961 - 1.6 - - - - 
Oas1g 2'-5' oligoadenylate synthetase 1G 23960 2.3 3.9 2.5 2.3 - - 
Oas2 2'-5' oligoadenylate synthetase 2 246728 2.1 3.4 2 1.6 - - 
Oas3 2'-5' oligoadenylate synthetase 3 246727 1.1 2.6 1.3 1 - - 
Oasl1 2'-5' oligoadenylate synthetase-like 1 231655 2.6 3.5 2.4 2.5 - - 
Oasl2 2'-5' oligoadenylate synthetase-like 2 23962 2 3.4 2 2 - - 
Ogfr opioid growth factor receptor 72075 - 1.4 - - - - 
Olfr56 olfactory receptor 56 18356 1.7 2.1 1.2 1.7 - - 
P2ry14 purinergic receptor P2Y, G-protein coupled, 14 140795 - - 1.3 1.1 - - 
Parp10 poly (ADP-ribose) polymerase family, member 10 671535 1.2 1.5 - 1.2 - - 
Parp11 poly (ADP-ribose) polymerase family, member 11 101187 1 1.4 - - - - 
Parp12 poly (ADP-ribose) polymerase family, member 12 243771 1.5 2.5 1.3 1.6 - - 
Parp14 poly (ADP-ribose) polymerase family, member 14 547253 1.1 1.7 - 1 - - 
Parp9 poly (ADP-ribose) polymerase family, member 9 80285 1.3 1.9 1.1 1.2 - - 
Pdcd5 programmed cell death 5 56330 - - - 1.2 - - 
Pde7b phosphodiesterase 7B 29863 1.8 2.3 2 1.6 - - 
Pdk4 pyruvate dehydrogenase kinase, isoenzyme 4 27273 1.5 1.1 1.7 1.4 1.8 1.8 
Pf4 platelet factor 4 56744 - - 1.2 1.1 - - 
Pfkp phosphofructokinase, platelet 56421 - 1 - 1.1 - - 
Phf11a PHD finger protein 11A 219131 1.2 1.4 1.1 1.1 - - 
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Phf11b PHD finger protein 11B 236451 2 1.8 1.7 1.8 - - 
Phf11c PHD finger protein 11C 628705 2 2.4 1.7 1.7 - - 
Phf11d PHD finger protein 11D 219132 2.4 2.9 2.4 2.4 1.1 - 
Pi4kb phosphatidylinositol 4-kinase, catalytic, beta 
polypeptide 
107650 1.4 1.4 1.3 1.2 - - 
Pkib protein kinase inhibitor beta, cAMP dependent, 
testis specific 
18768 1.2 1.4 - 1.2 - - 
Pla2g4a phospholipase A2, group IVA (cytosolic, calcium-
dependent) 
18783 - - - 1.2 - - 
Plac8 placenta-specific 8 231507 1.3 1.7 - 1.3 - - 
Plau plasminogen activator, urokinase 18792 1.2 1.1 - 1.1 - - 
Plin2 perilipin 2 11520 1.3 1.5 1.4 1.5 1.1 - 
Pno1 partner of NOB1 homolog (S. cerevisiae) 66249 - 1.1 - 1.1 - - 
Pnp purine-nucleoside phosphorylase 18950 - 1.2 1.2 1.3 - - 
Pnpt1 polyribonucleotide nucleotidyltransferase 1 71701 1.1 - 1.1 1.4 - - 
Pomp proteasome maturation protein 66537 - - 1 - - - 
Pop4 processing of precursor 4, ribonuclease P/MRP 
family, (S. cerevisiae) 
66161 - - 1 1.2 - - 
Ppa1 pyrophosphatase (inorganic) 1 67895 1.3 2.1 - 1.5 - - 
Pram1 PML-RAR alpha-regulated adaptor molecule 1 378460 - - 1.1 1.1 - - 
Prdx1 peroxiredoxin 1 18477 1 - 1 1.2 - - 
Prf1 perforin 1 (pore forming protein) 18646 1.2 1.4 1.1 1.2 - - 
Prmt1 protein arginine N-methyltransferase 1 15469 - - - 1 - - 
Procr protein C receptor, endothelial 19124 1 - - 1 - - 
Psat1 phosphoserine aminotransferase 1 107272 1.3 1.4 1 1.3 - - 
Psma1 proteasome (prosome, macropain) subunit, alpha 
type 1 
26440 - - 1.1 1.3 - - 
Psma7 proteasome (prosome, macropain) subunit, alpha 
type 7 
26444 - 1.1 - 1.1 - - 
Psmb10 proteasome (prosome, macropain) subunit, beta 
type 10 
19171 1.1 1.4 - 1.3 - - 
Psmb8 proteasome (prosome, macropain) subunit, beta 
type 8 (large multifunctional peptidase 7) 
16913 - 1.4 - 1.1 - - 
Psmc6 proteasome (prosome, macropain) 26S subunit, 
ATPase, 6 
67089 - - - 1 - - 
Psme1 proteasome (prosome, macropain) 28 subunit, 
alpha 
19186 - 1.1 - 1 - - 
Ptgs2 prostaglandin-endoperoxide synthase 2 19225 2.3 2 1.4 2 1.9 - 
Pydc3 pyrin domain containing 3 1000334
59 1.9 2.4 1.7 1.5 - - 
Pydc4 pyrin domain containing 4 623121 2.9 3.4 2.2 1.9 - - 
Pyhin1 pyrin and HIN domain family, member 1 236312 1.7 1.8 1.5 1.4 - - 
Rasa4 RAS p21 protein activator 4 54153 - 1.1 1 1 - - 
Retnlg resistin like gamma 245195 1.1 1.3 1.5 1.6 1.4 1.6 
Rgs1 regulator of G-protein signaling 1 50778 1.7 1.7 1.4 1.5 1.2 - 
Rnf19b ring finger protein 19B 75234 - 1.2 - 1.1 - - 
Rnf213 ring finger protein 213 672511 1.4 2.2 1 1 - - 
Rpf2 ribosome production factor 2 homolog (S. 
cerevisiae) 
67239 - 1.2 - 1.3 - - 
Rpl23a ribosomal protein L23A 268449 - - - 1.3 - - 
Rsl1d1 ribosomal L1 domain containing 1 66409 - - - 1.2 - - 
Rtp4 receptor transporter protein 4 67775 1.4 2.2 1.2 1.1 - - 
Rundc3b RUN domain containing 3B 242819 - 1 - - - - 
S100a8 S100 calcium binding protein A8 (calgranulin A) 20201 - 1.4 1.6 1.9 - - 
S100a9 S100 calcium binding protein A9 (calgranulin B) 20202 - 1.2 - 1.2 - - 
Scarna6 small Cajal body-specific RNA 6 1.00E+0
8 - - -1.6 - - - 
Scimp SLP adaptor and CSK interacting membrane 
protein 
327957 1.2 - 1.2 1.5 - - 
Sco1 SCO cytochrome oxidase deficient homolog 1 
(yeast) 
52892 1.5 1.6 1.4 1.6 - - 
Sepw1 selenoprotein W, muscle 1 20364 1.1 1.2 1.1 1.1 - - 
Serpina3f serine (or cysteine) peptidase inhibitor, clade A, 
member 3F 
238393 1.9 2.7 1.3 2.2 1.3 - 
Serpinb6b serine (or cysteine) peptidase inhibitor, clade B, 
member 6b 
20708 - - - 1.2 - - 
Serpinb9 serine (or cysteine) peptidase inhibitor, clade B, 
member 9 
20723 1.3 1.1 1.1 1.4 - - 
Serpinb9b serine (or cysteine) peptidase inhibitor, clade B, 
member 9b 
20706 1.2 1 1.1 - - - 
Serpine1 serine (or cysteine) peptidase inhibitor, clade E, 
member 1 
18787 1.1 - - 1 - - 
Setdb2 SET domain, bifurcated 2 239122 1.3 1.8 1.1 1.1 - - 
Sfrp1 secreted frizzled-related protein 1 20377 1 1 1.1 1.2 - - 




Slamf8 SLAM family member 8 74748 - 1.1 - 1.2 - - 
Slc15a3 solute carrier family 15, member 3 65221 - 1.3 - 1.1 - - 
Slc25a22 solute carrier family 25 (mitochondrial carrier, 
glutamate), member 22 
68267 - 1.2 1 1.2 - - 
Slfn1 schlafen 1 20555 1.8 1.9 1.3 1.5 - - 
Slfn2 schlafen 2 20556 - 1.1 - - - - 
Slfn3 schlafen 3 20557 1.3 1.7 1.5 1.7 - - 
Slfn4 schlafen 4 20558 1.9 3 2 1.8 - - 
Slfn5 schlafen 5 327978 1.5 2.4 1.4 1.1 - - 
Slfn8 schlafen 8 276950 1.2 1.5 - - - - 
Slfn9 schlafen 9 237886 1.5 2.4 1.4 1.7 - - 
Snora81 small nucleolar RNA, H/ACA box 81 1.00E+0
8 - 1.1 - - - - 
Snord12 small nucleolar RNA, C/D box 12 1.00E+0
8 - 1.9 - - - - 
Snord52 small nucleolar RNA, C/D box 52 1.00E+0
8 - 1.2 - - - - 
Snord72 small nucleolar RNA, C/D box 72 1.00E+0
8 - 1.4 - - - - 
Snrpb2 U2 small nuclear ribonucleoprotein B 20639 - - 1.1 1 - - 
Snx10 sorting nexin 10 71982 - 1.2 - 1.1 - - 
Snx6 sorting nexin 6 72183 - - 1.1 1.3 - - 
Socs1 suppressor of cytokine signaling 1 12703 1.6 2.2 - 1.9 - - 
Socs2 suppressor of cytokine signaling 2 216233 1 1.4 - 1.8 - - 
Sp100 nuclear antigen Sp100 20684 1.1 1.7 1.4 - - - 
Sp100 nuclear antigen Sp100 20684 - 1.4 - - - - 
Sp140 Sp140 nuclear body protein 434484 - 1.1 - - - - 
Spon1 spondin 1, (f-spondin) extracellular matrix protein 233744 1.6 1.9 1.5 1.7 - - 
Stat1 signal transducer and activator of transcription 1 20846 - 1.4 - - - - 
Stat2 signal transducer and activator of transcription 2 20847 1.4 1.9 1.2 1.5 - - 
Stxbp3a syntaxin binding protein 3A 20912 1.1 1.1 1.3 1.2 - - 
Taf1d TATA box binding protein (Tbp)-associated factor, 
RNA polymerase I, D 
75316 - 2.4 - - - - 
Tap1 transporter 1, ATP-binding cassette, sub-family B 
(MDR/TAP) 
21354 - 1.1 - - - - 
Tap2 transporter 2, ATP-binding cassette, sub-family B 
(MDR/TAP) 
21355 - 1 - - - - 
Tdrd7 tudor domain containing 7 100121 - 1.3 - - - - 
Tfec transcription factor EC 21426 1.6 1 1.7 1.6 - - 
Tgm2 transglutaminase 2, C polypeptide 21817 1.3 1.7 1.1 1.5 1 - 
Tgtp1 T cell specific GTPase 1 21822 - 1.4 - 1.1 - - 
Tgtp2 T cell specific GTPase 2 1.00E+0
8 1.6 2.7 - 1.5 - - 
Timp1 tissue inhibitor of metalloproteinase 1 21857 2.8 2.9 2.4 2.9 1.8 1.6 
Tlr13 toll-like receptor 13 279572 1.4 1 1.7 1.5 1 - 
Tlr3 toll-like receptor 3 142980 1 1.4 1.2 1.1 - - 
Tlr7 toll-like receptor 7 170743 1.1 1.2 1.2 - - - 
Tlr8 toll-like receptor 8 170744 1.1 1.1 1.3 1 - - 
Tm4sf1 transmembrane 4 superfamily member 1 17112 - - - 1 - - 
Tmem106a transmembrane protein 106A 217203 - 1.1 - 1.1 - - 
Tmem184b transmembrane protein 184b 223693 - 1.1 - - - - 
Tmem67 transmembrane protein 67 329795 1.3 1.4 1.2 1.4 - - 
Tnfsf10 tumor necrosis factor (ligand) superfamily, member 
10 
22035 2 2.3 2 1.9 - - 
Tnn tenascin N 329278 - 1.2 - - - - 
Tomm70a translocase of outer mitochondrial membrane 70 
homolog A (yeast) 
28185 - 1.1 - - - - 
Tor3a torsin family 3, member A 30935 1.6 2.1 1.4 1.4 - - 
Trafd1 TRAF type zinc finger domain containing 1 231712 1.1 1.6 1 1.1 - - 
Trem3 triggering receptor expressed on myeloid cells 3 58218 1.1 1.4 1.2 1.5 - - 
Trex1 three prime repair exonuclease 1 22040 - 1.2 - 1 - - 
Trim12c tripartite motif-containing 12C 319236 - 1.1 - - - - 
Trim12c tripartite motif-containing 12C 319236 - 1.5 1.2 1.3 - - 
Trim21 tripartite motif-containing 21 20821 1.1 1.3 - 1.4 - - 
Trim25 tripartite motif-containing 25 217069 - 1 - - - - 
Trim30a tripartite motif-containing 30A 20128 1.3 2.1 - 1.1 - - 
Trim30c tripartite motif-containing 30C 434219 2.6 3.4 2.5 2.2 - - 
Trim30d tripartite motif-containing 30D 209387 3.1 3.5 3.4 2.7 1.4 - 
Trim34b tripartite motif-containing 34B 434218 - 1.1 - - - - 
Tspo translocator protein 12257 1.1 1.4 1.3 1.3 - - 
Tubb1 tubulin, beta 1 class VI 545486 - - - 1.3 - - 
Uba7 ubiquitin-like modifier activating enzyme 7 74153 - 1.1 - - - - 
Upp1 uridine phosphorylase 1 22271 - 1.1 - - - - 
Usp18 ubiquitin specific peptidase 18 24110 2.2 3.1 2 1.8 - - 
167 
 
Vwa5a von Willebrand factor A domain containing 5A 67776 - 1.3 - 1.2 - - 
Wars tryptophanyl-tRNA synthetase 22375 1.1 1.6 - 1.4 - - 
Wfdc17 WAP four-disulfide core domain 17 1.00E+0
8 2.7 2.4 2.8 2.7 - - 
Xaf1 XIAP associated factor 1 327959 1.3 2.1 1.1 1.2 - - 
Xdh xanthine dehydrogenase 22436 2.3 3 2.4 2.4 1.2 - 
Zbp1 Z-DNA binding protein 1 58203 1.9 2.7 1.3 1.6 - - 
Zcchc2 zinc finger, CCHC domain containing 2 227449 - 1.1 - - - - 
Zfp1 zinc finger protein 1 22640 - 1.1 1.1 1.2 - - 
Znfx1 zinc finger, NFX1-type containing 1 98999 1 1.6 1 1.1 - - 
Znrd1 zinc ribbon domain containing, 1 66136 - - 1.1 1.2 - - 







Table a2. Full list of annotated down regulated genes in mouse spleens in response to canarypox virus (CNPV), pigeonpox 
(FeP2), fowlpox virus (FWPV), lumpy skin disease virus (LSDV), modified vaccinia Ankara (MVA) and penguinpox virus (PEPV). 
Differences in Log2 Fold Changes (between each virus and the control) are depicted. 
Symbol Name Entrez MVA LSDV CNPV FWPV PEPV FeP2 
2510003D18Rik RIKEN cDNA 2510003D18 gene 72317 -1.1 -1.3 - - - - 
2900052N01Rik RIKEN cDNA 2900052N01 gene 73040 - -1.1 - - - - 
5430401H09Rik RIKEN cDNA 5430401H09 gene 100504461 -1.5 -1.1 - - - - 
9430076G02Rik RIKEN cDNA 9430076G02 gene 77433 -2.2 -1.8 -1.9 -1.9 -1.5 -1.3 
A530099J19Rik RIKEN cDNA A530099J19 gene 319293 -1.3 -1.5 - - - - 
Abca9 ATP-binding cassette, sub-family A (ABC1), 
member 9 
217262 -1.3 -1.5 - -1.1 - - 
Adam23 a disintegrin and metallopeptidase domain 23 23792 -1.3 -1.3 -1.0 -1.2 - - 
Adamdec1 ADAM-like, decysin 1 58860 - -1.1 - - - - 
Add2 adducin 2 (beta) 11519 -1.3 - -1.1 - - - 
Ano1 anoctamin 1, calcium activated chloride 
channel 
101772 -1.4 -1.4 - - - - 
Aplnr apelin receptor 23796 -1.4 -1.5 -1.2 -1.2 - - 
Aqp1 aquaporin 1 11826 -1.5 -1.2 -1.2 -1.1 - - 
Aspm asp (abnormal spindle)-like, microcephaly 
associated (Drosophila) 
12316 -1.2 - - - - - 
Atp2b4 ATPase, Ca++ transporting, plasma 
membrane 4 
381290 -1.4 - -1.1 -1.1 - - 
B3gnt8 UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase 8 
232984 -1.3 -1.3 -1.1 -1.1 - - 
Btnl10 butyrophilin-like 10 192194 -1.8 -1.3 -1.2 -1.2 -1.1 - 
Cacna1g calcium channel, voltage-dependent, T type, 
alpha 1G subunit 
12291 -1.3 - - - - - 
Ccdc80 coiled-coil domain containing 80 67896 -1.4 -1.4 -1.3 - -1.1 - 
Ccl21a chemokine (C-C motif) ligand 21A (serine) 18829 -1.3 -1.7 - - - - 
Ccl21a chemokine (C-C motif) ligand 21A (serine) 18829 -1.3 -1.7 - - - - 
Ccl21b chemokine (C-C motif) ligand 21B (leucine) 100042493 -1.2 -1.6 - - - - 
Ccl21b chemokine (C-C motif) ligand 21B (leucine) 100042493 -1.3 -1.6 - - - - 
Ccl21b chemokine (C-C motif) ligand 21B (leucine) 100042493 -1.2 -1.7 - - - - 
Ccl21b chemokine (C-C motif) ligand 21B (leucine) 100042493 -1.2 -1.7 - - - - 
Ccl21b chemokine (C-C motif) ligand 21B (leucine) 100042493 -1.2 -1.7 - - - - 
Ccl21b chemokine (C-C motif) ligand 21B (leucine) 100042493 -1.2 -1.7 - - - - 
Ccl21c chemokine (C-C motif) ligand 21C (leucine) 65956 -1.2 -1.6 - - - - 
Cd209a CD209a antigen 170786 -1.7 -2.2 -1.1 -1.5 - - 
Cd209b CD209b antigen 69165 -1.2 -1.3 - - - - 
Cd59a CD59a antigen 12509 - -1.2 - - - - 
Cd7 CD7 antigen 12516 - -1.1 - - - - 
Cdh8 cadherin 8 12564 - -1.0 - - - - 
Cdkl1 cyclin-dependent kinase-like 1 (CDC2-related 
kinase) 
71091 -1.2 - - - - - 
Cdkn2c cyclin-dependent kinase inhibitor 2C (p18, 
inhibits CDK4) 
12580 -1.3 - - - - - 
Cep76 centrosomal protein 76 225659 -1.1 - - - - - 
Cit citron 12704 -1.3 - - - - - 
Cldn13 claudin 13 57255 -1.5 -1.2 -1.1 - - - 
Col14a1 collagen, type XIV, alpha 1 12818 -1.6 -1.6 -1.3 -1.4 -1.0 - 
Cpm carboxypeptidase M 70574 -1.3 -1.3 -1.1 -1.1 - - 
Csmd3 CUB and Sushi multiple domains 3 239420 -1.0 -1.1 - - - - 
Ctsf cathepsin F 56464 -1.1 - - - - - 
Depdc1a DEP domain containing 1a 76131 -1.1 - - - - - 
Diap3 diaphanous homolog 3 (Drosophila) 56419 -1.1 - - - - - 
E2f2 E2F transcription factor 2 242705 -1.5 - -1.2 -1.2 - - 
E2f8 E2F transcription factor 8 108961 -1.4 -1.0 -1.1 - - - 
Emr4 EGF-like module containing, mucin-like, 
hormone receptor-like sequence 4 
52614 -1.4 -1.8 -1.1 -1.5 -1.3 - 
Esm1 endothelial cell-specific molecule 1 71690 - -1.1 - - - - 
Fbln5 fibulin 5 23876 -2.0 -2.0 -1.4 -1.3 -1.1 - 
Fcamr Fc receptor, IgA, IgM, high affinity 64435 -1.1 - -1.5 - - - 
Fcer2a Fc receptor, IgE, low affinity II, alpha 
polypeptide 
14128 -2.6 -3.1 -2.4 -2.5 -2.2 -1.3 
Fhdc1 FH2 domain containing 1 229474 -
1.42824 
- - - - - 
Fn3k fructosamine 3 kinase 63828 -2.0 -1.5 -1.5 -1.5 -1.1 - 
Gas6 growth arrest specific 6 14456 - -1.1 - - - - 
Glrx5 glutaredoxin 5 homolog (S. cerevisiae) 73046 -1.3 - -1.1 - - - 
Gm12839 cytochrome P450, family 4, subfamily b, 
polypeptide 1 pseudogene 
631037 -1.7 -1.3 -1.1 -1.4 -1.4 - 
Gm20236 predicted gene, 20236 100504453 -1.9 -1.2 -1.5 -1.6 -1.3 - 
Gm20236 predicted gene, 20236 100504453 -1.9 -1.2 -1.5 -1.6 -1.3 - 
Gpsm2 G-protein signalling modulator 2 (AGS3-like, 
C. elegans) 
76123 -1.1 - - - - - 
H2-M2 histocompatibility 2, M region locus 2 14990 -1.1 -1.4 -1.0 -1.0 -1.1 - 
Hmmr hyaluronan mediated motility receptor 
(RHAMM) 












Hs3st2 heparan sulfate (glucosamine) 3-O-
sulfotransferase 2 
195646 -1.4 -1.3 -1.0 -1.0 - - 
Ifi27l1 interferon, alpha-inducible protein 27 like 1 52668 -1.4 -1.3 - - - - 
Igfbp3 insulin-like growth factor binding protein 3 16009 - -1.0 - - - - 
Igk immunoglobulin kappa chain complex 243469 - -1.0 - - - - 
Kcnj16 potassium inwardly-rectifying channel, 
subfamily J, member 16 
16517 - -1.1 - - - - 
Kel Kell blood group 23925 -1.5 -1.5 - - - - 
Kif14 kinesin family member 14 381293 -1.3 - - - - - 
Kif23 kinesin family member 23 71819 -1.1 - - - - - 
Klhl14 kelch-like 14 225266 -1.5 -1.6 -1.3 -1.4 -1.2 - 
Kynu kynureninase (L-kynurenine hydrolase) 70789 -1.3 -1.4 -1.0 -1.1 - - 
Lilra5 leukocyte immunoglobulin-like receptor, 
subfamily A (with TM domain), member 5 
232801 - -1.1 - - - - 
Limch1 LIM and calponin homology domains 1 77569 -1.1 -1.2 - - - - 
Lphn3 latrophilin 3 319387 - -1.1 - - - - 
Mgll monoglyceride lipase 23945 -1.3 - - - - - 
Mgst3 microsomal glutathione S-transferase 3 66447 -1.6 -1.0 - -1.0 - - 
Mir687 microRNA 687 751541 -1.4 - - - - - 
Nusap1 nucleolar and spindle associated protein 1 108907 -1.1 - - - - - 
Nxpe4 neurexophilin and PC-esterase domain family, 
member 4 
244853 -1.2 - - - - - 
Olfml2a olfactomedin-like 2A 241327 - -1.0 - - - - 
Paqr9 progestin and adipoQ receptor family member 
IX 
75552 -1.1 - - - - - 
Pcp4 Purkinje cell protein 4 18546 -1.2 -1.5 - - - - 
Pcx pyruvate carboxylase 18563 -1.4 - - - - - 
Pkhd1l1 polycystic kidney and hepatic disease 1-like 1 192190 -2.6 -2.0 -2.1 -2.1 -1.7 - 
Pklr pyruvate kinase liver and red blood cell 18770 -1.1 - - - - - 
Ppox protoporphyrinogen oxidase 19044 -1.1 -1.1 - - - - 
Prelp proline arginine-rich end leucine-rich repeat 116847 -1.0 -1.2 - - - - 
Prkcg protein kinase C, gamma 18752 - -
1.02954 
- - - - 
Reep6 receptor accessory protein 6 70335 -1.1 - - - - - 
Sec14l2 SEC14-like 2 (S. cerevisiae) 67815 -1.7 -1.3 -1.5 -1.3 -1.2 - 
Sh3yl1 Sh3 domain YSC-like 1 24057 -1.6 -1.2 - - - - 
Slc12a2 solute carrier family 12, member 2 20496 -1.0 -1.0 - - - - 
Slc16a10 solute carrier family 16 (monocarboxylic acid 
transporters), member 10 
72472 -1.4 - - -1.1 - - 
Slc2a4 solute carrier family 2 (facilitated glucose 
transporter), member 4 
20528 -1.7 -1.0 - -1.1 - - 
Slc38a5 solute carrier family 38, member 5 209837 -1.4 -1.2 -1.0 - - - 
Slc6a20a solute carrier family 6 (neurotransmitter 
transporter), member 20A 
102680 -1.4 -1.3 -1.0 -1.0 - - 
Sned1 sushi, nidogen and EGF-like domains 1 208777 -1.1 -1.1 0 -1.0 - - 
Snx22 sorting nexin 22 382083 -1.4 -1.1 - - - - 
Sox6 SRY-box containing gene 6 20679 -1.8 -1.2 -1.2 -1.4 -1.1 - 
Sptb spectrin beta, erythrocytic 20741 -1.9 -1.4 -1.6 -1.5 -1.3 -1.3 
St8sia6 ST8 alpha-N-acetyl-neuraminide alpha-2,8-
sialyltransferase 6 
241230 - -1.0 - - - - 
Tac2 tachykinin 2 21334 -1.0 -1.5 - - - - 
Tfrc transferrin receptor 22042 -1.2 - - - - - 
Timd4 T cell immunoglobulin and mucin domain 
containing 4 
276891 -1.1 -1.3 - - - - 
Tlr11 toll-like receptor 11 239081 -1.0 - - - - - 
Tspan33 tetraspanin 33 232670 -1.6 - -1.3 -1.1 - - 
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